<item><FPU_Page>Subacute Lymphocytic Thyroiditis</FPU_Page><FPU_LG_English>Subacute lymphocytic thyroiditis, Subacute lymphocytic thyroiditis (disorder), Subacute Lymphocytic Thyroiditis</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>361126006, 18018005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Subacute lymphocytic thyroiditis</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1306804</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/SbctLymphcytcThyrdts.htm</FPU_URL></item><item><FPU_Page>Riedel's Thyroiditis</FPU_Page><FPU_LG_English>REIDEL STRUMA, RIEDEL STRUMA, THYROIDITIS, INVASIVE, THYROIDITIS, LIGNEOUS, THYROIDITIS, RIEDEL, THYROIDITIS, WOODY, THYROIDITIS CHRONIC &amp;lt;RIEDELS&amp;gt;, Reidel's thyroiditis, Ligneous thyroiditis (disorder), Riedel's thyroiditis (diagnosis), THYROIDITIS CHRONIC RIEDELS, Riedel thyroiditis, reidel struma, riedel thyroiditis, invasive fibrous thyroiditis, riedels thyroiditis, riedel's thyroiditis, Invasive thyroiditis, Ligneous thyroiditis, Riedel's thyroiditis, Invasive fibrous thyroiditis, Struma fibrosa thyroid, Woody thyroiditis, Riedel's thyroiditis (disorder), Riedel; struma, Riedel; thyroiditis, ligneous; thyroiditis, struma; Riedel, thyroiditis; Riedel, thyroiditis; ligneous, thyroiditis; woody, woody; thyroiditis</FPU_LG_English><FPU_LG_French>Thyroïdite de Riedel, Thyroïdite ligneuse, Thyroïdite invasive</FPU_LG_French><FPU_SnomedCT>89024000, 237540002, 190298005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Riedel's thyroiditis</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0154162</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/RdlsThyrdts.htm</FPU_URL></item><item><FPU_Page>Riedel's Thyroiditis</FPU_Page><FPU_LG_English>Chronic fibrous thyroiditis, THYROIDITIS, CHRONIC FIBROUS, chronic fibrous thyroiditis, chronic fibrous thyroiditis (diagnosis), Thyroiditis fibrous chronic, Chr fibrous thyroiditis, Chronic thyroiditis, fibrous variant, Fibrous autoimmune thyroiditis, Hashimoto thyroiditis, fibrous variant, Noninvasive fibrous thyroiditis, Fibrous autoimmune thyroiditis (disorder), chronic; thyroiditis, fibrous, thyroiditis; chronic, fibrous</FPU_LG_English><FPU_LG_French>Thyroïdite fibreuse chronique</FPU_LG_French><FPU_SnomedCT>84362007, 190298005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Pathologic Function (T046)
</FPU_Concepts><FPU_Concepts_Codes>T046</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Fibrous autoimmune thyroiditis</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0271813</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/RdlsThyrdts.htm</FPU_URL></item><item><FPU_Page>Subclinical Hypothyroidism</FPU_Page><FPU_LG_English>Euthyroid Sick Syndrome, Euthyroid Sick Syndromes, EUTHYROID SICK SYNDROME &amp;lt;LOW T3/ LOW T4 SYNDROME&amp;gt;, Euthyroid sick syndrome, euthyroid sick syndrome, euthyroid sick syndrome (diagnosis), SICK EUTHYROID SYNDROME, EUTHYROID SICK SYNDROME LOW T3 LOW T4 SYNDROME, Euthyroid sick-syndrome, Euthyroid Sick Syndromes [Disease/Finding], sick euthyroid syndrome, Sick-euthyroid syndrome, Sick-euthyroid syndrome (disorder), sick-euthyroid; syndrome, syndrome; sick-euthyroid, Non Thyroidal Illness Syndrome, Non-Thyroidal Illness Syndrome, Sick Euthyroid Syndrome, Syndrome, Non-Thyroidal Illness, Syndrome, Sick Euthyroid, Syndromes, Non-Thyroidal Illness</FPU_LG_English><FPU_LG_French>Syndrome des maladies générales chez un euthyroïdien, Syndrome euthyroïdien, Syndrome normothyroïdien</FPU_LG_French><FPU_SnomedCT>237542005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Euthyroid Sick Syndromes</FPU_Name><FPU_DefMSH>Conditions of abnormal THYROID HORMONES release in patients with apparently normal THYROID GLAND during severe systemic illness, physical TRAUMA, and psychiatric disturbances. It can be caused by the loss of endogenous hypothalamic input or by exogenous drug effects. The most common abnormality results in low T3 THYROID HORMONE with progressive decrease in THYROXINE; (T4) and TSH. Elevated T4 with normal T3 may be seen in diseases in which THYROXINE-BINDING GLOBULIN synthesis and release are increased.</FPU_DefMSH><FPU_Code>C0015190</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/SbclnclHypthyrdsm.htm</FPU_URL></item><item><FPU_Page>Multinodular Goiter</FPU_Page><FPU_LG_English>MULTINODULAR TOXIC GOITER, PARRY DISEASE, Thyrotox + tox multinod goiter, Thyrotox + tox multinod goitre, Thyrotoxic - multinodul goiter, Thyrotoxic - multinodul goitre, Toxic multinodular goiter NOS, Toxic multinodular goitre NOS, toxic multinodular goiter, toxic multinodular goiter (diagnosis), Toxic multinodular goitre (disorder), THYROID GOITER TOXIC MULTINODULAR, Toxic multinodular goiter NOS (disorder), parry disease, multinodular toxic goiter, Goitre;multinodular;toxic, multinodular toxic goitre, Toxic multinodular goiter, Secondary thyroid hyperplasia, Thyrotoxicosis due to multinodular goiter, Thyrotoxicosis due to multinodular goitre, Thyrotoxicosis with toxic multinodular goiter, Thyrotoxicosis with toxic multinodular goitre, Toxic multinodular goitre, Toxic multinodular goiter (disorder), Parry, goiter; thyrotoxicosis, multinodular, multinodular; goiter, toxic or with hyperthyroidism, nodular; goiter, with thyrotoxicosis, struma; multinodular, toxic or with hyperthyroidism, struma; nodular, with thyrotoxicosis, struma; thyrotoxicosis, nodular, struma; toxic, multinodular, thyrotoxicosis; goiter, multinodular, thyrotoxicosis; goiter, nodular, toxic; goiter, multinodular, Goiter;multinodular;toxic, toxic multinodular goitre</FPU_LG_English><FPU_LG_French>Goitre multinodulaire toxique</FPU_LG_French><FPU_SnomedCT>154658002, 190249001, 26389007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Toxic multinodular goiter</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0154143</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/MltndlrGtr.htm</FPU_URL></item><item><FPU_Page>Multinodular Goiter</FPU_Page><FPU_LG_English>MULTINODULAR THYROID, MULTINODULAR GOITER, multinodular goiter, the thyroid had multiple nodules, Multinodular goiter, THYROID GOITER MULTINODULAR, multiple nodules of thyroid, multiple nodules of thyroid (physical finding), multinodular goitre, struma; multinodular, thyroid multinodular, goiters multinodular, multinodular thyroid, multiple nodules thyroid, multinodular; goiter, Multinodular goiter (disorder), Multiple thyroid nodules, Multinodular goitre</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>237570007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Multinodular goiter</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0342208</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/MltndlrGtr.htm</FPU_URL></item><item><FPU_Page>Multinodular Goiter</FPU_Page><FPU_LG_English>Nontoxic multinodular goiter, Nontoxic multinodular goitre, nontoxic multinodular goiter (diagnosis), nontoxic multinodular goiter, Non-toxic multinodular goitre (disorder), Nontox multinodul goiter, Goitre;multinodular;non toxic, Multinodular non-toxic goiter, Non-toxic multinodular goiter, Multinodular non-toxic goitre, Non-toxic multinodular goitre, Non-toxic multinodular goiter (disorder), nontoxic; goiter, multinodular, struma; nontoxic, multinodular, Goiter;multinodular;non toxic, non toxic multinodular goiter, non toxic multinodular goitre</FPU_LG_English><FPU_LG_French>Goitre multinodulaire non toxique</FPU_LG_French><FPU_SnomedCT>154653006, 36241006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Non-toxic multinodular goiter</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0271761</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/MltndlrGtr.htm</FPU_URL></item><item><FPU_Page>Subclinical Hyperthyroidism</FPU_Page><FPU_LG_English>Decreased thyroid stimulating hormone level -RETIRED-, Decreased thyroid stimulating hormone level (biological function) (finding), Decreased thyroid stimulating hormone level (finding), Decreased thyroid stimulating hormone level, Decreased thyroid stimulating hormone level (biological function)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>124773007, 131017004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Decreased thyroid stimulating hormone level</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1295607</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/SbclnclHyprthyrdsm.htm</FPU_URL></item><item><FPU_Page>Hypothyroidism</FPU_Page><FPU_LG_English>Hypothyroidism, Hypothyroidisms, Unspecified hypothyroidism, HYPOTHYROIDISM, THYROID ACTIVITY DECREASED, Hypothyroidism, NOS, Hypothyroidism NOS, Hypothyroidism, unspecified, hypothyroidism, hypothyroidism (diagnosis), Thyroid activity decreased, HYPOTHYROID, Hypothyroidism NOS (disorder), Hypothyroidism [Disease/Finding], hypothyroidisms, hypothyroid, Underactive Thyroid, underactive thyroid, Hypothyroid, Hypothyroidism (disorder), deficiency; thyroid, insufficiency; thyroid, subthyroidism, thyroid; deficiency, thyroid; insufficiency, Thyroid insufficiency, Hypothyroidism [Ambiguous], Thyroid deficiency</FPU_LG_English><FPU_LG_French>HYPOTHYROIDIE, Hypothyroïdisme non précisé, Activité thyroïdienne diminuée, DIMINUTION ACTIVITE THYROIDIENNE, Hypothyréose, Hypothyroïdie, Hypothyroïdisme</FPU_LG_French><FPU_SnomedCT>237572004, 267377003, 40930008, 154660000, 190274003, 267465007, 190290003</FPU_SnomedCT><FPU_DefCSP>deficiency of thyroid gland activity; characterized by decreased basal metabolic rate, fatigue and lethargy, sensitivity to cold, and menstrual disturbances; untreated it progresses to myxedema; in infants severe hypothyroidism leads to cretinism.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A condition in which the production of thyroid hormone by the thyroid gland is diminished. Signs and symptoms of hypothyroidism include low metabolic rate, tendency to weight gain, somnolence and sometimes myxedema. In the United States, the most common cause of hypothyroidism is Hashimoto's thyroiditis, an autoimmune disorder. A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland. Too little thyroid hormone. Symptoms include weight gain, constipation, dry skin, and sensitivity to the cold.</FPU_DefNCI><FPU_Name>Hypothyroidism</FPU_Name><FPU_DefMSH>A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA.</FPU_DefMSH><FPU_Code>C0020676</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Hypthyrdsm.htm</FPU_URL></item><item><FPU_Page>Hypothyroidism</FPU_Page><FPU_LG_English>Myxedema, Myxedemas, MYXOEDEMA, Myxedema, NOS, Hypothyroidism/myxedema, Myxoedema, NOS, MYXEDEMA, myxedema, myxedema (diagnosis), Myxedema NOS, Myxedema [Disease/Finding], Myxoedema, Myxedema (disorder), Hypothyroidism/myxoedema, myxoedema</FPU_LG_English><FPU_LG_French>MYXOEDEME, Hypothyroidie/myxoedeme, Myxoedème</FPU_LG_French><FPU_SnomedCT>43153006, 154660000, 190274003, 267465007</FPU_SnomedCT><FPU_DefCSP>condition characterized by a dry, waxy type of swelling with abnormal deposits of mucin in the skin and other tissues; it is produced by a functional insufficiency of the thyroid gland, resulting in deficiency of thyroid hormone.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Myxedema</FPU_Name><FPU_DefMSH>A condition characterized by a dry, waxy type of swelling (EDEMA) with abnormal deposits of MUCOPOLYSACCHARIDES in the SKIN and other tissues. It is caused by a deficiency of THYROID HORMONES. The skin becomes puffy around the eyes and on the cheeks. The face is dull and expressionless with thickened nose and lips.</FPU_DefMSH><FPU_Code>C0027145</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Hypthyrdsm.htm</FPU_URL></item><item><FPU_Page>Hyperthyroidism Management</FPU_Page><FPU_LG_English>Hyperthyroidism, HYPERTHYROIDISM, Hyperthyroidism, NOS, overactive thyroid, hyperthyroidism, hyperthyroidism (diagnosis), Hyperthyroidism NOS, Hyperthyroidism [Disease/Finding], Primary Hyperthyroidism, Primary Hyperthyroidisms, Hyperthyroidism, Primary, hyperthyroidism nos, Hyperthyroidism (disorder), Overactive Thyroid</FPU_LG_English><FPU_LG_French>HYPERTHYROIDIE, Hyperthyréose, Hyperthyroïdie, Hyperthyroïdisme</FPU_LG_French><FPU_SnomedCT>34486009, 154655004, 190239004, 267464006</FPU_SnomedCT><FPU_DefCSP>excessive functional activity of the thyroid gland.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor. A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose. Too much thyroid hormone. Symptoms include weight loss, chest pain, cramps, diarrhea, and nervousness.</FPU_DefNCI><FPU_Name>Hyperthyroidism</FPU_Name><FPU_DefMSH>Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.</FPU_DefMSH><FPU_Code>C0020550</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/HyprthyrdsmMngmnt.htm</FPU_URL></item><item><FPU_Page>Hashimoto's Thyroiditis</FPU_Page><FPU_LG_English>Hurthle Cell, Oxyphil cell of thyroid, Thyroid gland oxyphil cell, hurthle cells, hurthle cell, cells hurthles, Askenazy Cells, Cells, Askenazy, Cells, Hurthle, Thyroid Gland Oxyphil Cell, Thyroid Gland Oxyphilic Cell, Hurthle Cells</FPU_LG_English><FPU_LG_French>Cellule de Hürthle, Cellules de Hürthle</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Cell (T025)
</FPU_Concepts><FPU_Concepts_Codes>T025</FPU_Concepts_Codes><FPU_DefNCI>A large, granular eosinophilic cell derived from thyroid follicular epithelium by accumulation of mitochondria</FPU_DefNCI><FPU_Name>Hurthle Cells</FPU_Name><FPU_DefMSH>Oxyphil cells in the thyroid gland are known as Hurthle cells and Askenazy cells.</FPU_DefMSH><FPU_Code>C0949667</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/HshmtsThyrdts.htm</FPU_URL></item><item><FPU_Page>Hashimoto's Thyroiditis</FPU_Page><FPU_LG_English>Hashimoto's struma, Struma lymphomatosum, THYROIDITIS, HASHIMOTO, HASHIMOTO DISEASE, STRUMA LYMPHOMATOSA, THYROIDITIS, CHRONIC LYMPHADENOID, THYROIDITIS, LYMPHOID, Hashimoto's Thyroiditis, Chron lymphocytic thyroiditis, THYROIDITIS CHRONIC LYMPHOCYTIC &amp;lt;HASHIMOTOS&amp;gt;, HASHIMOTO THYROIDITIS, HASHIMOTO STRUMA, lymphomatous thyroiditis, HT, HASHIMOTOS DIS, HASHIMOTO DIS, hashimoto's thyroiditis, Struma lymphomatosis (disorder), Hashimoto's thyroiditis (disorder), Hashimoto's thyroiditis (diagnosis), THYROIDITIS HASHIMOTO, THYROIDITIS CHRONIC LYMPHOCYTIC HASHIMOTOS, Chr lymphocyt thyroidit, Hashimoto's Syndrome, Hashimoto's Syndromes, Hashimotos Syndrome, Syndromes, Hashimoto's, Hashimoto Syndrome, Syndrome, Hashimoto's, Hashimoto Disease [Disease/Finding], Hashimoto's Struma, hashimoto's disease, chronic thyroiditis, Disease;Hashimotos, chronic lymphocytic thyroiditis, hashimoto disease, autoimmune thyroiditides, hashimoto thyroiditis, lymphocytic thyroiditis, autoimmune thyroiditis, hashimoto's struma, Hashimoto's thyroiditis, Lymphocytic thyroiditis, Chronic lymphocytic thyroiditis, Autoimmune lymphocytic chronic thyroiditis, Hashimoto thyroiditis, Struma lymphomatosa, Hashimoto's disease, Struma lymphomatosis, Hashimoto thyroiditis (disorder), Hashimoto; thyroiditis, Hashimoto, chronic; thyroiditis, lymphadenoid, lymphocytic; thyroiditis, lymphoid; thyroiditis, lymphomatosa; goiter, lymphomatous; thyroiditis, struma; lymphomatosa, thyroiditis; Hashimoto, thyroiditis; chronic, lymphadenoid, thyroiditis; lymphocytic, thyroiditis; lymphoid, thyroiditis; lymphomatous, Lymphocytic Thyroiditis, Disease, Hashimoto, Hashimoto's Disease, Hashimotos Disease, Disease, Hashimoto's, Chronic Lymphocytic Thyroiditis, Chronic Lymphocytic Thyroiditides, Hashimoto Thyroiditides, Hashimoto Thyroiditis, Lymphocytic Thyroiditides, Chronic, Lymphocytic Thyroiditis, Chronic, Thyroiditides, Chronic Lymphocytic, Thyroiditides, Hashimoto, Thyroiditis, Chronic Lymphocytic, Thyroiditis, Hashimoto, Hashimoto Disease, Hashimotos disease</FPU_LG_English><FPU_LG_French>Thyroïdite chronique de Hashimoto, Thyroïdite lymphocytique, Thyroïdite lymphocytique chronique, Maladie d'Hashimoto, Maladie de Hashimoto, Thyroidite lymphocytaire de Hashimoto, Thyroïdite chronique lymphocytaire, Thyroïdite d'Hashimoto, Thyroïdite de Hashimoto</FPU_LG_French><FPU_SnomedCT>237537002, 237534009, 21983002, 190297000, 154667002, 267466008</FPU_SnomedCT><FPU_DefCSP>progressive enlargement of the thyroid gland, often associated with hypothyroidism.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>An inflammatory disorder that affects the thyroid gland. It is characterized by the infiltration of the thyroid parenchyma by lymphocytes. It includes Hashimoto thyroiditis and subacute lymphocytic thyroiditis.</FPU_DefNCI><FPU_Name>Hashimoto Disease</FPU_Name><FPU_DefMSH>Chronic autoimmune thyroiditis, characterized by the presence of high serum thyroid AUTOANTIBODIES; GOITER; and HYPOTHYROIDISM.</FPU_DefMSH><FPU_Code>C0677607</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/HshmtsThyrdts.htm</FPU_URL></item><item><FPU_Page>Hyperthyroidism</FPU_Page><FPU_LG_English>Hyperthyroidism, HYPERTHYROIDISM, Hyperthyroidism, NOS, overactive thyroid, hyperthyroidism, hyperthyroidism (diagnosis), Hyperthyroidism NOS, Hyperthyroidism [Disease/Finding], Primary Hyperthyroidism, Primary Hyperthyroidisms, Hyperthyroidism, Primary, hyperthyroidism nos, Hyperthyroidism (disorder), Overactive Thyroid</FPU_LG_English><FPU_LG_French>HYPERTHYROIDIE, Hyperthyréose, Hyperthyroïdie, Hyperthyroïdisme</FPU_LG_French><FPU_SnomedCT>34486009, 154655004, 190239004, 267464006</FPU_SnomedCT><FPU_DefCSP>excessive functional activity of the thyroid gland.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor. A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose. Too much thyroid hormone. Symptoms include weight loss, chest pain, cramps, diarrhea, and nervousness.</FPU_DefNCI><FPU_Name>Hyperthyroidism</FPU_Name><FPU_DefMSH>Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.</FPU_DefMSH><FPU_Code>C0020550</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Hyprthyrdsm1.htm</FPU_URL></item><item><FPU_Page>Hyperthyroidism</FPU_Page><FPU_LG_English>Thyrotoxicoses, THYROTOXICOSIS, Thyrotoxicosis, NOS, Thyrotoxicosis NOS, Thyrotoxicosis, unspecified, Thyrotoxicosis, Thyrotoxicosis +/- goiter, Thyrotoxicosis +/- goitre, thyrotoxicosis with or without goiter, thyrotoxicosis with or without goiter (diagnosis), Thyrotoxicosis NOS (disorder), Thyrotoxicosis [Disease/Finding], Thyrotoxicosis with or without goiter, Thyrotoxicosis with or without goitre, Thyrotoxicosis (disorder), Thyrotoxicosis with or without goiter (disorder), thyrotoxicosis, thyroid; toxic, toxic; thyroid, Thyrotoxicosis [Ambiguous]</FPU_LG_English><FPU_LG_French>Thyrotoxicose avec ou sans goitre, THYREOTOXICOSE, Thyrotoxicose, Thyréotoxicose</FPU_LG_French><FPU_SnomedCT>267373004, 154659005, 190267008, 90739004, 286909009, 154655004, 190239004, 267464006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A hypermetabolic syndrome caused by the elevation of thyroid hormone levels in the serum. Signs and symptoms include tachycardia, palpitations, tremor, weight loss, warm weather intolerance, and moist skin. Causes include Graves disease, toxic nodular goiter, toxic thyroid nodule, and lymphocytic thyroiditis.</FPU_DefNCI><FPU_Name>Thyrotoxicosis</FPU_Name><FPU_DefMSH>A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.</FPU_DefMSH><FPU_Code>C0040156</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Hyprthyrdsm1.htm</FPU_URL></item><item><FPU_Page>Grave's Disease</FPU_Page><FPU_LG_English>Basedow Disease, Basedow's Disease, Basedows Disease, Disease, Basedow, Exophthalmic Goiter, Exophthalmic Goiters, Goiter, Exophthalmic, Goiters, Exophthalmic, Disease, Basedow's, Disease, Graves', BASEDOW DISEASE, DISEASE GRAVES', EXOPHTHALMIC GOITER, EXOPHTHALMIC GOITRE, FLAJANI DISEASE, GOITER, EXOPHTHALMIC, GRAVES' DISEASE, GOITER EXOPHTHALMIC, HYPERTHYROIDISM &amp;lt;GRAVES DISEASE&amp;gt;, HYPERTHYROIDISM, AUTOIMMUNE, GRD, GRAVES DISEASE, BASEDOW DIS, BASEDOWS DIS, GRAVES DIS, Graves' disease (diagnosis), Grave's disease, Graves' disease (diffuse toxic goiter), grave's disease, Autoimmune hyperthyroidism, Disease Graves', Goiter exophthalmic, GRAVE DISEASE, HYPERTHYROIDISM GRAVES DISEASE, Graves Disease, Basedow disease, Graves Disease [Disease/Finding], Disease;Basedows, basedows disease, hyperthyroidism graves disease, Disease;Graves, disease graves, basedow's disease, graves' disease, graves disease, basedow disease, diseases graves, Basedow's disease, Graves' disease, Graves' disease with exophthalmos, Toxic diffuse goiter with exophthalmos, Exophthalmic goiter, Exophthalmic goitre, Toxic diffuse goitre with exophthalmos, Graves' disease (disorder), Toxic diffuse goiter with exophthalmos (disorder), Basedow's disease (disorder), Flajani, Graves, Basedow, exophthalmic; goiter, exophthalmos; goiter (etiology), exophthalmos; goiter (manifestation), goiter; exophthalmos (etiology), goiter; exophthalmos (manifestation), struma; exophthalmic, Graves' disease [Ambiguous], exophthalmic goiter, Graves' Disease, Disease, Graves, Graves disease, Basedows disease, Graves-Basedow disease</FPU_LG_English><FPU_LG_French>GOITRE EXOPHTALMIQUE, MALADIE DE GRAVES-BASEDOW, Hyperthyroïdie autoimmune, Goitre exophtalmique, Maladie de Basedow, Goitre toxique diffus, Maladie de Graves-Basedow, Maladie de Graves</FPU_LG_French><FPU_SnomedCT>237823003, 367367004, 237510004, 353295004, 55807009, 190240002, 38591003, 154655004, 267464006, 367449005</FPU_SnomedCT><FPU_DefCSP>exophthalmos occurring in association with goiter; hyperthyroidism with protrusion of the eyeballs.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secrets increased amounts of thyroid hormones. --2004</FPU_DefNCI><FPU_Name>Graves Disease</FPU_Name><FPU_DefMSH>A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).</FPU_DefMSH><FPU_Code>C0018213</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/GrvsDs.htm</FPU_URL></item><item><FPU_Page>Perioperative Corticosteroid</FPU_Page><FPU_LG_English>Preoperative hormone treatment</FPU_LG_English><FPU_LG_French>Traitement hormonal préopératoire</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Therapeutic or Preventive Procedure (T061)
</FPU_Concepts><FPU_Concepts_Codes>T061</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Preoperative hormone treatment</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1535921</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Surgery/PrprtvCrtcstrd.htm</FPU_URL></item><item><FPU_Page>Goiter</FPU_Page><FPU_LG_English>Enlarged thyroid gland, GOITER, GOITRE, THYROID ENLARGED, THYROID ENLARGEMENT, THYROMEGALY, Goiter, NOS, Goitre, NOS, Goiter NOS, Goiter, unspecified, Goitre NOS, Goiter (excl T85 T86), Goiter (excluding T85 T86), thyromegaly, Goitre (disorder), enlargement under Adam's apple (symptom), enlargement under Adam's apple, goiter, Goiter, Enlarged thyroid, Thyroid enlarged, Goitre, unspecified, THYROID GOITER, Goiter NOS (disorder), Goiter [Disease/Finding], enlargement of thyroid, swelling thyroid gland, Enlarged;thyroid, Enlargement;thyroid, goiter thyroid, thyroid goiter, Struma, enlarged thyroid gland, goitres, goiters, thyroid gland swelling, Thyromegaly, Enlargement of thyroid, Struma of thyroid, Goitre, Struma - goiter, Struma - goitre, Swelling of thyroid gland, Thyroid enlargement, Goiter (disorder), enlargement; thyroid, struma, thyroid; enlargement, Goiters, enlarged thyroid, goitre, thyroid enlargement</FPU_LG_English><FPU_LG_French>GOITRE, Goitre, non précisé, Hypertrophie thyroïdienne, Goitre non précisé, Thyromégalie, AUGMENTATION VOLUME THYROIDE, Goitre (SF T85 T86), Goitre</FPU_LG_French><FPU_SnomedCT>237568003, 267370001, 3716002, 190235005, 190232008</FPU_SnomedCT><FPU_DefCSP>enlargement of the thyroid gland.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Enlargement of the thyroid gland usually caused by lack of iodine in the diet, hyperthyroidism, or thyroid nodules. Symptoms include difficulty in breathing and swallowing. An enlarged thyroid. It may be caused by too little iodine in the diet or by other conditions. Most goiters are not cancer.</FPU_DefNCI><FPU_Name>Goiter</FPU_Name><FPU_DefMSH>Enlargement of the THYROID GLAND that may increase from about 20 grams to hundreds of grams in human adults. Goiter is observed in individuals with normal thyroid function (euthyroidism), thyroid deficiency (HYPOTHYROIDISM), or hormone overproduction (HYPERTHYROIDISM). Goiter may be congenital or acquired, sporadic or endemic (GOITER, ENDEMIC).</FPU_DefMSH><FPU_Code>C0018021</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Gtr.htm</FPU_URL></item><item><FPU_Page>Goiter</FPU_Page><FPU_LG_English>GOITER, COLLOID, Goiter, colloid, Non-tox diffus colloid goiter, Non-tox diffus colloid goitre, Diffuse (colloid) nontoxic goiter, colloid goitre, colloid goiter, goiter colloid, Colloid goiter, Colloid goitre, Non-toxic diffuse colloid goiter, Non-toxic diffuse colloid goitre, Non-toxic colloid goiter, Non-toxic colloid goitre, Colloid goiter (disorder), nontoxic; goiter, diffuse (colloid), struma; nontoxic, diffuse (colloid)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>61037007, 190234009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Colloid goiter</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0221268</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Gtr.htm</FPU_URL></item><item><FPU_Page>Goiter</FPU_Page><FPU_LG_English>Endemic Goiters, Goiter, Endemic, Goiters, Endemic, Goiter, specified as simple, GOITER ENDEMIC, Goiter, endemic, Iodine goiter, Endemic goiter, Endemic goiter - iodine defic, Endemic goitre - iodine defic, Iod-def-rel (endm) goit,uns, Iod-def-reltd df(endemic)goitr, Iodine-deficiency-related (endemic) goiter, unspecified, Iodine-deficiency-related (endemic) goitre, unspecified, [X]Iod-def-rel (endm) goit,uns, [X]Iodine-deficiency-related (endemic) goiter, unspecified, [X]Iodine-deficiency-related (endemic) goitre, unspecified, simple goiter (diagnosis), iodine deficient endemic goiter, iodine deficient endemic goiter (diagnosis), simple goiter, [X]Iodine-deficiency-related (endemic) goitre, unspecified (disorder), Iodine-deficiency-related endemic goitre (disorder), Goitre, specified as simple, [X]Iodine-deficiency-related (endemic) goiter, unspecified (disorder), Endemic goiter NOS, Iodine-deficiency related diffuse (endemic) goiter, Iodine-deficiency related (endemic) goiter, unspecified, Goiter, Endemic [Disease/Finding], endemic goiter, goiters iodine, iodine goiter, endemic goitre, Simple goiter, Simple iodine deficiency goiter, Endemic goitre, Iodine-deficiency-related diffuse (endemic) goiter, Iodine-deficiency-related diffuse (endemic) goitre, Simple goitre, Simple iodine deficiency goitre, Iodine-deficiency-related endemic goiter, Iodine-deficiency-related endemic goitre, Endemic goiter (disorder), Iodine-deficiency-related endemic goiter (disorder), Simple goiter (disorder), endemic; goiter, iodine-deficiency; goiter (endemic), simple; goiter, struma; endemic, struma; iodine-deficiency (endemic), struma; simple, Simple Goiter, Endemic Goiter</FPU_LG_English><FPU_LG_French>Goitre, précisé simple, Goitre simple, Goitre endémique</FPU_LG_French><FPU_SnomedCT>190319000, 190316007, 191043000, 267369002, 56805008, 271949009, 190234009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Endemic goiter</FPU_Name><FPU_DefMSH>A form of IODINE deficiency disorders characterized by an enlargement of the THYROID GLAND in a significantly large fraction of a POPULATION GROUP. Endemic goiter is common in mountainous and iodine-deficient areas of the world where the DIET contains insufficient amount of iodine.</FPU_DefMSH><FPU_Code>C0018022</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Gtr.htm</FPU_URL></item><item><FPU_Page>Gynecomastia</FPU_Page><FPU_LG_English>GYNECOMASTIA, FAMILIAL</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>GYNECOMASTIA, FAMILIAL</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1844375</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sx/Gyncmst.htm</FPU_URL></item><item><FPU_Page>Gynecomastia</FPU_Page><FPU_LG_English>BREAST ENLARGEMENT MALE, ENLARGEMENT BREAST MALE, GYNAECOMASTIA, GYNECOMASTIA, Gynecomastia, Breast enlargement male, Enlargement breast male, Gynecomastia [Disease/Finding], male breast enlargement, Gynaecomastia, Hypertrophy of male breast, Gynaecomazia, Gynecomazia, Gynecomastia (disorder), gynecomastia, Breast Enlargement, Male, Enlargement, Male Breast, Male Breast Enlargement, gynaecomastia</FPU_LG_English><FPU_LG_French>GYNECOMASTIE, Augmentation du volume mammaire chez l'homme, AUGM VOLUME SEIN CHEZ L'HOMME, Gynécomastie</FPU_LG_French><FPU_SnomedCT>4754008, 155963008, 198112004, 266646002</FPU_SnomedCT><FPU_DefCSP>female mammary morphology in a XY genotype.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A disorder characterized by excessive development of the breasts in males. Excessive development of the breasts in males; usually the result of hormonal imbalance or treatment with certain drugs.</FPU_DefNCI><FPU_Name>Gynecomastia</FPU_Name><FPU_DefMSH>Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.</FPU_DefMSH><FPU_Code>C0018418</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sx/Gyncmst.htm</FPU_URL></item><item><FPU_Page>Night Sweats</FPU_Page><FPU_LG_English>NIGHT SWEAT, NIGHT SWEATS, sweating heavily at night, night sweats, sweating heavily at night (symptom), Night Sweating, Night Sweats, Night sweat, night sweat, nights sweats, Nocturnal perspiration, Night sweats, Night sweats (finding), nocturnal; sweating, sweat; night sweats, sweating; night, Problem;sweating;night</FPU_LG_English><FPU_LG_French>Transpiration nocturne, Sueurs nocturnes</FPU_LG_French><FPU_SnomedCT>42984000, 139115006, 161859009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Sign or Symptom (T184)
</FPU_Concepts><FPU_Concepts_Codes>T184</FPU_Concepts_Codes><FPU_DefNCI>Nocturnal periods of profuse diaphoresis.</FPU_DefNCI><FPU_Name>Night sweats</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0028081</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sx/NghtSwts.htm</FPU_URL></item><item><FPU_Page>Internal Hernia</FPU_Page><FPU_LG_English>Abdominal Hernia, Hernia of abdominal cavity, HERNIA, INTERNAL, Hernia, abdominal, HERNIAS OF THE ABDOMINAL CAVITY, Hernia of abdominal cavity, NOS, Intra-abdominal hernia, NOS, Abdominal cavity hernia NOS, Unsp.abd.cavity hernia NOS, Unspecified abdominal cavity hernia NOS, abdominal hernia, hernia of abdominal cavity, abdominal hernia (physical finding), abdomen hernia, SECTION 5-6 HERNIAS OF THE ABDOMINAL CAVITY, intra-abdominal hernia, intra-abdominal hernia (diagnosis), Abdominal cavity hernia NOS (disorder), Abdominal hernia NOS, Abdominal herniation, Unspecified abdominal cavity hernia NOS (disorder), Unspecified abdominal hernia, Hernia, Abdominal [Disease/Finding], hernia abdominal, internal hernia, intraperitoneal hernia, abdominal hernias, abdominal herniation, Abdominal hernia, Internal hernia, Hernia of abdominal cavity (disorder), Intra-abdominal hernia (disorder), Intra-abdominal hernia, Intraperitoneal hernia, hernia; abdominal, Hernia of abdominal cavity [Ambiguous], Abdominal Hernias, Hernia, Abdominal, Hernias, Abdominal, HERNIA OF ABDOMINAL CAVITY</FPU_LG_English><FPU_LG_French>Hernie abdominale SAI, Hernie interne, Hernie abdominale, Hernie de la paroi abdominale, Laparocèle</FPU_LG_French><FPU_SnomedCT>155758000, 155737006, 196799009, 196968002, 196973008, 52515009, 30477007, 359801000, 6515007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
, Anatomical Abnormality (T190)
</FPU_Concepts><FPU_Concepts_Codes>T047 T190</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hernia of abdominal cavity</FPU_Name><FPU_DefMSH>A protrusion of abdominal structures through the retaining ABDOMINAL WALL. It involves two parts: an opening in the abdominal wall, and a hernia sac consisting of PERITONEUM and abdominal contents. Abdominal hernias include groin hernia (HERNIA, FEMORAL; HERNIA, INGUINAL) and VENTRAL HERNIA.</FPU_DefMSH><FPU_Code>C0178282</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Surgery/IntrnlHrn.htm</FPU_URL></item><item><FPU_Page>Myxedema Coma</FPU_Page><FPU_LG_English>MYXEDEMA COMA, Myxoedema coma (disorder), myxedema coma, myxedema coma (diagnosis), Myxedema coma, Hypothyroid coma, Myxoedema coma, Myxedema coma (disorder), coma; myxedema, myxedema; coma</FPU_LG_English><FPU_LG_French>Coma de myxoedème, Coma myxoedèmateux</FPU_LG_French><FPU_SnomedCT>190292006, 21263006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Myxedema coma</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0238298</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/MyxdmCm.htm</FPU_URL></item><item><FPU_Page>Obesity Surgery</FPU_Page><FPU_LG_English>Bilio Pancreatic Bypass, Bilio Pancreatic Bypasses, Bilio Pancreatic Diversion, Bilio Pancreatic Diversions, Bilio-Pancreatic Bypass, Bilio-Pancreatic Bypasses, Bilio-Pancreatic Diversion, Bilio-Pancreatic Diversions, Biliopancreatic Bypass, Biliopancreatic Bypasses, Biliopancreatic Diversion, Biliopancreatic Diversions, Bypass, Bilio-Pancreatic, Bypass, Biliopancreatic, Bypasses, Bilio Pancreatic, Bypasses, Bilio-Pancreatic, Bypasses, Biliopancreatic, Diversion, Bilio Pancreatic, Diversion, Bilio-Pancreatic, Diversions, Bilio Pancreatic, Diversions, Bilio-Pancreatic, Diversions, Biliopancreatic, Pancreatic Bypasses, Bilio, Pancreatic Diversion, Bilio, Pancreatic Diversions, Bilio, biliopancreatic bypass, biliopancreatic diversion, Biliopancreatic bypass</FPU_LG_English><FPU_LG_French>Court-circuit biliopancréatique, Bypass biliopancréatique, Bypass bilio-pancréatique, Dérivation bilio-pancréatique, DBP (Dérivation BilioPancréatique), Dérivation biliopancréatique</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Therapeutic or Preventive Procedure (T061)
</FPU_Concepts><FPU_Concepts_Codes>T061</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Biliopancreatic Diversion</FPU_Name><FPU_DefMSH>A surgical procedure which diverts pancreatobiliary secretions via the duodenum and the jejunum into the colon, the remaining small intestine being anastomosed to the stomach after antrectomy. The procedure produces less diarrhea than does jejunoileal bypass.</FPU_DefMSH><FPU_Code>C0005435</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Surgery/ObstySrgry.htm</FPU_URL></item><item><FPU_Page>Obesity Surgery</FPU_Page><FPU_LG_English>Gastroplasties, Gastroplasty, Gastroplasty, NOS, gastroplasty, Plastic repair with reconstruction of stomach, Gastroplasty (procedure), GP - Gastroplasty, Plastic repair with reconstruction of stomach (procedure)</FPU_LG_English><FPU_LG_French>Gastroplastie</FPU_LG_French><FPU_SnomedCT>9429009, 149361001, 149355004, 265867007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Therapeutic or Preventive Procedure (T061)
</FPU_Concepts><FPU_Concepts_Codes>T061</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Gastroplasty</FPU_Name><FPU_DefMSH>Surgical procedures involving the STOMACH and sometimes the lower ESOPHAGUS to correct anatomical defects, or to treat MORBID OBESITY by reducing the size of the stomach. There are several subtypes of bariatric gastroplasty, such as vertical banded gastroplasty, silicone ring vertical gastroplasty, and horizontal banded gastroplasty.</FPU_DefMSH><FPU_Code>C0017193</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Surgery/ObstySrgry.htm</FPU_URL></item><item><FPU_Page>Obesity Surgery</FPU_Page><FPU_LG_English>Bariatric surgery, Weight Loss Surgery, Gastrointestinal Bariatric Surgery, Bariatric Surgery, Bariatric Surgeries, Surgeries, Bariatric, Surgery, Bariatric, weight loss surgery, bariatric surgery</FPU_LG_English><FPU_LG_French>Chirurgie bariatrique, Chirurgie baryatrique, Chirurgie de l'obésité</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP>surgical treatment of obesity.</FPU_DefCSP><FPU_Concepts>Therapeutic or Preventive Procedure (T061)
</FPU_Concepts><FPU_Concepts_Codes>T061</FPU_Concepts_Codes><FPU_DefNCI>Surgery performed in morbidly obese patients to help promote weight loss. The procedure aims at the reduction of the stomach size and it is usually achieved either with the implantation of a medical device or the removal of part of the stomach.</FPU_DefNCI><FPU_Name>Bariatric Surgery</FPU_Name><FPU_DefMSH>Surgical procedures aimed at producing major WEIGHT REDUCTION in patients with MORBID OBESITY.</FPU_DefMSH><FPU_Code>C1456587</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Surgery/ObstySrgry.htm</FPU_URL></item><item><FPU_Page>Turner's Syndrome</FPU_Page><FPU_LG_English>Turner's Syndrome, DWARFISM, OVARIAN, TURNER SYNDROME, TURNER'S SYNDROME, TURNER-VARNY SYNDROME, ULLRICH-TURNER SYNDROME, Ullrich-Turner syndrome, XO SYNDROME, Turner syndrome, NOS, Turner's syndrome NOS, Karyotype 45,X, Turner's syndrome, unspecified, monosomy X syndrome, Karyotype 45, X (disorder), Turner's syndrome (diagnosis), Primary ovarian insufficiency, XO genotype, Turner Syndrome, Morgagni-Turner-Albright syndrome, Turner-Albright syndrome, chromosome XO syndrome, genital dwarfism, ovarian dwarfism, pseudonuchal infantilism, primary ovarian insufficiency, Morgagni-Turner syndrome, ovarian short stature syndrome, Shereshevskii-Turner syndrome, Turner syndrome (TS), Ullrich-Turner syndrome (UTS), Turner's syndrome NOS (disorder), Turner Syndrome (XO Syndrome), XO Syndrome, Turner Syndrome [Disease/Finding], gonadal dysgenesis, xo syndrome, bonnevie-ullrich syndrome, turner's syndrome, gonadal dysgenesis syndrome, Syndrome, Ullrich-Turner, Ullrich Turner Syndrome, Ullrich-Turner Syndrome, Pterygolymphangiectasia syndrome, XO syndrome, Turner's syndrome, 45, X syndrome, Karyotype 45, X, TS - Turner's syndrome, X0 - Turner's syndrome, 45X0 - Turner's syndrome, Turner syndrome, Turner syndrome (disorder), chromosome; anomaly, sex, Turner, Morgagni-Turner, Turner-Ullrich, Turner; sex chromosome abnormality, Turner; syndrome, X; monosomy, karyotype; 45,X, monosomy; X, syndrome; Turner, anomaly; chromosomes, chromosomal, sex, Turner, Gonadal dysgenesis - Turner, Turners Syndrome, Monosomy X, turner syndrome</FPU_LG_English><FPU_LG_French>Génotype XO, SYNDROME DE TURNER, Syndrome de Turner</FPU_LG_French><FPU_SnomedCT>205685008, 268299006, 38804009, 157020008, 268356004, 205691005</FPU_SnomedCT><FPU_DefCSP>genetic disease that produces sterile females due to monosomy for X chromosome; the ovaries are rudimentary or missing; other abnormalities include short stature, webbed neck, and a broad chest with widely spaced nipples.</FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI>A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the complete absence of one of the sex chromosomes. Signs and symptoms include short stature and hypogonadism. A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the absence of a part or all of one of the sex chromosomes. Signs and symptoms include short stature, webbing of neck, low-set ears, hypogonadism, and sterility.</FPU_DefNCI><FPU_Name>Turner Syndrome</FPU_Name><FPU_DefMSH>A syndrome of defective gonadal development in phenotypic females associated with the karyotype 45,X (or 45,XO). Patients generally are of short stature with undifferentiated GONADS (streak gonads), SEXUAL INFANTILISM, HYPOGONADISM, webbing of the neck, cubitus valgus, elevated GONADOTROPINS, decreased ESTRADIOL level in blood, and CONGENITAL HEART DEFECTS. NOONAN SYNDROME (also called Pseudo-Turner Syndrome and Male Turner Syndrome) resembles this disorder; however, it occurs in males and females with a normal karyotype and is inherited as an autosomal dominant.</FPU_DefMSH><FPU_Code>C0041408</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/TrnrsSyndrm.htm</FPU_URL></item><item><FPU_Page>Thyroid Storm</FPU_Page><FPU_LG_English>Crisis, Thyrotoxic, Storm, Thyrotoxic, Thyroid Crisis, Thyroid Storm, Thyrotoxic Crisis, Thyrotoxic Storm, CRISIS THYROID, Crisis, Thyroid, Storm, Thyroid, THYROID CRISIS, THYROID STORM, THYROTOXIC CRISIS, THYROTOXIC STORM, Hyperthyroidism with Storm, Thyroid crisis or storm, thyroid storm, THYROTOX STORM, THYROTOX CRISIS, CRISIS THYROTOX, Thyroid crisis (disorder), thyrotoxic crisis (diagnosis), thyrotoxic crisis, thyroid crisis (storm), thyrotoxic storm, Crisis thyroid, Thyroid Crisis [Disease/Finding], storm thyroid, crisis thyroid, thyrotoxic crises, thyroid crisis, thyroid storms, Thyroid storm, Thyrotoxic crisis, Thyroid crisis, Thyrotoxic crisis (disorder), crisis; thyroid, crisis; thyrotoxic, storm; thyrotoxic, thyroid; crisis, thyrotoxic; crisis, thyrotoxic; storm</FPU_LG_English><FPU_LG_French>HYPERTHYROIDIE, Crise thyroïdienne aiguë, Basedowisme aigu, Crise thyréotoxique, Crise thyrotoxique</FPU_LG_French><FPU_SnomedCT>190262002, 29028009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Thyroid Crisis</FPU_Name><FPU_DefMSH>A dangerous life-threatening hypermetabolic condition characterized by high FEVER and dysfunction of the cardiovascular, the nervous, and the gastrointestinal systems.</FPU_DefMSH><FPU_Code>C0040127</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/ThyrdStrm.htm</FPU_URL></item><item><FPU_Page>Precocious Puberty</FPU_Page><FPU_LG_English>Pubertas praecox, Puberty, Precocious, ACCELERATED SEXUAL MATURITY, PRECOCIOUS PUBERTY, PUBERTY PRECOCIOUS, SEXUAL PRECOCITY, Precocious true puberty, Sexual precocity, NOS, Premature puberty, Sexual Precocity, MATURATION SEX ACCELERATED, Precocious Puberty, precocious puberty (diagnosis), precocious puberty, (Sexual precocity NOS) or (puberty - precocious) (disorder), Maturation sex accelerated, Accelerated sexual maturation, Accelerated sexual maturity, Early puberty, Precocious puberty NOS, Puberty precocious, True precocious puberty, Puberty, Precocious [Disease/Finding], premature puberty, early puberty, precocious sexual development, puberty precocious, Puberty;precocious, sexual precocity, true precocious puberty, puberty early, Precocious puberty, Sexual precocity, Precocious sexual development, Precocious puberty (disorder), Precocious sexual development (disorder), precocious; puberty, premature; puberty, pubertas praecox, puberty; precocious, puberty; premature, (Sexual precocity NOS) or (puberty - precocious), Puberty - precocious, Sexual precocity NOS</FPU_LG_English><FPU_LG_French>PUBERTE PRECOCE, Puberté précoce SAI, Maturation sexuelle accélérée, Maturité sexuelle accélérée, Puberté précoce vraie, Puberté précoce</FPU_LG_French><FPU_SnomedCT>154716006, 267488008, 400179000, 123527003, 190575003, 190576002, 70387004</FPU_SnomedCT><FPU_DefCSP>unusually early sexual maturity.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Unusually early sexual maturity. A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys. Unusually early sexual development or maturity; premature puberty.</FPU_DefNCI><FPU_Name>Precocious Puberty</FPU_Name><FPU_DefMSH>Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.</FPU_DefMSH><FPU_Code>C0034013</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/PrcsPbrty.htm</FPU_URL></item><item><FPU_Page>Precocious Puberty Causes</FPU_Page><FPU_LG_English>Pubertas praecox, Puberty, Precocious, ACCELERATED SEXUAL MATURITY, PRECOCIOUS PUBERTY, PUBERTY PRECOCIOUS, SEXUAL PRECOCITY, Precocious true puberty, Sexual precocity, NOS, Premature puberty, Sexual Precocity, MATURATION SEX ACCELERATED, Precocious Puberty, precocious puberty (diagnosis), precocious puberty, (Sexual precocity NOS) or (puberty - precocious) (disorder), Maturation sex accelerated, Accelerated sexual maturation, Accelerated sexual maturity, Early puberty, Precocious puberty NOS, Puberty precocious, True precocious puberty, Puberty, Precocious [Disease/Finding], premature puberty, early puberty, precocious sexual development, puberty precocious, Puberty;precocious, sexual precocity, true precocious puberty, puberty early, Precocious puberty, Sexual precocity, Precocious sexual development, Precocious puberty (disorder), Precocious sexual development (disorder), precocious; puberty, premature; puberty, pubertas praecox, puberty; precocious, puberty; premature, (Sexual precocity NOS) or (puberty - precocious), Puberty - precocious, Sexual precocity NOS</FPU_LG_English><FPU_LG_French>PUBERTE PRECOCE, Puberté précoce SAI, Maturation sexuelle accélérée, Maturité sexuelle accélérée, Puberté précoce vraie, Puberté précoce</FPU_LG_French><FPU_SnomedCT>154716006, 267488008, 400179000, 123527003, 190575003, 190576002, 70387004</FPU_SnomedCT><FPU_DefCSP>unusually early sexual maturity.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Unusually early sexual maturity. A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys. Unusually early sexual development or maturity; premature puberty.</FPU_DefNCI><FPU_Name>Precocious Puberty</FPU_Name><FPU_DefMSH>Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.</FPU_DefMSH><FPU_Code>C0034013</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/PrcsPbrtyCs.htm</FPU_URL></item><item><FPU_Page>Hypogonadotropic Hypogonadism</FPU_Page><FPU_LG_English>Hypogonadotropic hypogonadism, Secondary hypogonadism, NOS, Gonadotropin deficiency syndrome, male, HYPOGONADOTROPIC HYPOGONADISM, HYPOGONADISM, ISOLATED HYPOGONADOTROPIC, Gonadotropin deficiency, hypogonadotrophic hypogonadism (diagnosis), hypogonadotrophic hypogonadism, Secondary hypogonadism (disorder), secondary testicular failure (diagnosis), secondary testicular failure, Hypogonadotrophic hypogonadism, secondary hypogonadism, hypogonadotropic hypogonadism, Gonadotrophin deficiency, Secondary hypogonadism, Hypogonadotropic hypogonadism (disorder), deficiency; gonadotropin, gonadotropin; deficiency, Secondary hypogonadism -RETIRED-, Hypogonadotropic Hypogonadism, Hypogonadism, Hypogonadotropic</FPU_LG_English><FPU_LG_French>Hypogonadisme hypogonadotrophique, Déficit gonadotrope, Hypogonadisme secondaire</FPU_LG_French><FPU_SnomedCT>67718002, 33927004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hypogonadotropic hypogonadism</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0271623</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/HypgndtrpcHypgndsm.htm</FPU_URL></item><item><FPU_Page>Kallmann's Syndrome</FPU_Page><FPU_LG_English>Syndrome, Kallmann's, Kallmann's Syndrome, Kallmanns Syndrome, Syndrome, Kallmann, HYPOGONADISM, HYPOGONADOTROPIC, WITH ANOSMIA, KALLMANN SYNDROME, OLFACTOGENITAL DYSPLASIA, Gonadotrophin defic + anosmia, KALLMANN SYNDROME 3, KAL3, HYPOGONADOTROPIC HYPOGONADISM AND ANOSMIA, de Morsier's syndrome, Kallmann Syndrome, familial hypogonadism with anosmia, Kallmann's syndrome (diagnosis), Kallmann syndrome 3, congenital anosmia-hypogonadotropic hypogonadism syndrome, hypogonadotropic hypogonadism-anosmia (HHA) syndrome, hypogonadotropic hypogonadism-anosmia syndrome, hypogonadism-anosmia syndrome, Maestre de San Juan-Kallmann-de Morsier syndrome, de Morsier-Gauthier syndrome, Mastre de San Juan-Kallmann syndrome, Maestre-Kallmann-de Morsier syndrome, Kallmann-de Morsier syndrome, de Morsier syndrome, olfacto-ethmoidohypothalamic dysplasia, olfactogenital dysplasia, olfacto-ethmoidodypothalamic dysraphia, hyposmia-hypogonadotropic hypogonadism syndrome, idiopathic hypothalamic hypogonadism, idiopathic hypothalamic hypogonadism (IHH), olfactogenital syndrome, Kallmann Syndrome [Disease/Finding], kallmans syndrome, de morsier syndrome, kallman's syndrome, kallmann syndrome, kallman syndrome, de morsiers syndrome, kallmanns syndrome, Dysplasia olfactogenitalis of De Morsier, Anosmic Hypogonadism, Hypogonadism, Anosmic, Hypogonadisms, Anosmic, Dysplasia Olfactogenitalis of De Morsier, Anosmic Hypogonadisms, Olfacto genital dysplasia, de Morsier-Kallman's syndrome, Kallmann's syndrome, Anosmia eunuchoidism, Dysplasia olfactogenitalis of de Morsier, Kallman syndrome, Kallman's syndrome, Olfactogenital dysplasia, Gonadotrophin deficiency with anosmia, Hypogonadism with anosmia, Hypogonadism with anosmia (disorder), kallmann's syndrome</FPU_LG_English><FPU_LG_French>Syndrome de De Morsier-Kallman, Syndrome de De Morsier, Dysplasie olfactogénitale, Dysplasie olfacto-génitale de De Morsier, Dysplasie olfacto-génitale de Kallmann-De Morsier, Dysplasie olfactogénitale de De Morsier, Dysplasie olfactogénitale de Kallmann-De Morsier, Syndrome de Kallmann, Syndrome de De Morsier-Kallmann, Syndrome de Kallman-De Morsier</FPU_LG_French><FPU_SnomedCT>93559003, 190559001, 33927004</FPU_SnomedCT><FPU_DefCSP>anosmia due to failure of the olfactory lobes to develop, with secondary hypogonadism due to gonadotropic hormone deficiency.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>An X-linked or autosomal dominant genetic syndrome characterized by hypogonadotropic hypogonadism and anosmia.</FPU_DefNCI><FPU_Name>Kallmann Syndrome</FPU_Name><FPU_DefMSH>A genetically heterogeneous disorder caused by hypothalamic GNRH deficiency and OLFACTORY NERVE defects. It is characterized by congenital HYPOGONADOTROPIC HYPOGONADISM and ANOSMIA, possibly with additional midline defects. It can be transmitted as an X-linked (GENETIC DISEASES, X-LINKED), an autosomal dominant, or an autosomal recessive trait.</FPU_DefMSH><FPU_Code>C0162809</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/KlmnsSyndrm.htm</FPU_URL></item><item><FPU_Page>Kallmann's Syndrome</FPU_Page><FPU_LG_English>FERTILE EUNUCH SYNDROME, Isolated lutropin deficiency (disorder), Fertile eunuch syndrome, Fertile eunuch, Isolated lutropin deficiency, fertile eunuch syndrome, fertile eunuch; syndrome, syndrome; fertile eunuch</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>8829008</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Isolated lutropin deficiency (disorder)</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0271582</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/KlmnsSyndrm.htm</FPU_URL></item><item><FPU_Page>Hypergonadotropic Hypogonadism</FPU_Page><FPU_LG_English>PRIMARY HYPOGONADISM, Primary hypogonadism, GONADAL FAILURE PRIMARY, HYPOGONADISM PRIMARY, hypergonadotropic hypogonadism, primary hypogonadism, Hypergonadotrophic hypogonadism, Hypergonadotropic hypogonadism, Primary hypogonadism (disorder), Hypergonadotropic Hypogonadism, Hypogonadism, Hypergonadotropic</FPU_LG_English><FPU_LG_French>Hypogonadisme hypergonadotrophique, Hypogonadisme primaire</FPU_LG_French><FPU_SnomedCT>370999003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Primary hypogonadism</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0948896</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/HyprgndtrpcHypgndsm.htm</FPU_URL></item><item><FPU_Page>Hypogonadism</FPU_Page><FPU_LG_English>Hypogonadism, HYPOGONADISM, Hypogonadism, NOS, Hypogonadotropism, hypogonadism (diagnosis), hypogonadism, Hypogonadism [Disease/Finding], hypogonadotropism, Hypogonadism (disorder)</FPU_LG_English><FPU_LG_French>Hypogonadisme</FPU_LG_French><FPU_SnomedCT>48130008</FPU_SnomedCT><FPU_DefCSP>condition resulting from or characterized by abnormally decreased functional activity of the gonads, with retardation of growth and sexual development.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hypogonadism</FPU_Name><FPU_DefMSH>Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).</FPU_DefMSH><FPU_Code>C0020619</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/Hypgndsm.htm</FPU_URL></item><item><FPU_Page>Male Pseudohermaphroditism</FPU_Page><FPU_LG_English>PSEUDOHERMAPHRODITISM, MALE, Pseudohermaphroditism syndrome, male, Pseudohermaphroditism male, Male pseudohermaphroditism NOS, Male Pseudohermaphroditism, Pseudohermaphroditism, Male, Male Pseudohermaphroditisms, Pseudohermaphroditisms, Male, merm, male pseudohermaphroditism, Male pseudohermaphroditism, Merms, Male pseudohermaphroditism (disorder), pseudohermaphroditism; male</FPU_LG_English><FPU_LG_French>Pseudohermaphrodisme masculin, Pseudo-hermaphrodisme masculin, Pseudo-hermaphrodisme mâle</FPU_LG_French><FPU_SnomedCT>111332007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Male Pseudohermaphroditism</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0238395</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/MlPsdhrmphrdtsm.htm</FPU_URL></item><item><FPU_Page>Klinefelter Syndrome</FPU_Page><FPU_LG_English>Syndrome, Klinefelter's, KLINEFELTER SYNDROME, KLINEFELTER'S SYNDROME, XXY SYNDROME, Klinefelter's karyotype 47,XXY, Klinefelter's syndrome NOS, Klinefelter's syndrome karyotype 47,XXY, Klinefelter's syndrome, unspecified, Klinefelter's Syndrome, XXY trisomy, seminiferous tubule dysgenesis, seminiferous tubule dysgenesis (diagnosis), XXY Klinefelter's syndrome (disorder), XXY Klinefelter's syndrome (diagnosis), XXY male, KLINEFELTER DISEASE, Klinefelter Syndrome, Klinefelter-Reifenstein-Albright syndrome, chromosome XXY syndrome, hypogonadotropic hypogonadism, primary hypogonadism, Klinefelter syndrome (KS), Klinefelter-Reifenstein syndrome, Xq Klinefelter syndrome, 47,XXY complex intersex, 47,XXY complex intersex (diagnosis), intersex complex 47,XXY, Klinefelter's syndrome NOS (disorder), Klinefelter syndrome, XXY, XXY Syndrome (Klinefelter Syndrome), Klinefelter syndrome karyotype 47, XXY, Klinefelter syndrome, unspecified, Klinefelter Syndrome [Disease/Finding], klinefelter's syndrome, XXY, Syndrome, XX Male, XX Male Syndromes, XX Male Syndrome, Syndromes, XX Male, chromosome xxy syndrome, xxy syndrome, klinefelter's syndrome, klinefelter 's syndrome, klinefelter disease, klinefelters syndrome, klinefelter's syndromes, Syndrome, XXY, XXY Syndromes, XXY Syndrome, Syndromes, XXY, Klinefelter Syndromes, Syndrome, Klinefelter, Syndromes, Klinefelter, XXY syndrome, Klinefelter's syndrome, Klinefelter syndrome, Klinefelter's syndrome karyotype 47 XXY, XXY Klinefelter's syndrome, Klinefelter's syndrome, XXY (disorder), Klinefelter's syndrome, XXY, Klinefelter, chromosome; anomaly, sex, Klinefelter, XXY; syndrome, hypogonadism; hypogonadotropic, hypogonadotropic; hypogonadism, karyotype; 47,XXY, Klinefelter, syndrome; XXY, anomaly; chromosomes, chromosomal, sex, Klinefelter, Klinefelter syndrome (disorder), Klinefelter's syndrome (disorder), Klinefelters Syndrome, Hypogonadotropic Hypogonadism, klinefelter syndrome</FPU_LG_English><FPU_LG_French>Syndrome XXY, SYNDROME DE KLINEFELTER, Syndrome de Klinefelter</FPU_LG_French><FPU_SnomedCT>205712007, 205696000, 205701007, 405769009, 22053006, 157021007, 268357008, 405770005</FPU_SnomedCT><FPU_DefCSP>genetic disease that produces sterile males with small testes lacking sperm due to XXY karyotype.</FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI>A sex chromosome disorder caused by the presence of an extra X chromosome in the male karyotype. Affected individuals are infertile and have a small penis and testes. They tend to have tall stature and long legs and may have difficulties with speech and language development. Gynecomastia may be present. A genetic disorder in males caused by having one or more extra X chromosomes. Males with this disorder may have larger than normal breasts, a lack of facial and body hair, a rounded body type, and small testicles. They may learn to speak much later than other children and may have difficulty learning to read and write. Klinefelter syndrome increases the risk of developing extragonadal germ cell tumors and breast cancer.</FPU_DefNCI><FPU_Name>Klinefelter Syndrome</FPU_Name><FPU_DefMSH>A form of male HYPOGONADISM, characterized by the presence of an extra X CHROMOSOME, small TESTES, seminiferous tubule dysgenesis, elevated levels of GONADOTROPINS, low serum TESTOSTERONE, underdeveloped secondary sex characteristics, and male infertility (INFERTILITY, MALE). Patients tend to have long legs and a slim, tall stature. GYNECOMASTIA is present in many of the patients. The classic form has the karyotype 47,XXY. Several karyotype variants include 48,XXYY; 48,XXXY; 49,XXXXY, and mosaic patterns ( 46,XY/47,XXY; 47,XXY/48,XXXY, etc.).</FPU_DefMSH><FPU_Code>C0022735</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/KlnfltrSyndrm.htm</FPU_URL></item><item><FPU_Page>Female Pseudohermaphroditism</FPU_Page><FPU_LG_English>PSEUDOHERMAPHRODITISM, FEMALE, Female Pseudohermaphroditism, Pseudohermaphroditism syndrome, female, female pseudohermaphroditism, female pseudohermaphroditism (diagnosis), Pseudohermaphroditism female, Female pseudohermaphroditism NOS, Pseudohermaphroditisms, Female, Female Pseudohermaphroditisms, Pseudohermaphroditism, Female, ferm, Female pseudohermaphroditism, Ferms, Female pseudohermaphroditism (disorder), pseudohermaphroditism; female</FPU_LG_English><FPU_LG_French>Pseudohermaphrodisme féminin, Pseudo-hermaphrodisme féminin, Pseudo-hermaphrodisme femelle</FPU_LG_French><FPU_SnomedCT>8800006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Female Pseudohermaphroditism</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0238394</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/FmlPsdhrmphrdtsm.htm</FPU_URL></item><item><FPU_Page>Benign Premature Adrenarche</FPU_Page><FPU_LG_English>precocious adrenarche (diagnosis), precocious adrenarche, Premature adrenarche (disorder), premature adrenarche, Premature adrenarche, Premature adrenarche (finding), adrenarche; premature, premature; adrenarche</FPU_LG_English><FPU_LG_French>Adrénarche précoce</FPU_LG_French><FPU_SnomedCT>190521009, 103021001, 190516006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Premature adrenarche</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0342546</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/BngnPrmtrAdrnrch.htm</FPU_URL></item><item><FPU_Page>Benign Premature Thelarche</FPU_Page><FPU_LG_English>Premature thelarche, Premature developmnt of breast, precocious breast development (symptom), premature thelarche, premature thelarche (diagnosis), precocious breast development, Premature thelarche (disorder), precocious thelarche, premature breast development, Precocious breast development, Precocious thelarche, Premature development of the breasts, Premature breast development at puberty, Premature development of the breasts (finding), precocious; thelarche, premature; thelarche, thelarche; precocious, thelarche; premature</FPU_LG_English><FPU_LG_French>Thélarche précoce</FPU_LG_French><FPU_SnomedCT>102889008, 190577006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Premature development of the breasts</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0425772</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/BngnPrmtrThlrch.htm</FPU_URL></item><item><FPU_Page>Ambiguous Genitalia</FPU_Page><FPU_LG_English>Genital ambiguity, Ambiguous Genitalia, Ambiguity, Genital, Genitalia, Ambiguous, Genital Ambiguities, Genital Ambiguity, Ambiguities, Genital, genitalia ambiguous, Ambiguous genitalia, Ambiguous genitalia (disorder), genital organs; ambiguous, ambiguous genitalia</FPU_LG_English><FPU_LG_French>Ambiguïté de l'organe génital, Ambiguïté des organes génitaux, Ambiguïté génitale, Organes génitaux ambigüs, Ambigüité des organes génitaux, Ambigüité génitale, Organe génital ambigü, Ambigüité de l'organe génital</FPU_LG_French><FPU_SnomedCT>21321009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
</FPU_Concepts><FPU_Concepts_Codes>T019</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Ambiguous Genitalia</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0266362</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/AmbgsGntl.htm</FPU_URL></item><item><FPU_Page>Pubertal Delay</FPU_Page><FPU_LG_English>Puberty, Delayed, DELAYED PUBERTY, Puberty, delayed, SEXUAL DEVELOPMENT RETARDATION, delayed puberty (diagnosis), delayed puberty, Delayed Puberty, Delayed puberty (&amp;amp; [NOS]) (disorder), PUBERTY DELAYED, Puberty, Delayed [Disease/Finding], puberty delayed, Delayed;puberty, delay puberty, Delayed puberty, Delayed sexual development, Delay in sexual development AND/OR puberty (disorder), Delay in sexual development AND/OR puberty, Delayed puberty (disorder), delayed; development, sexual, delayed; puberty, development; delayed, sexual, puberty; delayed, puberty; delay, sexual; development delayed, Delay in sexual development AND/OR puberty (finding), Delayed puberty (&amp;amp; [NOS]), Delayed puberty NOS, Puberty - delayed</FPU_LG_English><FPU_LG_French>Puberté tardive, Retard pubertaire, Puberté retardée, Retard de la puberté</FPU_LG_French><FPU_SnomedCT>154715005, 267487003, 400003000, 123526007, 39760001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Pathologic Function (T046)
</FPU_Concepts><FPU_Concepts_Codes>T046</FPU_Concepts_Codes><FPU_DefNCI>A disorder characterized by unusually late sexual maturity. Unusually late sexual maturity.</FPU_DefNCI><FPU_Name>Delayed Puberty</FPU_Name><FPU_DefMSH>The lack of development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations above the mean age at onset of PUBERTY in a population. Delayed puberty can be classified by defects in the hypothalamic LHRH pulse generator, the PITUITARY GLAND, or the GONADS. These patients will undergo spontaneous but delayed puberty whereas patients with SEXUAL INFANTILISM will not.</FPU_DefMSH><FPU_Code>C0034012</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Sex/PbrtlDly.htm</FPU_URL></item><item><FPU_Page>Diabetic Nephropathy</FPU_Page><FPU_LG_English>Diabetic Nephropathies, Nephropathies, Diabetic, Diabetes with renal manifestations, DIABETIC NEPHROPATHY, Diabetic nephropathies, Nephropathy, Diabetic, Diabetic nephropathy syndrome, Nephrotic syndrome+diabetes M., Diabetes with renal manifestations (disorder), Renal disorder associated with diabetes mellitus, diabetic nephropathy, diabetic nephropathy (diagnosis), Diabetic Kidney Problems, Diabetic nephropathy NOS, DIABETIC RENAL MANIFESTATION, NEPHROPATHY DIABETIC, Diabetic Nephropathies [Disease/Finding], diabetic nephropathi, Nephropathy;diabetic, diabetic nephropathies, nephropathy diabetic, diabetic renal disease, diabetes with renal manifestations (diagnosis), diabetes with renal manifestations, Diabetes-nephrosis syndrome, Diabetic nephropathy, Nephrotic syndrome in diabetes mellitus, Diabetic renal disease, Diabetes-nephrosis syndrome (disorder), Diabetic renal disease (disorder), Nephrotic syndrome in diabetes mellitus (disorder), diabetes; nephropathy (manifestation), diabetes; nephrosis (manifestation), nephropathy; diabetes (manifestation), nephrosis; diabetes (manifestation), Diabetes + nephropathy, Nephropathy - diabetic, Diabetic Nephropathy, Diabetic Kidney Diseases, Diabetic Kidney Disease, Kidney Disease, Diabetic, Kidney Diseases, Diabetic</FPU_LG_English><FPU_LG_French>Diabète avec manifestations rénales, Néphropathie diabétique SAI, Néphropathie diabétique, Néphropathies diabétiques, Maladie rénale diabétique</FPU_LG_French><FPU_SnomedCT>21858001, 127013003, 54181000, 197605007, 190338009, 267470000, 60009009</FPU_SnomedCT><FPU_DefCSP>kidney disease and resultant kidney function impairment due to the long standing effects of diabetes on the microvasculature (glomerulus) of the kidney; features include increased urine protein and declining kidney function.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.</FPU_DefNCI><FPU_Name>Diabetic Nephropathy</FPU_Name><FPU_DefMSH>KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.</FPU_DefMSH><FPU_Code>C0011881</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Renal/DbtcNphrpthy.htm</FPU_URL></item><item><FPU_Page>Thyroiditis</FPU_Page><FPU_LG_English>Acute Thyroiditis, Acute thyroiditis NOS, acute thyroiditis, acute thyroiditis (diagnosis), Thyroiditis acute, THYROIDITIS ACUTE, Acute thyroiditis NOS (disorder), thyroiditis acute, Acute thyroiditis, Acute thyroiditis (disorder), acute; thyroiditis, thyroiditis; acute</FPU_LG_English><FPU_LG_French>Thyroïdite aiguë</FPU_LG_French><FPU_SnomedCT>154665005, 190295008, 190293001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Acute thyroiditis</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0001360</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Thyrdts.htm</FPU_URL></item><item><FPU_Page>Thyroiditis</FPU_Page><FPU_LG_English>Thyroiditides, THYROIDITIS, Thyroiditis, NOS, Thyroiditis NOS, Thyroiditis, unspecified, Thyroiditis, thyroiditis, thyroiditis (diagnosis), Thyroiditis NOS (disorder), Thyroiditis [Disease/Finding], unspecified thyroiditis, Thyroiditis (disorder)</FPU_LG_English><FPU_LG_French>THYROIDITE, Thyroïdite SAI, Thyroïdite, non précisée, Thyroïdite</FPU_LG_French><FPU_SnomedCT>154664009, 154668007, 190301009, 82119001</FPU_SnomedCT><FPU_DefCSP>inflammation of the thyroid gland.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Inflammation of the thyroid gland. Thyroiditis may be an autoimmune disease that affects the thyroid gland over time, causing hypothyroidism (too little thyroid hormone). A temporary form of thyroiditis may also occur after the birth of a baby, or when viral or bacterial infections spread to the thyroid.</FPU_DefNCI><FPU_Name>Thyroiditis</FPU_Name><FPU_DefMSH>Inflammatory diseases of the THYROID GLAND. Thyroiditis can be classified into acute (THYROIDITIS, SUPPURATIVE), subacute (granulomatous and lymphocytic), chronic fibrous (Riedel's), chronic lymphocytic (HASHIMOTO DISEASE), transient (POSTPARTUM THYROIDITIS), and other AUTOIMMUNE THYROIDITIS subtypes.</FPU_DefMSH><FPU_Code>C0040147</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Thyroid/Thyrdts.htm</FPU_URL></item><item><FPU_Page>Adrenal Mass</FPU_Page><FPU_LG_English>ADRENAL MASS, Mass of adrenal gland, adrenal masses, mass adrenal, Adrenal mass, Adrenal Mass, Mass;adrenal, adrenal mass, Mass of adrenal gland (finding), Adrenal mass (disorder)</FPU_LG_English><FPU_LG_French>Masse de la glande surrénale</FPU_LG_French><FPU_SnomedCT>237783006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Adrenal mass</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0342500</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Rad/AdrnlMs.htm</FPU_URL></item><item><FPU_Page>Hyperprolactinemia</FPU_Page><FPU_LG_English>Hyperprolactinemias, HYPERPROLACTINAEMIA, HYPERPROLACTINEMIA, Hyperprolactinaemia, NOS, Hyperprolactinemia, NOS, INAPPROPRIATE PROLACTIN SECRET SYNDROME, PROLACTIN HYPERSECRET SYNDROME, INAPPROPRIATE PROLACTIN SECRET, PROLACTIN INAPPROPRIATE SECRET, hyperprolactinemia (diagnosis), hyperprolactinemia, Idiopathic hyperprolactinemia (disorder), Idiopathic hyperprolactinemia [dup], Idiopathic hyperprolactinemia, Hyperprolactinaemia (disorder), Hyperprolactinemia, Hypersecretion Syndrome, Prolactin, Prolactin Hypersecretion Syndrome, Syndrome, Prolactin Hypersecretion, Inappropriate Prolactin Secretion, Inappropriate Secretion Prolactin, Prolactin Secretion, Inappropriate, Prolactin, Inappropriate Secretion, Secretion Prolactin, Inappropriate, Secretion, Inappropriate Prolactin, Inappropriate Prolactin Secretion Syndrome, Hyperprolactinemia [Disease/Finding], Hyperprolactinaemia, Hyperprolactinemia (disorder), hyperprolactinaemia</FPU_LG_English><FPU_LG_French>HYPERPROLACTINEMIE, Hyperprolactinémie, Syndrome de sécrétion inappropriée d'hormone lutéotrope, Syndrome de sécrétion inappropriée de LTH, Syndrome de sécrétion inappropriée de PRL, Syndrome de sécrétion inappropriée de prolactine</FPU_LG_French><FPU_SnomedCT>367422005, 190468001, 237662005, 21170004</FPU_SnomedCT><FPU_DefCSP>increased levels of prolactin in the blood, which may be associated with amenorrhea and galactorrhea; relatively common etiologies include prolactinoma, medication effect, kidney failure, granulomatous diseases of the pituitary gland, and disorders which interfere with the hypothalamic inhibition of prolactin release; ectopic (non-pituitary) production of prolactin may also occur.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hyperprolactinemia</FPU_Name><FPU_DefMSH>Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)</FPU_DefMSH><FPU_Code>C0020514</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pituitary/Hyprprlctnm.htm</FPU_URL></item><item><FPU_Page>Prolactinoma</FPU_Page><FPU_LG_English>Adenoma, Prolactin-Secreting, Pituitary, Pituitary Adenoma, PRL-Secreting, Pituitary Adenoma, Prolactin-Producing, Pituitary Adenoma, Prolactin-Secreting, Pituitary Adenomas, PRL-Secreting, Pituitary Adenomas, Prolactin-Producing, Pituitary Adenomas, Prolactin-Secreting, PRL Secreting Pituitary Adenoma, PRL-Secreting Pituitary Adenoma, PRL-Secreting Pituitary Adenomas, Prolactin-Producing Pituitary Adenoma, Prolactin-Producing Pituitary Adenomas, Prolactin-Secreting Pituitary Adenomas, Prolactinomas, PITUITARY ADENOMA, PROLACTIN SECRETING, PROLACTINOMA, Pituitary Adenoma, Prolactin Secreting, PITUITARY NEOPLASM (PROLACTINOMA), Prolactin Producing Pituitary Gland Adenoma, Prolactin Secreting Pituitary Gland Adenoma, PRL Producing Pituitary Gland Adenoma, prolactinoma, prolactinoma of pituitary gland (diagnosis), prolactinoma of pituitary gland, pituitary prolactinoma, Prolactin-secret pit adenoma, PITUITARY PROLACTINOMA, PROLACTINOMA, FAMILIAL, PITUITARY ADENOMA, PROLACTIN-SECRETING, Prolactinoma, Prolactinoma [Disease/Finding], prolactinomas, adenoma prolactin secreting, pituitary prolactinomas, [M] Prolactinoma, Prolactinoma (morphologic abnormality), [M]Prolactinoma, Prolactin-secreting pituitary adenoma, Prolactinoma (disorder), prolactin secreting adenoma, adenoma, prolactin secreting, prolactinoma; unspecified site, Prolactin Producing Pituitary Adenoma, Prolactin Secreting Pituitary Adenoma, Pituitary Gland Prolactinoma, Pituitary Prolactinoma, Prolactin Producing Adenoma of Pituitary Gland, Prolactin Producing Adenoma of Pituitary, Prolactin Producing Adenoma of the Pituitary Gland, Prolactin Producing Adenoma of the Pituitary, Prolactin Secreting Adenoma of Pituitary Gland, Prolactin Secreting Adenoma of Pituitary, Prolactin Secreting Adenoma of the Pituitary Gland, Prolactin Secreting Adenoma of the Pituitary, Prolactin Secreting Adenoma, Prolactinoma of Pituitary Gland, Prolactinoma of Pituitary, Prolactinoma of the Pituitary Gland, Prolactinoma of the Pituitary, Prolactin-Secreting Pituitary Adenoma, Lactotroph Adenomas, Lactotroph Adenoma, Adenoma, Lactotroph, Adenomas, Lactotroph</FPU_LG_English><FPU_LG_French>Prolactinome, Adénome lactotrope, Adénome à prolactine, Adénome hypophysaire sécrétant la PRL, Adénome hypophysaire sécrétant la prolactine</FPU_LG_French><FPU_SnomedCT>367098005, 34337008, 134209002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Neoplastic Process (T191)
</FPU_Concepts><FPU_Concepts_Codes>T191</FPU_Concepts_Codes><FPU_DefNCI>An adenoma of the anterior lobe of the pituitary gland that produces prolactin. It is the most common type of pituitary gland adenomas and it is associated with hyperprolactinemia. Clinical manifestations include amenorrhea, galactorrhea, impotence, headache, and visual disturbances.</FPU_DefNCI><FPU_Name>Prolactinoma</FPU_Name><FPU_DefMSH>A pituitary adenoma which secretes PROLACTIN, leading to HYPERPROLACTINEMIA. Clinical manifestations include AMENORRHEA; GALACTORRHEA; IMPOTENCE; HEADACHE; visual disturbances; and CEREBROSPINAL FLUID RHINORRHEA.</FPU_DefMSH><FPU_Code>C0033375</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pituitary/Prlctnm.htm</FPU_URL></item><item><FPU_Page>Carbohydrate Count</FPU_Page><FPU_LG_English>Carbohydrate counting (regime/therapy), Carbohydrate counting</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>416576000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Health Care Activity (T058)
</FPU_Concepts><FPU_Concepts_Codes>T058</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Carbohydrate counting</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1562940</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Prevent/CrbhydrtCnt.htm</FPU_URL></item><item><FPU_Page>Variable Rate Insulin Infusion</FPU_Page><FPU_LG_English>Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin</FPU_LG_English><FPU_LG_French>Insuline ordinaire, Insuline</FPU_LG_French><FPU_SnomedCT>67866001, 39487003, 412222002</FPU_SnomedCT><FPU_DefCSP>protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04) Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.</FPU_DefNCI><FPU_Name>Insulin</FPU_Name><FPU_DefMSH>A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).</FPU_DefMSH><FPU_Code>C0021641</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/VrblRtInslnInfsn.htm</FPU_URL></item><item><FPU_Page>Acromegaly</FPU_Page><FPU_LG_English>Eosinophilic adenoma syndrome, Marie's syndrome, ACROMEGALY, SOMATOTROPIN HYPERSECRET SYNDROME ACROMEGALY, INAPPROPRIATE GROWTH HORMONE SECRET SYNDROME ACROMEGALY, INAPPROPRIATE GH SECRET SYNDROME ACROMEGALY, acromegaly (diagnosis), acromegaly, Inappropriate GH Secretion Syndrome (Acromegaly), Inappropriate Growth Hormone Secretion Syndrome (Acromegaly), Somatotropin Hypersecretion Syndrome (Acromegaly), Acromegaly [Disease/Finding], acromegalia, acromegali, marie disease, Hypersecretion Syndrome, Somatotropin (Acromegaly), Hypersecretion Syndromes, Somatotropin (Acromegaly), Somatotropin Hypersecretion Syndromes (Acromegaly), Syndrome, Somatotropin Hypersecretion (Acromegaly), Syndromes, Somatotropin Hypersecretion (Acromegaly), Acromegalia, Anterior pituitary adenoma syndrome, Growth hormone hypersecretion syndrome, Marie disease, STH hypersecretion syndrome, Acromegaly (disorder), Acromegaly</FPU_LG_English><FPU_LG_French>ACROMEGALIE, Acromégalie, Syndrome d'hypersécrétion d'hormone somatotrope (Acromégalie), Syndrome de sécrétion inappropriée d'hormone de croissance (Acromégalie), Syndrome de sécrétion inappropriée de GH (Acromégalie)</FPU_LG_French><FPU_SnomedCT>74107003, 154698000, 267480001</FPU_SnomedCT><FPU_DefCSP>disorder caused by excessive secretion of somatotropin, characterized by bony enlargement of face, hands, feet, head and thorax.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A syndrome characterized by enlargement of the hands, feet, ears, nose, lips, and tongue, skin thickening and swelling of internal organs. It is caused by overproduction of growth hormone in the pituitary gland, usually by a pituitary adenoma. A condition in which the pituitary gland makes too much growth hormone after normal growth of the skeleton is finished. This causes the bones of the hands, feet, head, and face to grow larger than normal. Acromegaly can be caused by a pituitary gland tumor.</FPU_DefNCI><FPU_Name>Acromegaly</FPU_Name><FPU_DefMSH>A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)</FPU_DefMSH><FPU_Code>C0001206</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pituitary/Acrmgly.htm</FPU_URL></item><item><FPU_Page>Gigantism</FPU_Page><FPU_LG_English>Gigantism, GIGANTISM, GIGANTISM, PITUITARY, Giant, NOS, Giant, genetic, Giantism, NOS, Gigantism, NOS, Gigantosoma, gigantism (diagnosis), gigantism, gigantism (physical finding), Giant (disorder), gigantism was noted, Gigantism [Disease/Finding], giant, giantism, gigantism disorder, genetics giant, giants, Giant, Pituitary gigantism, Genetic giant, Normal giant, Primordial giant, Disorders with tall stature (disorder), Disorders with tall stature, Giantism, Gigantism (disorder), gigantism; pituitary, pituitary; gigantism, Giant -RETIRED-, Gigantism, Pituitary, Pituitary Gigantism</FPU_LG_English><FPU_LG_French>GIGANTISME, Gigantisme, Gigantisme hypophysaire</FPU_LG_French><FPU_SnomedCT>123111004, 80849007, 86073008, 363094008, 154698000, 267480001</FPU_SnomedCT><FPU_DefCSP>condition of abnormal overgrowth or excessive size of the whole body or any of its parts.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A clinical finding indicating abnormal and excessive body growth and height resulting from the overproduction of human growth hormone. A condition in which the whole body or any of its parts grow much larger than normal.</FPU_DefNCI><FPU_Name>Gigantism</FPU_Name><FPU_DefMSH>The condition of accelerated and excessive GROWTH in children or adolescents who are exposed to excess HUMAN GROWTH HORMONE before the closure of EPIPHYSES. It is usually caused by somatotroph hyperplasia or a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.</FPU_DefMSH><FPU_Code>C0017547</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pituitary/Ggntsm.htm</FPU_URL></item><item><FPU_Page>Hyperprolactinemia Causes</FPU_Page><FPU_LG_English>Hyperprolactinemias, HYPERPROLACTINAEMIA, HYPERPROLACTINEMIA, Hyperprolactinaemia, NOS, Hyperprolactinemia, NOS, INAPPROPRIATE PROLACTIN SECRET SYNDROME, PROLACTIN HYPERSECRET SYNDROME, INAPPROPRIATE PROLACTIN SECRET, PROLACTIN INAPPROPRIATE SECRET, hyperprolactinemia (diagnosis), hyperprolactinemia, Idiopathic hyperprolactinemia (disorder), Idiopathic hyperprolactinemia [dup], Idiopathic hyperprolactinemia, Hyperprolactinaemia (disorder), Hyperprolactinemia, Hypersecretion Syndrome, Prolactin, Prolactin Hypersecretion Syndrome, Syndrome, Prolactin Hypersecretion, Inappropriate Prolactin Secretion, Inappropriate Secretion Prolactin, Prolactin Secretion, Inappropriate, Prolactin, Inappropriate Secretion, Secretion Prolactin, Inappropriate, Secretion, Inappropriate Prolactin, Inappropriate Prolactin Secretion Syndrome, Hyperprolactinemia [Disease/Finding], Hyperprolactinaemia, Hyperprolactinemia (disorder), hyperprolactinaemia</FPU_LG_English><FPU_LG_French>HYPERPROLACTINEMIE, Hyperprolactinémie, Syndrome de sécrétion inappropriée d'hormone lutéotrope, Syndrome de sécrétion inappropriée de LTH, Syndrome de sécrétion inappropriée de PRL, Syndrome de sécrétion inappropriée de prolactine</FPU_LG_French><FPU_SnomedCT>367422005, 190468001, 237662005, 21170004</FPU_SnomedCT><FPU_DefCSP>increased levels of prolactin in the blood, which may be associated with amenorrhea and galactorrhea; relatively common etiologies include prolactinoma, medication effect, kidney failure, granulomatous diseases of the pituitary gland, and disorders which interfere with the hypothalamic inhibition of prolactin release; ectopic (non-pituitary) production of prolactin may also occur.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hyperprolactinemia</FPU_Name><FPU_DefMSH>Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)</FPU_DefMSH><FPU_Code>C0020514</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pituitary/HyprprlctnmCs.htm</FPU_URL></item><item><FPU_Page>Hyperprolactinemia Causes</FPU_Page><FPU_LG_English>Galactorrhea, LACTATION PUERPERAL INCREASED, Galactorrhea associated with childbirth, Galactorrhoea, Lactation puerperal increased, Galactorrhea preg-unspec, galactorrhoea, Persistent secretion of milk associated with childbirth, Polygalactia, Increased postpartum lactation, Increased puerperal lactation, Galactorrhea associated with childbirth (disorder), Galactorrhoea associated with childbirth, Polygalactia (disorder), galactorrhea, Galactorrhea associated with childbirth, unspecified as to episode of care</FPU_LG_English><FPU_LG_French>Galactorrhée associée à l'accouchement, épisode de soins non précisé, LACTATION PUERPERALE EXCESSIVE, Hypersécrétion lactée puerpérale</FPU_LG_French><FPU_SnomedCT>71639005, 65377004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Galactorrhea associated with childbirth</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0269995</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pituitary/HyprprlctnmCs.htm</FPU_URL></item><item><FPU_Page>Sitagliptin</FPU_Page><FPU_LG_English>Januvia</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Januvia</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1702177</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Stglptn.htm</FPU_URL></item><item><FPU_Page>Sitagliptin</FPU_Page><FPU_LG_English>4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine, sitagliptin, Sitagliptin (product), Sitagliptin, Sitagliptin (substance), SITAGLIPTIN, sitagliptin [Chemical/Ingredient], sitaGLIPtin</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>424106006, 423307000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>sitagliptin</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1565750</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Stglptn.htm</FPU_URL></item><item><FPU_Page>Symlin</FPU_Page><FPU_LG_English>pramlintide, PRAMLINTIDE, Pramlintide, pramlintide [Chemical/Ingredient], Pramlintide (product), Pramlintide (substance)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>416392006, 416425000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A synthetic analogue of the hormone amylin with antidiabetic activities. Upon administration, pramlintide mimics the actions of the naturally occurring amylin (islet amyloid polypeptide), a hormone that is produced by the beta cells of the pancreas and helps regulate blood glucose levels by 1) Inhibiting glucagon secretion; 2) Decreasing the rate of gastric emptying and 3) Suppressing appetite. Production of amylin is absent or decreased in patients with diabetes type I or II, respectively.</FPU_DefNCI><FPU_Name>Pramlintide</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0537551</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Symln.htm</FPU_URL></item><item><FPU_Page>Symlin</FPU_Page><FPU_LG_English>Symlin, Amylin Pharmaceuticals brand of pramlintide acetate</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Symlin</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1174780</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Symln.htm</FPU_URL></item><item><FPU_Page>Thiazolidinedione</FPU_Page><FPU_LG_English>Actos, pioglitazone (Actos), actos, acto, Eli Lilly brand of pioglitazone hydrochloride, Takeda brand of pioglitazone hydrochloride</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A drug that is used to treat type 2 diabetes and is being studied in the prevention of head and neck cancer. It may be able to stop leukoplakia (a condition affecting the mouth ) from developing into cancer. It is a type of thiazolidinedione.</FPU_DefNCI><FPU_Name>Actos</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0875954</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Thzldndn.htm</FPU_URL></item><item><FPU_Page>Thiazolidinedione</FPU_Page><FPU_LG_English>5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione, pioglitazone, pioglitazone [Chemical/Ingredient], Pioglitazone (product), Pioglitazone (substance), Pioglitazone, PIOGLITAZONE</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>326058001, 395828009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. A drug that is used to treat type 2 diabetes and is being studied in the prevention of head and neck cancer. It may be able to stop leukoplakia (a condition affecting the mouth ) from developing into cancer. It is a type of thiazolidinedione.</FPU_DefNCI><FPU_Name>pioglitazone</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0071097</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Thzldndn.htm</FPU_URL></item><item><FPU_Page>Thiazolidinedione</FPU_Page><FPU_LG_English>Avandia, rosiglitazone maleate (Avandia), avandia, Glaxo Wellcome brand of rosiglitazone maleate, GlaxoSmithKline brand of rosiglitazone maleate, SmithKline Beecham brand of rosiglitazone maleate</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Avandia</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0875967</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Thzldndn.htm</FPU_URL></item><item><FPU_Page>Thiazolidinedione</FPU_Page><FPU_LG_English>2,4-Thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-, 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione), troglitazone, 5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione, 5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl\-2,4-thiazolidinedione, 5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl-2,4-thiazolidinedione, troglitazone [Chemical/Ingredient], Troglitazone, Troglitazone (product), Troglitazone (substance), TROGLITAZONE</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>109085002, 386967007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity. Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)</FPU_DefNCI><FPU_Name>troglitazone</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0245514</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Thzldndn.htm</FPU_URL></item><item><FPU_Page>Thiazolidinedione</FPU_Page><FPU_LG_English>thiazolidinediones, thiazolidinediones (medication), Thiazolidinediones [Chemical/Ingredient], Thiazolidinedione-class Agent, Thiazolidinedione [EPC], glitazone, glitazones, thiazolidinedione, Glitazones, Thiazolidinedione (product), Thiazolidinedione (substance), Thiazolidinedione, Thiazolidinediones</FPU_LG_English><FPU_LG_French>Glitazones, Thiazolidine-diones, Thiazolidinediones</FPU_LG_French><FPU_SnomedCT>109086001, 372568004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Thiazolidinediones</FPU_Name><FPU_DefMSH>THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).</FPU_DefMSH><FPU_Code>C1257987</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Thzldndn.htm</FPU_URL></item><item><FPU_Page>Thiazolidinedione</FPU_Page><FPU_LG_English>Rezulin, rezulin, Parke Davis brand of troglitazone, Warner-Lambert brand of troglitazone</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Rezulin</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0701265</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Thzldndn.htm</FPU_URL></item><item><FPU_Page>Thiazolidinedione</FPU_Page><FPU_LG_English>5-((4-(2-methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate, rosiglitazone, rosiglitazone [Chemical/Ingredient], rosiglitazones, 2,4-Thiazolidinedione, 5-004-02-((((methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, Rosiglitazone (product), Rosiglitazone (substance), Rosiglitazone, ROS, ROSIGLITAZONE</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>326053005, 395869000</FPU_SnomedCT><FPU_DefCSP>peroxisome proliferator activated receptor agonist; reduces lipid availability; improves insulin action and glucoregulation.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>The active ingredient in a drug that helps control the amount of glucose (sugar) in the blood and is being studied in the prevention and treatment of some types of cancer. Rosiglitazone stops cells from growing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of thiazolidinedione and a type of antiangiogenesis agent. An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)</FPU_DefNCI><FPU_Name>rosiglitazone</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0289313</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Thzldndn.htm</FPU_URL></item><item><FPU_Page>Thyroid Hormone Replacement</FPU_Page><FPU_LG_English>synthroid, Abbot Brand of Levothyroxine Sodium, Synthroid</FPU_LG_English><FPU_LG_French>Synthroid</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Synthroid</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0728762</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/ThyrdHrmnRplcmnt.htm</FPU_URL></item><item><FPU_Page>Sulfonylurea</FPU_Page><FPU_LG_English>Compounds, Sulfonylurea, SULFONYLUREAS, Sulfonylurea, NOS, SULFONYLUREA CPDS, Sulfonylurea and its derivs, Sulphonylurea and its derivs, sulfonylureas (medication), sulfonylureas, sulfonylurea compounds, oral hypoglycemics sulfonylureas, A24 SULFONYLUREAS, Sulfonylurea Compounds, Sulfonylurea Compounds [Chemical/Ingredient], Sulfonylurea [EPC], Sulfonylurea-class Agent, sulphonylureas, sulphonylurea, Sulfonylurea, Sulfonylurea compounds, Sulfonylurea product, Sulphonylurea, Sulphonylurea compounds, Sulphonylurea product, Sulfonylurea and its derivatives, Sulphonylurea and its derivatives, Sulfonylurea (product), Sulfonylurea (substance), Sulfonylurea and its derivatives (substance), sulfonylurea, Sulfonylurea [dup] (substance), Sulfonylureas</FPU_LG_English><FPU_LG_French>Sulfonylurées</FPU_LG_French><FPU_SnomedCT>273950002, 34012005, 372711004, 259552008</FPU_SnomedCT><FPU_DefCSP>compounds of the type R-SO2-NHCONH-; when R=Ph, these are a group of hypoglycemic agents which enhance insulin secretion by beta cells and insulin sensitivity in target tissue, and so are effective in type II (noninsulin-dependent) diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Sulfonylurea Compounds</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0038766</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Slfnylr.htm</FPU_URL></item><item><FPU_Page>Second Generation Sulfonylurea</FPU_Page><FPU_LG_English>Glidiazinamide, Glipizide, Glydiazinamide, Glypidizine, Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-, glipizide, GLIPIZIDE, glipizide (medication), Glipizide [Chemical/Ingredient], glipiZIDE, Glipizide product, Glipizide (product), Glipizide (substance), GlipiZIDE</FPU_LG_English><FPU_LG_French>Glipizide</FPU_LG_French><FPU_SnomedCT>26124005, 387143009</FPU_SnomedCT><FPU_DefCSP>1-cyclohexyl-3-(p-(2-(5-methyl pyrazinecarboxamido) ethyl) phenyl) sulfonylurea; a typical member of the sulfonylurea family of type II (NIDDM) antidiabetic drugs.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A member of the second generation of the sulfonylurea hypoglycemic agents. Glipizide inhibits the ATP-sensitive potassium channels on the beta-cell membrane, thereby preventing potassium efflux leading to membrane depolarization and subsequent calcium influx. The increased intracellular calcium levels induce insulin secretion from functioning beta-cells of the pancreatic islet tissue and reduces blood glucose levels.</FPU_DefNCI><FPU_Name>Glipizide</FPU_Name><FPU_DefMSH>An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.</FPU_DefMSH><FPU_Code>C0017642</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/ScndGnrtnSlfnylr.htm</FPU_URL></item><item><FPU_Page>Second Generation Sulfonylurea</FPU_Page><FPU_LG_English>Glibenclamide, Glybenclamide, Benzamide, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy-, glyburide, Glyburide, Gyburide, Glyburide (substance), glyburide (medication), GLYBURIDE, Glyburide [Chemical/Ingredient], glibenclamide, glybenclamide, glyBURIDE, Glybenzcyclamide, Glyburide (product), Glibenclamide (substance), GlyBURIDE</FPU_LG_English><FPU_LG_French>Glibenclamide</FPU_LG_French><FPU_SnomedCT>387466004, 384978002, 80870001</FPU_SnomedCT><FPU_DefCSP>N-4-beta-(2-methoxy-5-chlorobenzamido) -ethylbenzosulfonyl-N'- cyclohexylurea; hypoglycemic used against non-insulin dependent diabetes mellitus; thought to act by increasing insulin receptor expression in target tissues.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A member of the second generation of the sulfonylurea hypoglycemic agents. Glyburide inhibits the ATP-sensitive potassium channels on the beta-cell membrane, thereby preventing potassium efflux leading to membrane depolarization and subsequent calcium influx. The increased intracellular levels of calcium induce insulin secretion from functioning beta-cells of the pancreatic islet tissue and leads to a lowering in blood glucose levels.</FPU_DefNCI><FPU_Name>Glyburide</FPU_Name><FPU_DefMSH>An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.</FPU_DefMSH><FPU_Code>C0017628</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/ScndGnrtnSlfnylr.htm</FPU_URL></item><item><FPU_Page>Systemic Corticosteroid</FPU_Page><FPU_LG_English>Prednisolone, Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-, Prednisolone [for preparations see rectal prednisolone], Prednisolone [see rectal pred], .delta.1-Hydrocortisone, 1,2-Dehydrohydrocortisone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, Metacortandralone, Delta(1)Hydrocortisone, Delta-F, Delta1-dehydro-hydrocortisone, Prednisolonum, Prednisolone [endocrine use], Prednisolone [for preparations see rectal prednisolone] (product), Prednisolone [endocrine use] (product), prednisolone (medication), PREDNISOLONE, Prednisolone [Chemical/Ingredient], prednisoLONE, Deltahydrocortisone, Deltahydrocortisone preparation, Metacortandralone preparation, Prednisolone preparation, Prednisolone product, Prednisolone (substance), Prednisolone preparation (product), PRDL, Prednisolone [endocrine use] (substance), Prednisolone [for preparations see rectal prednisolone] (substance), Prednisolone preparation (substance), prednisolone, PrednisoLONE</FPU_LG_English><FPU_LG_French>Prednisolone</FPU_LG_French><FPU_SnomedCT>325425005, 317418003, 116601002, 52388000</FPU_SnomedCT><FPU_DefCSP>synthetic glucocorticoid with the general properties of the corticosteroids.</FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121</FPU_Concepts_Codes><FPU_DefNCI>A drug that lessens inflammation and suppresses the body's immune response. It may also kill cancer cells. Prednisolone is used to treat disorders in many organ systems and to treat the symptoms of several types of leukemia and lymphoma. It is also being studied in the treatment of other types of cancer. Prednisolone is a type of therapeutic glucocorticoid. A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)</FPU_DefNCI><FPU_Name>prednisolone</FPU_Name><FPU_DefMSH>A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.</FPU_DefMSH><FPU_Code>C0032950</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/SystmcCrtcstrd.htm</FPU_URL></item><item><FPU_Page>Systemic Corticosteroid</FPU_Page><FPU_LG_English>Corticoid, Adrenal Cortex Hormones, Corticoids, Corticosteroids, Hormones, Adrenal Cortex, Adrenal cortical hormone, NOS, Corticoid preparation, NOS, Corticosteroids [resp], Corticosteroids [skin], Corticosteroids [skin] (product), Corticosteroids [respiratory use] (product), Corticosteroids [respiratory use], adrenal cortex hormone, corticosteroids, adrenal cortex hormones, corticoids, Corticosteroid [EPC], Adrenal Cortex Hormones [Chemical/Ingredient], Corticosteroid, Adrenal cortex hormones, adrenal corticosteroids, adrenal cortical hormone, adrenal corticosteroid, adrenocorticosteroids, corticoid, Adrenal cortical hormone, Adrenocorticosteroids, Corticoid preparation (product), Corticoid preparation, Adrenal cortical hormone (substance), corticosteroid, Corticoid preparation (substance), Corticosteroids [respiratory use] (substance), Corticosteroids [skin] (substance), Adrenal Cortex Steroids, Therapeutic Corticosteroid</FPU_LG_English><FPU_LG_French>Hormones cortico-surrénaliennes, Corticoïdes, Corticostéroïdes, Hormones corticosurrénaliennes</FPU_LG_French><FPU_SnomedCT>332333008, 320476006, 79440004, 21568003</FPU_SnomedCT><FPU_DefCSP>any of the 21-carbon steroids elaborated by the adrenal cortex (excluding the sex hormones of adrenal origin) in response to adrenocorticotropic hormone (ACTH) released by the pituitary gland or to angiotensin II; called also adrenocorticoid, corticoid, adrenal cortical or adrenocortical steroid, and adrenocortical or cortical hormone.</FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>Any steroid hormone made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias. Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).</FPU_DefNCI><FPU_Name>Adrenal Cortex Hormones</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0001617</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/SystmcCrtcstrd.htm</FPU_URL></item><item><FPU_Page>Systemic Corticosteroid</FPU_Page><FPU_LG_English>Betadexamethasone, Betamethasone, Flubenisolone, Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16beta)-, betamethasone, betamethasone (medication), Betamethasone [Chemical/Ingredient], Betamethasone preparation, Flubenisolone preparation, Betamethasone (substance), Betamethasone preparation (product), Betamethasone preparation (substance), BETAMETHASONE</FPU_LG_English><FPU_LG_French>Bétaméthasone</FPU_LG_French><FPU_SnomedCT>116571008, 29896003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities. Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.</FPU_DefNCI><FPU_Name>Betamethasone</FPU_Name><FPU_DefMSH>A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)</FPU_DefMSH><FPU_Code>C0005308</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/SystmcCrtcstrd.htm</FPU_URL></item><item><FPU_Page>Systemic Corticosteroid</FPU_Page><FPU_LG_English>Dexamethasone, Hexadecadrol, Methylfluorprednisolone, Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-, 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone, 9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione, 9Alpha-fluoro-16alpha-methylprednisolone, 9alpha-Fluoro-16alpha- methylprednisolone, Fluoro-9alpha Methyl-16alpha Prednisolone, (11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione, 16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione, 16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone, 16Alpha-methyl-9alpha-fluoroprednisolone, dexamethasone, Dexamethasonum, Desamethasone, Dexamethasone [endocrine use], DEXAMETHASONE, Dexamethasone [endocrine use] (product), dexamethasone (medication), Dexamethasone [Chemical/Ingredient], dexamethasone (DMX), Dexamethasone preparation, Dexamethasone (substance), Dexamethasone preparation (product), DXM, DM, Dexamethasone (product), Dexamethasone [endocrine use] (substance), Dexamethasone preparation (substance)</FPU_LG_English><FPU_LG_French>Dexaméthasone</FPU_LG_French><FPU_SnomedCT>325354000, 372584003, 7561000, 116568000</FPU_SnomedCT><FPU_DefCSP>anti-inflammatory 9-fluoro-glucocorticoid.</FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121</FPU_Concepts_Codes><FPU_DefNCI>A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) A synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland). Dexamethasone is used to treat leukemia and lymphoma and may be used to treat some of the problems caused by other cancers and their treatment.</FPU_DefNCI><FPU_Name>Dexamethasone</FPU_Name><FPU_DefMSH>An anti-inflammatory 9-fluoro-glucocorticoid.</FPU_DefMSH><FPU_Code>C0011777</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/SystmcCrtcstrd.htm</FPU_URL></item><item><FPU_Page>Systemic Corticosteroid</FPU_Page><FPU_LG_English>Compound F, Cortisol, Hydrocortisone, Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-, Dihydrocortisone, (11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione, hydrocortisone, Cortisol (substance), Domolene, Therapeutic Hydrocortisone, hydrocortisone (medication), 17-hydroxycorticosterone, HYDROCORTISONE, Hydrocortisone [Chemical/Ingredient], cortisols, hydrocortisones, Compound F preparation, Cortisol preparation, Cortisol product, HC - Hydrocortisone, Hydrocortisone preparation, Hydrocortisone product, Hydrocortisone (substance), Hydrocortisone preparation (product), cortisol, HC, Hydrocortisone preparation (substance)</FPU_LG_English><FPU_LG_French>Cortisol, Hydrocortisone</FPU_LG_French><FPU_SnomedCT>396458002, 56423005, 16602005</FPU_SnomedCT><FPU_DefCSP>main glucocorticoid secreted by the adrenal cortex; its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.</FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone. A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04) A drug used to relieve the symptoms of certain hormone shortages and to suppress an immune response.</FPU_DefNCI><FPU_Name>Hydrocortisone</FPU_Name><FPU_DefMSH>The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.</FPU_DefMSH><FPU_Code>C0020268</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/SystmcCrtcstrd.htm</FPU_URL></item><item><FPU_Page>Systemic Corticosteroid</FPU_Page><FPU_LG_English>6 Methylprednisolone, 6-Methylprednisolone, Methylprednisolone, Metipred, Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-, Methylprednisolone [endoc], 6Alpha-Methylprednisolone, (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione, methylprednisolone, Methylprednisolonum, Methylprednisolone [endocrine use], Methylprednisolone [endocrine use] (product), methylprednisolone (medication), METHYLPREDNISOLONE, Methylprednisolone [Chemical/Ingredient], methylPREDNISolone, 6-alpha-Methylprednisolone preparation, Methylprednisolone preparation, Methylprednisolone (substance), Methylprednisolone preparation (product), MePRDL, Methylprednisolone [endocrine use] (substance), Methylprednisolone preparation (substance), MethylPREDNISolone</FPU_LG_English><FPU_LG_French>6-Méthylprednisolone, Méthylprednisolone</FPU_LG_French><FPU_SnomedCT>325387001, 116593003, 27242001</FPU_SnomedCT><FPU_DefCSP>synthetic glucocorticoid derived from progesterone, used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant.</FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A corticosteroid hormone replacement. A synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.</FPU_DefNCI><FPU_Name>Methylprednisolone</FPU_Name><FPU_DefMSH>A PREDNISOLONE derivative with similar anti-inflammatory action.</FPU_DefMSH><FPU_Code>C0025815</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/SystmcCrtcstrd.htm</FPU_URL></item><item><FPU_Page>Systemic Corticosteroid</FPU_Page><FPU_LG_English>cortisone, Pregn-4-ene-3,11,20-trione, 17,21-dihydroxy-, 17,21-Dihydroxypregn-4-ene-3,11,20-trione, Cortisone, Cortisone [Chemical/Ingredient], cortisones, Compound E, Cortisone preparation, Cortisone (substance), Cortisone preparation (product), Cortisone product, CORT, Cortisone preparation (substance), Therapeutic Cortisone, CORTISONE</FPU_LG_English><FPU_LG_French>Cortisone</FPU_LG_French><FPU_SnomedCT>32498003, 111150008</FPU_SnomedCT><FPU_DefCSP>naturally occurring glucocorticoid used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent; cortisone itself is inactive and is converted in the liver to the active metabolite cortisol.</FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A corticosteroid with potent glucocorticoid activity. Therapeutic cortisone is the inactive precursor molecule of the active hormone cortisol, which is the hydroxylation product of cortisone by 11-beta-steroid dehydrogenase. Cortisol increases blood pressure and blood sugar levels, and suppresses the immune system, therefore cortisone is used to treat allergies or inflammation. A natural steroid hormone produced in the adrenal gland. It can also be made in the laboratory. Cortisone reduces swelling and can suppress immune responses. A steroid hormone synthesized and secreted by the adrenal gland and necessary for life. It is involved with maintaining cardiovascular function, blood glucose balance, regulating the inflammatory response and metabolism of proteins, carbohydrates, and fat.</FPU_DefNCI><FPU_Name>Cortisone</FPU_Name><FPU_DefMSH>A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite HYDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)</FPU_DefMSH><FPU_Code>C0010137</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/SystmcCrtcstrd.htm</FPU_URL></item><item><FPU_Page>Sibutramine</FPU_Page><FPU_LG_English>sibutramine, SIBUTRAMINE, sibutramine [Chemical/Ingredient], Sibutramine (product), Sibutramine (substance), Sibutramine, Sibutramine product (product), Sibutramine product</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>108373009, 386838007, 371164009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>sibutramine</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0074493</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Sbtrmn.htm</FPU_URL></item><item><FPU_Page>Sibutramine</FPU_Page><FPU_LG_English>Meridia, sibutramine hydrochloride (Meridia), meridia</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Meridia</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0635898</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Sbtrmn.htm</FPU_URL></item><item><FPU_Page>Phentermine</FPU_Page><FPU_LG_English>Phentermine, Benzeneethanamine, alpha,alpha-dimethyl-, phentermine, Phentermine [Chemical/Ingredient], 1,1-Dimethyl-2-phenylethylamine, 2-Phenyl-tert-butylamine, 2-Amino-2-methyl-1-phenylpropane, PHENTERMINE, Phenyl-tertiary-butylamine, Phentermine (product), Phentermine (substance)</FPU_LG_English><FPU_LG_French>Phentermine</FPU_LG_French><FPU_SnomedCT>373343009, 53480001</FPU_SnomedCT><FPU_DefCSP>central nervous system stimulant and sympathomimetic with actions and uses similar to dextroamphetamine; used in the treatment of obesity.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A natural monoamine alkaloid derivative and a sympathomimetic stimulant with appetite suppressant property. Phentermine, which was part of the Fen-Phen anti-obesity medication, stimulates hypothalamic release of norepinephrine, a neurotransmitter involved in stress responses (fight-or-flight reactions), and reduces hunger sensation. Phentermine also causes the release of epinephrine or adrenaline outside of the brain, resulting in breakdown of stored fat.</FPU_DefNCI><FPU_Name>Phentermine</FPU_Name><FPU_DefMSH>A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.</FPU_DefMSH><FPU_Code>C0031447</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Phntrmn.htm</FPU_URL></item><item><FPU_Page>Orlistat</FPU_Page><FPU_LG_English>xenical, Hoffmann-La Roche brand of orlistat, Roche brand of orlistat, Xenical</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Xenical</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0732649</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Orlst.htm</FPU_URL></item><item><FPU_Page>Orlistat</FPU_Page><FPU_LG_English>1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate, L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-, tetrahydrolipstatin, THLP, orlistat, orlistat (medication), ORLISTAT, orlistat [Chemical/Ingredient], Orlistat, Orlistat (product), Orlistat (substance)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>116093009, 387007000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A reversible active-site inhibitor of gastrointestinal lipases. Orlistat forms a covalent bond with the active serine site in gastric and pancreatic lipases, thereby inhibiting their activity and preventing dietary fat from being hydrolyzed and absorbed. (NCI04)</FPU_DefNCI><FPU_Name>orlistat</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0076275</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Orlst.htm</FPU_URL></item><item><FPU_Page>Oral Hypoglycemic</FPU_Page><FPU_LG_English>Agents, Hypoglycemic, Hypoglycemic Agents, hypoglycemic agent, Hypoglycemic agents, Drugs, Hypoglycemic, Hypoglycemic Drugs, Hypoglycemic drug, Hypoglycemics, Drugs for hypoglycaemia, Drugs for hypoglycemia, Hypoglycemic drug, NOS, Hypoglycaemic drug, NOS, Drugs for hypoglycemia (product), antihyperglycemic, Hypoglycaemic drug, Anti-hyperglycemics, hypoglycemic drugs, hypoglycemic agents, hypoglycaemic, hypoglycemic, hypoglycemic drug, Diabetes Medicines, Hypoglycemic Medicines, Agents, Antihyperglycemic, Antihyperglycemic Agents, Antihyperglycemics, Hypoglycaemic, Hypoglycemic agent (substance), Hypoglycemic, Hypoglycaemic agent, Hypoglycemic agent, Hypoglycaemic product, Hypoglycemic agent (product), Hypoglycemic product, Drugs for hypoglycemia (substance), Hypoglycemic drug (substance), Hypoglycemic product (product)</FPU_LG_English><FPU_LG_French>Agents hypoglycémiques, Agents hypoglycémiants, Médicaments hypoglycémiants, Médicaments hypoglycémiques, Hypoglycémiants</FPU_LG_French><FPU_SnomedCT>325290009, 373299009, 9356005, 312064005</FPU_SnomedCT><FPU_DefCSP>class of agents which lower blood glucose levels.</FPU_DefCSP><FPU_Concepts>Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hypoglycemic Agents</FPU_Name><FPU_DefMSH>Substances which lower blood glucose levels.</FPU_DefMSH><FPU_Code>C0020616</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/OrlHypglycmc.htm</FPU_URL></item><item><FPU_Page>Medications Affecting Thyroid Function</FPU_Page><FPU_LG_English>Drug-induced thyroiditis, Drug-induced thyroiditis (disorder), drug; thyroiditis, thyroiditis; drug-induced</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>237539004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Pathologic Function (T046)
</FPU_Concepts><FPU_Concepts_Codes>T046</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Drug-induced thyroiditis</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0342179</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/MdctnsAfctngThyrdFnctn.htm</FPU_URL></item><item><FPU_Page>Non-Sulfonylurea Insulin Secretagogues</FPU_Page><FPU_LG_English>repaglinide, (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic Acid, Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)-, repa-glinide, repaglinide (medication), REPAGLINIDE, repaglinide [Chemical/Ingredient], (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid, Repaglinide, Repaglinide (product), Repaglinide (substance)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>109074004, 386964000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A benzoic acid derivative belonging to the meglitinide class of antidiabetic agents. Repaglinide blocks ATP-dependent potassium channels in pancreatic beta cells, thereby causing depolarization of the cell membrane and subsequent opening of calcium channels. The increased calcium influx into the pancreatic beta cells induces insulin secretion, thereby lowering blood glucose levels.</FPU_DefNCI><FPU_Name>repaglinide</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0246689</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/NnSlfnylrInslnScrtgs.htm</FPU_URL></item><item><FPU_Page>Non-Sulfonylurea Insulin Secretagogues</FPU_Page><FPU_LG_English>starlix, Starlix, Novartis brand of nateglinide</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Starlix</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1323198</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/NnSlfnylrInslnScrtgs.htm</FPU_URL></item><item><FPU_Page>Non-Sulfonylurea Insulin Secretagogues</FPU_Page><FPU_LG_English>4-(2-(5-chloro-2-methoxybenzamido)ethyl)benzoic acid, meglitinide, MEGLITINIDE, meglitinide [Chemical/Ingredient], meglitinides, Meglitinide, Meglitinide (product), Meglitinide (substance)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>109075003, 372566000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Meglitinide</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0065880</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/NnSlfnylrInslnScrtgs.htm</FPU_URL></item><item><FPU_Page>Non-Sulfonylurea Insulin Secretagogues</FPU_Page><FPU_LG_English>IPCCPA, N-((4-isopropylcyclohexyl)carbonyl)phenylalanine, nate-glinide, nateglinide (medication), NATEGLINIDE, nateglinide [Chemical/Ingredient], nateglinide, D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-, senaglinide, Nateglinide (product), Nateglinide (substance), Nateglinide</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>129496008, 134604002, 387070004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>nateglinide</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0903898</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/NnSlfnylrInslnScrtgs.htm</FPU_URL></item><item><FPU_Page>Non-Sulfonylurea Insulin Secretagogues</FPU_Page><FPU_LG_English>Prandin, repaglinide (Prandin), prandin, Novo Nordisk brand 2 of repaglinide</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Prandin</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0722725</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/NnSlfnylrInslnScrtgs.htm</FPU_URL></item><item><FPU_Page>Liothyronine</FPU_Page><FPU_LG_English>cytomel, Cytomel</FPU_LG_English><FPU_LG_French>Cytomel</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Cytomel</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0010826</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Lthyrn.htm</FPU_URL></item><item><FPU_Page>Liothyronine</FPU_Page><FPU_LG_English>Liothyronine, Triiodothyronine, L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, liothyronine, Triiodothyronine preparation, triiodothyronine, T-3, 3,3',5-triiodo-L-thyronine, T3, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, Triiodothyronine (T3), L-triiodothyronine preparation, T&amp;gt;3&amp;lt; preparation, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; preparation, T3 preparation, Triiodothyronine preparation (product), therapeutic triiodothyronine, L-Triiodothyronine, T AAA THYROID HORMONE 003, Triiodothyronine [Chemical/Ingredient], t3 thyroid hormone, t3, LIOTHYRONINE, T3 Thyroid Hormone, Thyroid Hormone, T3, 3,5,3' Triiodothyronine, T3 - Liothyronine, Tri-iodothyronine product, T3 - Triiodothyronine, Total triiodothyronine, T&amp;gt;3&amp;lt;, Liothyronine (product), Triiodothyronine (substance), Liothyronine (substance), Triiodothyronine preparation (substance), Therapeutic T3</FPU_LG_English><FPU_LG_French>T3 (Hormone thyroïdienne), Tri-iodothyronine, Hormone thyroïdienne T3, Triiodothyronine, 3,5,3'-triiodothyronine, Liothyronine</FPU_LG_French><FPU_SnomedCT>61275002, 350358003, 74495008, 36437009</FPU_SnomedCT><FPU_DefCSP>one of the thyroid hormones; an organic iodine containing compound secreted in small amounts by the thyroid gland; most circulating triiodothyroinine is produced by the deiodination of thyroxine in the peripheral tissues.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A thyroid hormone. A thyroid hormone containing 3 iodine atoms generally synthesized from levothyroxine, and has greater biological activity. A thyroid hormone. Also called triiodothyronine or liothyronine sodium. A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)</FPU_DefNCI><FPU_Name>Triiodothyronine</FPU_Name><FPU_DefMSH>A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.</FPU_DefMSH><FPU_Code>C0041014</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Lthyrn.htm</FPU_URL></item><item><FPU_Page>Insulin Simulation</FPU_Page><FPU_LG_English>Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin</FPU_LG_English><FPU_LG_French>Insuline ordinaire, Insuline</FPU_LG_French><FPU_SnomedCT>67866001, 39487003, 412222002</FPU_SnomedCT><FPU_DefCSP>protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04) Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.</FPU_DefNCI><FPU_Name>Insulin</FPU_Name><FPU_DefMSH>A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).</FPU_DefMSH><FPU_Code>C0021641</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/InslnSmltn.htm</FPU_URL></item><item><FPU_Page>Insulin Pump</FPU_Page><FPU_LG_English>Insulin pump, NOS, PUMP, INFUSION, INSULIN, Pumps, Insulin, Insulin Pumps, Insulin pump, device, insulin pumps, insulin infusion pump, Insulin Infusion Pump - Device, Insulin pump, device (physical object), Insulin pump, insulin pump</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>69805005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Medical Device (T074)
</FPU_Concepts><FPU_Concepts_Codes>T074</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Insulin pump</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1140609</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/InslnPmp.htm</FPU_URL></item><item><FPU_Page>Insulin Sliding Scale</FPU_Page><FPU_LG_English>Sliding scale insulin regime, Sliding scale insulin regime (regime/therapy), Sliding scale insulin regime (procedure)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>225301004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Therapeutic or Preventive Procedure (T061)
</FPU_Concepts><FPU_Concepts_Codes>T061</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Sliding scale insulin regime</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0557977</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/InslnSldngScl.htm</FPU_URL></item><item><FPU_Page>Inhaled Insulin</FPU_Page><FPU_LG_English>EXUBERA, Exubera</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Exubera</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1176237</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/InhldInsln.htm</FPU_URL></item><item><FPU_Page>Insulin Dosing in Type 1 Diabetes</FPU_Page><FPU_LG_English>Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin</FPU_LG_English><FPU_LG_French>Insuline ordinaire, Insuline</FPU_LG_French><FPU_SnomedCT>67866001, 39487003, 412222002</FPU_SnomedCT><FPU_DefCSP>protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04) Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.</FPU_DefNCI><FPU_Name>Insulin</FPU_Name><FPU_DefMSH>A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).</FPU_DefMSH><FPU_Code>C0021641</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/InslnDsngInTypDbts.htm</FPU_URL></item><item><FPU_Page>Insulin Dosing</FPU_Page><FPU_LG_English>Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin</FPU_LG_English><FPU_LG_French>Insuline ordinaire, Insuline</FPU_LG_French><FPU_SnomedCT>67866001, 39487003, 412222002</FPU_SnomedCT><FPU_DefCSP>protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04) Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.</FPU_DefNCI><FPU_Name>Insulin</FPU_Name><FPU_DefMSH>A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).</FPU_DefMSH><FPU_Code>C0021641</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/InslnDsng.htm</FPU_URL></item><item><FPU_Page>Insulin</FPU_Page><FPU_LG_English>humalog, HumaLOG, Humalog, Eli Lilly brand of Insulin Lispro</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Humalog</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0528249</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Insln.htm</FPU_URL></item><item><FPU_Page>Insulin</FPU_Page><FPU_LG_English>Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin</FPU_LG_English><FPU_LG_French>Insuline ordinaire, Insuline</FPU_LG_French><FPU_SnomedCT>67866001, 39487003, 412222002</FPU_SnomedCT><FPU_DefCSP>protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04) Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.</FPU_DefNCI><FPU_Name>Insulin</FPU_Name><FPU_DefMSH>A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).</FPU_DefMSH><FPU_Code>C0021641</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Insln.htm</FPU_URL></item><item><FPU_Page>Insulin</FPU_Page><FPU_LG_English>Humulin insulin, insulin, human (Humulin), insulin humulin, humulin, humulin insulin, Humulin insulin (substance)</FPU_LG_English><FPU_LG_French>Humulin</FPU_LG_French><FPU_SnomedCT>350348002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Humulin insulin</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0020171</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Insln.htm</FPU_URL></item><item><FPU_Page>Insulin</FPU_Page><FPU_LG_English>Insulin Lispro, Insulin lispro, insulin lispro, insulin LISPRO, lispro, 28(B)-Lys-29(B)-Pro-insulin, insulin LISPRO [Chemical/Ingredient], insulin, lysine(B28)-proline(B29), 28(B)-lysine-29(B)-prolineinsulin, insulin, lysyl(28B)-prolyl(28B)-, insulin, Lys(B28)-Pro(B29), B28-Lys-B29-Pro-insulin, insulin, Lys(28B)-Pro(29B)-, insulin human lispro, lispro human insulin, lispro insulin, INSULIN LISPRO, Lispro, 28(B)-Lys-29(B)-Pro-Insulin, LYSPRO, Lispro, Insulin, 28(B)-Lysine-29(B)-Prolineinsulin, Insulin, Lysyl(28B)-Prolyl(28B)-, Insulin, Lys(28B)-Pro(29B)-, Lispro insulin (product), Lispro insulin, Lispro insulin (substance), INSULIN,LISPRO,HUMAN/rDNA</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>388454007, 412210000, 125703000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A recombinant therapeutic agent which is chemically identical to or similar to endogenous human insulin. In lispro insulin, the amino acid proline at B-28 and the amino acid lysine at B-29 are reversed, resulting in the rapid dissolution of this insulin to a monomer that is absorbed rapidly after subcutaneous administration. Lispro insulin is equipotent to human insulin on a molar basis but its effects are faster and of shorter duration. Endogenous insulin, a pancreatic hormone composed of two polypeptide chains, is important in the normal metabolism of carbohydrates, proteins and fats, promoting glucose utilization and protein synthesis; it has anabolic effects on many types of tissues. (NCI04)</FPU_DefNCI><FPU_Name>Insulin Lispro</FPU_Name><FPU_DefMSH>Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE.</FPU_DefMSH><FPU_Code>C0293359</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Insln.htm</FPU_URL></item><item><FPU_Page>Insulin</FPU_Page><FPU_LG_English>novolin, Novolin</FPU_LG_English><FPU_LG_French>Novolin</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Novolin</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0028467</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Insln.htm</FPU_URL></item><item><FPU_Page>Insulin</FPU_Page><FPU_LG_English>Novolog, novolog, novorapid, NovoLOG, NovoRapid, Novo Nordisk Brand of Insulin Aspart, NovoLog</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>NovoLog</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0939412</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Insln.htm</FPU_URL></item><item><FPU_Page>Insulin Dosing in Type 2 Diabetes</FPU_Page><FPU_LG_English>Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin</FPU_LG_English><FPU_LG_French>Insuline ordinaire, Insuline</FPU_LG_French><FPU_SnomedCT>67866001, 39487003, 412222002</FPU_SnomedCT><FPU_DefCSP>protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04) Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.</FPU_DefNCI><FPU_Name>Insulin</FPU_Name><FPU_DefMSH>A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).</FPU_DefMSH><FPU_Code>C0021641</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/InslnDsngInTypDbts1.htm</FPU_URL></item><item><FPU_Page>Incretin Mimetic</FPU_Page><FPU_LG_English>Byetta</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Byetta</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1636686</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/IncrtnMmtc.htm</FPU_URL></item><item><FPU_Page>Incretin Mimetic</FPU_Page><FPU_LG_English>exendin-4, EXENATIDE, exenatide (medication), exenatide [Chemical/Ingredient], Ex4 peptide, exendin 4, exenatide, Exendin 4, Exenatide (product), Exenatide (substance), Exenatide</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>416859008, 417734003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>exenatide</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0167117</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/IncrtnMmtc.htm</FPU_URL></item><item><FPU_Page>Hourly Subcutaneous Insulin</FPU_Page><FPU_LG_English>Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin</FPU_LG_English><FPU_LG_French>Insuline ordinaire, Insuline</FPU_LG_French><FPU_SnomedCT>67866001, 39487003, 412222002</FPU_SnomedCT><FPU_DefCSP>protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04) Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.</FPU_DefNCI><FPU_Name>Insulin</FPU_Name><FPU_DefMSH>A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).</FPU_DefMSH><FPU_Code>C0021641</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/HrlySbctnsInsln.htm</FPU_URL></item><item><FPU_Page>Human Growth Hormone</FPU_Page><FPU_LG_English>Somatotropic hormone (STH), Growth Hormone, Pituitary, Pituitary Growth Hormone, Somatotropin, GH - Growth hormone, Growth hormone, STH, Somatotrophin, Somatotropic hormone, Somatrophic hormone, somatotropin, Growth Hormone, STH (somatotropic hormone), Somatrophic hormone (product), Growth Hormone [Chemical/Ingredient], growth hormones, somatotrophin, pituitary growth hormone, somatotropic hormone, growth hormone, Growth hormone preparation, Growth hormone product, Somatotropin preparation, Somatotropin preparation (product), Somatotropin preparation (substance), Somatrophic hormone (substance), GH, GHN, Growth Hormone 1, Somatotropic Hormone, hGHN, SOMATOTROPIN</FPU_LG_English><FPU_LG_French>Somatotrophine, Hormone de croissance, Hormone somatotrope, Somatotropine, GH (Growth hormone), STH (Somatotrophic hormone), Somathormone</FPU_LG_French><FPU_SnomedCT>76765004, 350365006, 56234005</FPU_SnomedCT><FPU_DefCSP>polypeptide that is secreted by the anterior pituitary gland; affects protein, carbohydrate and lipid metabolism; stimulates mitosis, cell differentiation and cell growth.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A protein made by the pituitary gland that helps control body growth and the use of glucose and fat in the body. A peptide hormone secreted by the anterior lobe of the pituitary gland and regulates several physiologic processes, including growth and metabolism.</FPU_DefNCI><FPU_Name>Growth Hormone</FPU_Name><FPU_DefMSH>A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.</FPU_DefMSH><FPU_Code>C0037663</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/HmnGrwthHrmn.htm</FPU_URL></item><item><FPU_Page>Human Growth Hormone</FPU_Page><FPU_LG_English>Human growth hormone (HGH), Somatotropin (human), Biosynthetic human growth horm, Growth Hormone, Human, HGH, HGH - Growth hormone, Human Growth Hormone, Somatotropin (Human), Somatropin, somatropin, Somatotrophin, Human growth hormone, Human growth hormone (substance), GH - Growth hormone, Somatropin [2] (product), Somatropin [2], Somatotropic hormone, Growth hormone, hGH (human growth hormone), SOMATROPIN, growth hormones, growth hormones (medication), Human Growth Hormone [Chemical/Ingredient], hgh growth hormone, hgh human hormone growth, human growth hormone hgh, hgh human growth hormone, growth hormone hgh, human growth hormone (HGH), human growth hormone, hGH, Somatropin (Human), hGH (Human Growth Hormone), Biosynthetic human growth hormone, Somatropin (product), Somatropin (substance), Somatropin [2] (substance)</FPU_LG_English><FPU_LG_French>Somatotropine humaine, Somatropine humaine, Hormone de croissance humaine, hGH (Human Growth Hormone)</FPU_LG_French><FPU_SnomedCT>395883003, 76765004, 325892008, 325831003, 129495007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Somatropin</FPU_Name><FPU_DefMSH>A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.</FPU_DefMSH><FPU_Code>C0169964</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/HmnGrwthHrmn.htm</FPU_URL></item><item><FPU_Page>Glucagon</FPU_Page><FPU_LG_English>GlucaGen, glucagen</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>GlucaGen</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0591569</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Glcgn.htm</FPU_URL></item><item><FPU_Page>Glucagon</FPU_Page><FPU_LG_English>Glucagon, Glucagon (1-29), Glucagon preparation, Glucagon, NOS, Hyperglycemic-glycogenolytic factor preparation, Hyperglycaemic-glycogenolytic factor preparation, Proglucagon (33-61), glucagon, Hyperglycemic-Glycogenolytic Factor, HG Factor, HG-Factor, Glukagon, antidiabetic hormone, glucagon (medication), GLUCAGON, Glucagon [Chemical/Ingredient], glucagons, Glucagon product, Glucagon (substance), Glucagon product (product), Hyperglycaemic-glycogenolytic factor product, Hyperglycemic-glycogenolytic factor product, Glucagon preparation (substance), Hyperglycemic Glycogenolytic Factor, GCG, Antidiabetic Hormone</FPU_LG_English><FPU_LG_French>Glucagon, Facteur glycogénolytique hyperglycémique, Glucagon (1-29)</FPU_LG_French><FPU_SnomedCT>10712001, 66603002</FPU_SnomedCT><FPU_DefCSP>pancreatic hormone secreted by the alpha cells of the pancreatic islets; a 29-amino acid straight chain polypeptide that plays an important role in regulation of blood glucose concentration, ketone metabolism, and several other biochemical and physiological processes.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Neuroreactive Substance or Biogenic Amine (T124)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T124 T125</FPU_Concepts_Codes><FPU_DefNCI>A hormone produced by the pancreas that increases the level of glucose (sugar) in the blood. A hormone produced by the pancreas that increases the level of glucose (sugar) in the blood. A pancreatic hormone consisting of 29 amino acids that causes increases in blood sugar levels by stimulating hepatic glycogenolysis and gluconeogenesis.</FPU_DefNCI><FPU_Name>Glucagon</FPU_Name><FPU_DefMSH>A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)</FPU_DefMSH><FPU_Code>C0017687</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Glcgn.htm</FPU_URL></item><item><FPU_Page>Glucometer</FPU_Page><FPU_LG_English>Blood-Glucose Meter, BLOOD-GLUCOSE MEASURING EQUIP. MISC. EACH, BLOOD-GLUCOSE METER @ @ EACH, BLOOD-GLUCOSE METER EACH, Glucometers, Glucose Analyzers, Blood glucose meters (medical device), Glucose Blood Test, BLOOD-GLUCOSE METER MISCELL EACH, BLOOD-GLUCOSE METER@@MISCELL@EACH, glucose analyzer, blood glucose meter, glucometers, glucometer, blood glucose meters, Blood glucose meters, Blood glucose meters (physical object), Glucometer</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>337414009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Medical Device (T074)
</FPU_Concepts><FPU_Concepts_Codes>T074</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Blood glucose meters (medical device)</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0472226</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Glcmtr.htm</FPU_URL></item><item><FPU_Page>First Generation Sulfonylurea</FPU_Page><FPU_LG_English>First generation sulfonylurea (product), First generation sulfonylurea, First generation sulphonylurea</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>386049002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>First generation sulfonylurea</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1300197</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/FrstGnrtnSlfnylr.htm</FPU_URL></item><item><FPU_Page>First Generation Sulfonylurea</FPU_Page><FPU_LG_English>Tolbutamide, tolbutamide, Benzenesulfonamide, N-((butylamino)carbonyl)-4-methyl-, tolbutamide (medication), Tolbutamide [Chemical/Ingredient], TOLBUTamide, TOLBUTAMIDE, Tolbutamide (product), Tolbutamide (substance)</FPU_LG_English><FPU_LG_French>Tolbutamide</FPU_LG_French><FPU_SnomedCT>33124007, 373481003</FPU_SnomedCT><FPU_DefCSP>sulfonylurea compound used as a hypoglycemic in the treatment of noninsulin dependent diabetes mellitus.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A first-generation sulfonylurea with hypoglycemic activity. Tolbutamide binds to and blocks adenosine triphosphate (ATP)-sensitive potassium channels on the beta cell membrane of the pancreatic islet tissues. This leads to potassium efflux, which results in depolarization, calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis. In addition, tolbutamide may increase the number and affinity of cell surface insulin receptors, thereby enhancing the peripheral response to insulin. Tolbutamide is a CYP2C9 substrate.</FPU_DefNCI><FPU_Name>Tolbutamide</FPU_Name><FPU_DefMSH>A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)</FPU_DefMSH><FPU_Code>C0040374</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/FrstGnrtnSlfnylr.htm</FPU_URL></item><item><FPU_Page>First Generation Sulfonylurea</FPU_Page><FPU_LG_English>Chlorpropamide, Clorpropamid, chlorpropamide, Benzenesulfonamide, 4-chloro-N-((propylamino)carbonyl)-, Urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl-, CHLORPROPAMIDE, 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide, Chlorpropamide [Chemical/Ingredient], chlorproPAMIDE, Chlorpropamide (product), Chlorpropamide (substance), ChlorproPAMIDE</FPU_LG_English><FPU_LG_French>Chlorpropamide</FPU_LG_French><FPU_SnomedCT>111154004, 386991003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A sulfonylurea with oral hypoglycemic properties that is used in the treatment of Type II diabetes mellitus. Chlorpropamide stimulates pancreatic secretion of insulin and improves insulin release by increasing sensitivity of beta cells to glucose stimuli. This drug also increases the sensitivity of insulin receptors in muscle, liver, and adipose tissue thereby promoting glucose transport across cell membranes. This results in better controlled blood glucose levels. Chlorpropamide has the longest duration of action of the sulfonylurea class but could cause more severe and frequent side effects, including hypoglycemia and hyponatremia.</FPU_DefNCI><FPU_Name>Chlorpropamide</FPU_Name><FPU_DefMSH>A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)</FPU_DefMSH><FPU_Code>C0008287</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/FrstGnrtnSlfnylr.htm</FPU_URL></item><item><FPU_Page>First Generation Sulfonylurea</FPU_Page><FPU_LG_English>Benzenesulfonamide, 4-acetyl-N-((cyclohexylamino)carbonyl)-, 3-Cyclohexyl-1-(p-acetylphenylsulfonyl)urea, Cyclamide, 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide, 1-(p-Acetylbenzenesulfonyl)-3-Cyclohexylurea, N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea, N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea, Acetohexamide, acetohexamide (medication), Acetylcholine chloride - chemical (substance), Acetohexamide - chemical (substance), acetohexamide, Acetohexamide [Chemical/Ingredient], acetoHEXAMIDE, Acetohexamide (product), Acetohexamide (substance), Acetohexamide - chemical, Acetylcholine chloride - chemical, ACETOHEXAMIDE, AcetoHEXAMIDE</FPU_LG_English><FPU_LG_French>Acétohexamide</FPU_LG_French><FPU_SnomedCT>391708007, 391707002, 387210001, 39064002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A sulfonylurea with oral hypoglycemic properties that is used in the treatment of Type II diabetes mellitus. Acetohexamide lowers blood sugar by stimulating insulin release from the pancreas and increases the sensitivity of beta cells to glucose stimulus. This drug also increases the sensitivity of insulin receptors in muscle, liver, and adipose tissue thereby promoting glucose transport across cell membranes. This results in better controlled blood glucose levels. (NCI05)</FPU_DefNCI><FPU_Name>Acetohexamide</FPU_Name><FPU_DefMSH>A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.</FPU_DefMSH><FPU_Code>C0000992</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/FrstGnrtnSlfnylr.htm</FPU_URL></item><item><FPU_Page>First Generation Sulfonylurea</FPU_Page><FPU_LG_English>Tolazamide, Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methyl-, tolazamide, tolazamide (medication), TOLAZAMIDE, Tolazamide [Chemical/Ingredient], TOLAZamide, Tolazamide (product), Tolazamide (substance)</FPU_LG_English><FPU_LG_French>Tolazamide</FPU_LG_French><FPU_SnomedCT>34393009, 387186009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A sulfonylurea derivative and an antidiabetic agent with hypoglycemic property. Tolazamide binds to the ATP-dependent potassium channels on the plasma membrane of pancreatic beta-cells, which results in an inhibition of potassium efflux and membrane depolarization. Membrane depolarization stimulates calcium influx through voltage-gated calcium channels and subsequently induces the release of insulin from viable beta-cells thereby leading to a decrease in blood glucose levels. In addition, this agent potentiates the anti-diuretic effect of antidiuretic hormone (ADH).</FPU_DefNCI><FPU_Name>Tolazamide</FPU_Name><FPU_DefMSH>A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.</FPU_DefMSH><FPU_Code>C0040372</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/FrstGnrtnSlfnylr.htm</FPU_URL></item><item><FPU_Page>Dexfenfluramine</FPU_Page><FPU_LG_English>Dexfenfluramine, DEXFENFLURAMINE, Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-, dexfenfluramine, Dexfenfluramine [Chemical/Ingredient], Dexfenfluramine (product), Dexfenfluramine (substance)</FPU_LG_English><FPU_LG_French>Dexfenfluramine</FPU_LG_French><FPU_SnomedCT>322047008, 412366002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Dexfenfluramine</FPU_Name><FPU_DefMSH>The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.</FPU_DefMSH><FPU_Code>C0011786</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Dxfnflrmn.htm</FPU_URL></item><item><FPU_Page>Dexfenfluramine</FPU_Page><FPU_LG_English>redux, Redux, Wyeth Brand of Dexfenfluramine Hydrochloride</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Redux</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0728749</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Dxfnflrmn.htm</FPU_URL></item><item><FPU_Page>Glucophage</FPU_Page><FPU_LG_English>Biguanides, Biguanides [Chemical/Ingredient], Biguanide-class Agent, Biguanide [EPC], biguanide, biguanides, Biguanide, Biguanide (product), Biguanide (substance)</FPU_LG_English><FPU_LG_French>Biguanides</FPU_LG_French><FPU_SnomedCT>109082004, 373306007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Biguanides</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0005382</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Glcphg.htm</FPU_URL></item><item><FPU_Page>Glucophage</FPU_Page><FPU_LG_English>glucophage, Glucophage [brand name], Glucophage</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Glucophage</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0591573</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Glcphg.htm</FPU_URL></item><item><FPU_Page>Glucophage</FPU_Page><FPU_LG_English>Dimethylbiguanidine, Dimethylguanylguanidine, Metformin, Imidodicarbonimidic diamide, N,N-dimethyl-, METFORMIN, 1,1-Dimethylbiguanide, N,N-Dimethylimidodicarbonimidic Diamide, metformin, Metformin [Chemical/Ingredient], metFORMIN, Metformin (product), Metformin (substance)</FPU_LG_English><FPU_LG_French>Diméthylbiguanide, Metformine</FPU_LG_French><FPU_SnomedCT>109081006, 372567009</FPU_SnomedCT><FPU_DefCSP>N,N-dimethylimidodicarbonimidic diamide; an oral hypogylcemic agent.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A biguanide with antihyperglycemic activity. Metformin exerts its action by improving hepatic sensitivity to insulin, thereby suppressing hepatic glucose production and increasing hepatic glycogen stores. In addition, metformin increases the number and/or affinity of insulin receptors on cell surface membranes in muscle and adipose tissue, thereby increasing the sensitivity to insulin at receptor and post-receptor binding sites and increasing glucose uptake peripherally. The active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Metformin is a type of antidiabetic agent.</FPU_DefNCI><FPU_Name>Metformin</FPU_Name><FPU_DefMSH>A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)</FPU_DefMSH><FPU_Code>C0025598</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Glcphg.htm</FPU_URL></item><item><FPU_Page>Fludrocortisone</FPU_Page><FPU_LG_English>9 alpha-Fluorohydrocortisone, 9-Fluorocortisol, 9-Fluorohydrocortisone, Fludrocortisone, 9 Fluorocortisol, 9 Fluorohydrocortisone, 9 alpha Fluorohydrocortisone, fludrocortisone, Pregn-4-ene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-, (11beta)-, 9 Fluoro 17 Hydroxycortisone, 9 alpha Fludrohydrocortisone, 9 alpha Fluoro 17 Hydroxycorticosterone, 9 alpha-Fluoro-17-Hydroxycorticosterone, 9-Fluoro-17-Hydroxycortisone, FLUOROCORTISOL 09, Fludrocortisone [Chemical/Ingredient], 9-fluorohydrocortisone, Fludrocortisone preparation, Fludrocortisone (substance), Fludrocortisone preparation (product), Fludrocortisone preparation (substance), FLUDROCORTISONE</FPU_LG_English><FPU_LG_French>Fludrocortisone</FPU_LG_French><FPU_SnomedCT>116586002, 89192008</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A synthetic corticosteroid. It is used to replace steroid hormones normally produced by the adrenal gland. A synthetic corticosteroid with antiinflammatory and antiallergic properties. Fludrocortisone is a mineralocorticoid receptor and glucocorticoid receptor agonist that binds to cytoplasmic receptors, translocates to the nucleus and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2. This prevents the release of arachidonic acid, a precursor to prostaglandins and leukotrienes, both important mediators in the pro-inflammatory response mechanism. In addition, this agent exerts its mineralocorticoid effect on the distal tubules and collecting ducts of the kidney by inducing permease, an enzyme that regulates Na+ permeability in cells, thereby enhancing Na+ reabsorption and water retention as well as increasing K+, H+ excretion.</FPU_DefNCI><FPU_Name>Fludrocortisone</FPU_Name><FPU_DefMSH>A synthetic mineralocorticoid with anti-inflammatory activity.</FPU_DefMSH><FPU_Code>C0016280</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Fldrcrtsn.htm</FPU_URL></item><item><FPU_Page>Fludrocortisone</FPU_Page><FPU_LG_English>Florinef Acetate, Florinef, Florinef acetate, florinef, florinef acetate, acetate florinef, Bristol-Myers Squibb brand of fludrocortisone 21-acetate, Monarch brand of fludrocortisone 21-acetate, Shire brand of fludrocortisone 21-acetate</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Steroid (T110)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T110 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Florinef</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0060486</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/Fldrcrtsn.htm</FPU_URL></item><item><FPU_Page>Carbohydrate Count in Insulin Dosing</FPU_Page><FPU_LG_English>Carbohydrate counting (regime/therapy), Carbohydrate counting</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>416576000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Health Care Activity (T058)
</FPU_Concepts><FPU_Concepts_Codes>T058</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Carbohydrate counting</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1562940</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/CrbhydrtCntInInslnDsng.htm</FPU_URL></item><item><FPU_Page>Chromium Picolinate</FPU_Page><FPU_LG_English>CHROMIUM PICOLINATE, mineral supplements chromium picolinate, chromium picolinate (medication), Chromium Picolinate, Chromium picolinate (substance), Chromium picolinate, chromium picolinate</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>442428005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>Chromium Piccolinate is a salt of the trace metallic element chromium (Cr), essential in glucose metabolism. Found in vitamins and mineral supplements, Chromium may be necessary for utilization of dietary sugars and carbohydrates by optimizing the effects of insulin. Animal studies suggest that chromium picolinate may be carcinogenic, it enters cells directly and can causes mutations. (NCI04)</FPU_DefNCI><FPU_Name>CHROMIUM PICOLINATE</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0163657</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/ChrmPclnt.htm</FPU_URL></item><item><FPU_Page>Dopamine Agonist</FPU_Page><FPU_LG_English>Agonists, Dopamine, Agonists, Dopamine Receptor, Dopamine Receptor Agonists, Receptor Agonists, Dopamine, dopamine agonist, Agonist, Dopamine, Agonist, Dopamine Receptor, Agonist, Dopaminergic, Agonists, Dopaminergic, Dopamine Agonist, Dopamine Receptor Agonist, Dopaminergic Agonist, Dopaminergic Agonists, Receptor Agonist, Dopamine, Dopaminergic drugs used in parkinsonism, Dopaminergics in parkinsons, RECEPT AGON DOPAMINE, DOPAMINE AG, DOPAMINERGIC AG, DOPAMINERGIC AGON, AGON DOPAMINERGIC, DOPAMINE RECEPT AG, AGON DOPAMINE RECEPT, DOPAMINE AGON, DOPAMINE RECEPT AGON, Dopaminergics, dopamine receptor agonist, dopamine agonists (medication), dopamine agonists, Dopamine Agonists, Dopaminergic Agonist [EPC], dopaminergic agonists, agonist dopamine receptor, agonists dopamine receptor, Dopamine agonist product (product), Dopamine agonist product, Dopamine agonist (substance), Dopamine agonist (product), Dopamine agonist, Dopamine receptor agonist (substance), Dopamine receptor agonist, Dopamine agonist agent (substance), Dopamine agonist agent</FPU_LG_English><FPU_LG_French>Agonistes de la dopamine, Agonistes du récepteur de la dopamine, Agonistes des récepteurs dopaminergiques, Agonistes dopaminergiques</FPU_LG_French><FPU_SnomedCT>384952006, 108808007, 395987003, 418222008</FPU_SnomedCT><FPU_DefCSP>class of drugs and natural products which enhance dopaminergic function by increasing dopamine biosynthesis, decreasing dopamine degradation or reuptake, or interacting positively with dopamine receptors.</FPU_DefCSP><FPU_Concepts>Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T121</FPU_Concepts_Codes><FPU_DefNCI>Any agent that binds to and activates dopamine receptors.</FPU_DefNCI><FPU_Name>Dopamine Agonists</FPU_Name><FPU_DefMSH>Drugs that bind to and activate dopamine receptors.</FPU_DefMSH><FPU_Code>C0178601</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/DpmnAgnst.htm</FPU_URL></item><item><FPU_Page>Dopamine Agonist</FPU_Page><FPU_LG_English>parlodel, Parlodel</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Parlodel</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0000266</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/DpmnAgnst.htm</FPU_URL></item><item><FPU_Page>Dopamine Agonist</FPU_Page><FPU_LG_English>Dostinex, Cabaser, Cabaseril, Pfizer brand of cabergoline, cabaser, dostinex</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Dostinex</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0526034</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/DpmnAgnst.htm</FPU_URL></item><item><FPU_Page>Dopamine Agonist</FPU_Page><FPU_LG_English>cabergoline, 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, Cabergoline [parkinsons], Cabergoline [parkinsons] (product), cabergoline (medication), dopamine agonists cabergoline, 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, CABERGOLINE, cabergoline [Chemical/Ingredient], cabergoline parkinsons, Cabergoline, Cabergoline (product), Cabergoline (substance), Cabergoline [parkinsons] (substance)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>323191001, 109139002, 386979007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.</FPU_DefNCI><FPU_Name>cabergoline</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0107994</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/DpmnAgnst.htm</FPU_URL></item><item><FPU_Page>Dopamine Agonist</FPU_Page><FPU_LG_English>2 Bromoergocryptine, 2-Bromoergocryptine, 2-Bromoergokryptine, Bromocriptin, Bromocriptine, Bromocryptin, 2 Bromoergokryptine, bromocriptine, 2 Bromo alpha ergocryptine, 2 Bromo alpha ergokryptine, 2-Bromo-alpha-ergocryptine, 2-Bromo-alpha-ergokryptine, Bromocriptine [endocrine], BROMOERGOCRYPTINE 02, Bromocriptine [endocrine use], Bromocriptine [parkinsons], Bromocriptine [endocrine use] (product), Bromocriptine [parkinsons] (product), Bromocriptine [endocrine] (product), Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha)-, BROMOCRIPTINE, Bromocriptine [Chemical/Ingredient], bromocriptin, bromocryptin, bromocryptine, Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-, 2-Br-alpha-ergocryptine, Brom-ergocryptine, Bromocryptine, Bromocriptine (product), Bromocriptine (substance), BRCR, Bromocriptine [endocrine use] (substance), Bromocriptine [endocrine] (substance), Bromocriptine [parkinsons] (substance)</FPU_LG_English><FPU_LG_French>Bromocriptine</FPU_LG_French><FPU_SnomedCT>325985002, 323134006, 325986001, 116656002, 387039007, 46293006</FPU_SnomedCT><FPU_DefCSP>D2 dopamine agonist used as a prolactin inhibitor.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI>A semisynthetic, ergot alkaloid with antiparkinson and lactation inhibitory activities. Bromocriptine selectively binds to and activates the postsynaptic dopamine D2-like receptors in the corpus striatum of the central nervous system (CNS). D2-like receptors are coupled to inhibitory G-proteins, which inhibit adenylyl cyclase, thereby preventing signal transduction mediated via cAMP and leading to an inhibitory effect on neurotransmission. This improves Parkinson symptoms, such as dyskinesia. Bromocriptine also has an inhibitory effect on the anterior pituitary gland, which results in blockage of prolactin secretion, thereby suppressing lactation.</FPU_DefNCI><FPU_Name>Bromocriptine</FPU_Name><FPU_DefMSH>A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.</FPU_DefMSH><FPU_Code>C0006230</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/DpmnAgnst.htm</FPU_URL></item><item><FPU_Page>Antithyroid Drug</FPU_Page><FPU_LG_English>Antagonists, Thyroid, Antithyroid Drugs, Drugs, Antithyroid, Thyroid Antagonists, thyroid inhibitor, Thyroid antagonists, Agents, Antithyroid, Antithyroid Agents, Antithyroid preparation, NOS, Thyroid inhibitor preparation, NOS, Thyroid inhibitor, THYROID ANTAG, ANTITHYROID AGENTS, anti-thyroid agents, anti-thyroid agents (medication), thyroid antagonists, [HS852] ANTITHYROID AGENTS, antithyroid drug, inhibitors thyroid, antithyroid agents, antithyroid preparations, antithyroid drugs, Antithyroid drugs, Antithyroid agent (product), Antithyroid agent, Thyroid inhibitor preparation, antithyroid agent, Antithyroid Agent, Antithyroid agent (substance)</FPU_LG_English><FPU_LG_French>Anti-thyroïdiens, Agents antithyroïdiens, Thyréostatiques, Médicaments antithyroïdiens, Agents anti-thyroïdiens, Médicaments anti-thyroïdiens, Antithyroïdiens</FPU_LG_French><FPU_SnomedCT>5067008, 418416001</FPU_SnomedCT><FPU_DefCSP>any agent or substance which suppresses, prevents or opposes the biosynthesis of thyroid hormones.</FPU_DefCSP><FPU_Concepts>Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Antithyroid Agents</FPU_Name><FPU_DefMSH>Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones.</FPU_DefMSH><FPU_Code>C0040125</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnthyrdDrg.htm</FPU_URL></item><item><FPU_Page>Antithyroid Drug</FPU_Page><FPU_LG_English>1 Methyl 2 mercaptoimidazole, 1-Methyl-2-mercaptoimidazole, Mercasolyl, Mercazolyl, Merkazolil, Methimazole, Methylmercaptoimidazole, Methymazol, Thiamazole, Thimazol, Tiamazol, 2H-Imidazole-2-thione, 1,3-dihydro-1-methyl-, Methimazole preparation, Thiamazole preparation, methimazole, METHIMAZOLE, methimazole (medication), Methimazole [Chemical/Ingredient], tiamazol, thiamazole, Methimazole (substance), Methimazole (product)</FPU_LG_English><FPU_LG_French>Thiamazole</FPU_LG_French><FPU_SnomedCT>37656002, 404864000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Methimazole</FPU_Name><FPU_DefMSH>A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.</FPU_DefMSH><FPU_Code>C0025644</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnthyrdDrg.htm</FPU_URL></item><item><FPU_Page>Antithyroid Drug</FPU_Page><FPU_LG_English>Thioamides, thioamide, Thioamides [Chemical/Ingredient], thioamides, Thioamide (substance), Thioamide</FPU_LG_English><FPU_LG_French>Thioamides</FPU_LG_French><FPU_SnomedCT>406762005</FPU_SnomedCT><FPU_DefCSP>compounds of the type R-(C=S)-N=.</FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
</FPU_Concepts><FPU_Concepts_Codes>T109</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Thioamides</FPU_Name><FPU_DefMSH>Organic compounds containing the radical -CSNH2.</FPU_DefMSH><FPU_Code>C0039875</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnthyrdDrg.htm</FPU_URL></item><item><FPU_Page>Antithyroid Drug</FPU_Page><FPU_LG_English>6-Propyl-2-Thiouracil, Propylthiouracil, 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo-, 6 Propyl 2 Thiouracil, propylthiouracil, Propylthiouracil preparation, 6-Propyl-2-thiouracil, anti-thyroid agents propylthiouracil (propylthiouracil), propylthiouracil (medication), PTU (propylthiouracil), PROPYLTHIOURACIL, Propylthiouracil [Chemical/Ingredient], PTU preparation, Propylthiouracil product, Propylthiouracil (product), Propylthiouracil (substance)</FPU_LG_English><FPU_LG_French>Propylthiouracile</FPU_LG_French><FPU_SnomedCT>3814009, 387203007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Nucleic Acid, Nucleoside, or Nucleotide (T114)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T114 T121</FPU_Concepts_Codes><FPU_DefNCI>A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity.</FPU_DefNCI><FPU_Name>Propylthiouracil</FPU_Name><FPU_DefMSH>A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)</FPU_DefMSH><FPU_Code>C0033511</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnthyrdDrg.htm</FPU_URL></item><item><FPU_Page>Antithyroid Drug</FPU_Page><FPU_LG_English>tapazole, Tapazole, Eli Lilly Brand of Methimazole, Jones Brand of Methimazole</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Tapazole</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0728778</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnthyrdDrg.htm</FPU_URL></item><item><FPU_Page>Obesity in Children</FPU_Page><FPU_LG_English>Obesity in Children, Pediatric Obesity, Childhood obesity, Childhood obesity (disorder), Childhood Obesity</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>444862003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Having a high amount of body fat during childhood.</FPU_DefNCI><FPU_Name>Childhood obesity</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C2362324</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Peds/ObstyInChldrn.htm</FPU_URL></item><item><FPU_Page>Alpha-glucosidase Inhibitor</FPU_Page><FPU_LG_English>Glyset, glyset</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Glyset</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0720692</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AlphGlcsdsInhbtr.htm</FPU_URL></item><item><FPU_Page>Alpha-glucosidase Inhibitor</FPU_Page><FPU_LG_English>miglitol, N-hydroxyethyl-1-desoxynojirimycin, N-hydroxyethyl-1-desoxy-nojirimycin, miglitol (medication), miglitol [Chemical/Ingredient], Miglitol (product), Miglitol (substance), Miglitol, MIGLITOL</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>386046009, 109071007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Organic Chemical (T109)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T109 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>miglitol</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0066535</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AlphGlcsdsInhbtr.htm</FPU_URL></item><item><FPU_Page>Alpha-glucosidase Inhibitor</FPU_Page><FPU_LG_English>glucobay, precose, Glucobay, Bayer Brand of Acarbose, Glucor, Prandase, Precose</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Carbohydrate (T118)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T118 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Precose</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0591572</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AlphGlcsdsInhbtr.htm</FPU_URL></item><item><FPU_Page>Alpha-glucosidase Inhibitor</FPU_Page><FPU_LG_English>Acarbose, O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose, acarbose, acarbose (medication), oral hypoglycemics acarbose, Acarbose - chemical (substance), ACARBOSE, Acarbose [Chemical/Ingredient], D-glucose, O-4,6-dideoxy-4-(((1S-(1 alpha,4 alpha,5 beta,6 alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyr anosyl-(1-4)-, Acarbose (product), Acarbose (substance), Acarbose - chemical</FPU_LG_English><FPU_LG_French>Acarbose</FPU_LG_French><FPU_SnomedCT>391700000, 109077006, 386965004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Carbohydrate (T118)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T118 T121</FPU_Concepts_Codes><FPU_DefNCI>A complex oligosaccharide used as a hypoglycemic agent in diabetes management. Acarbose inhibits enzymes required in catabolism of carbohydrates, specifically pancreatic alpha-amylase, which hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, and the membrane-bound intestinal alpha-glucosidases, which hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. When acarbose is orally administered, less digestion of complex carbohydrates occur and less glucose is absorbed in the small intestine, thereby producing a smaller rise in postprandial blood glucose levels after a carbohydrate load.</FPU_DefNCI><FPU_Name>Acarbose</FPU_Name><FPU_DefMSH>An inhibitor of alpha glucosidase that retards the digestion and absorption of carbohydrates in the small intestine and hence reduces the increase in blood-glucose concentrations after a carbohydrate load. It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (From Martindale The Extra Pharmacopoeia, 31st ed)</FPU_DefMSH><FPU_Code>C0050393</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AlphGlcsdsInhbtr.htm</FPU_URL></item><item><FPU_Page>Alpha-glucosidase Inhibitor</FPU_Page><FPU_LG_English>Alpha-glucoside inhibitor, alpha glucosidase inhibitor, alpha glucosidase inhibitors, alpha glucoside inhibitors, alpha-glucosidase inhibitor, alpha glucosides inhibitors, Alpha-glucosidase inhibitor, Alpha-glucoside inhibitor (product), Alpha-glucoside inhibitor (substance), Alpha Glucosidase Inhibitors</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>109072000, 372565001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Alpha-glucoside inhibitor</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1299007</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AlphGlcsdsInhbtr.htm</FPU_URL></item><item><FPU_Page>Prader-Willi Syndrome</FPU_Page><FPU_LG_English>Prader-Willi Syndrome, Syndrome, Prader-Willi, OBESITY-CRYPTORCHIDISM-DWARFISM-SUBNORMAL MENTALITY SYNDROME, Prader Willi syndrome, PWS, PRADER-WILLI SYNDROME, PRADER-LABHART-WILLI SYNDROME, Prader-Willi syndrome (diagnosis), PRADER WILLI SYNDROME, Labhart Willi Prader Fanconi Syndrome, Labhart-Willi-Prader-Fanconi Syndrome, Syndrome, Labhart-Willi-Prader-Fanconi, Labhart Willi Syndrome, Labhart-Willi Syndrome, Syndrome, Labhart-Willi, Prader-willi syndrome, Syndrome, Willi-Prader, Willi Prader Syndrome, Willi-Prader Syndrome, Prader Labhart Willi Syndrome, cardiorespiratory syndrome of obesity in child, hypogenital dystrophy with diabetic tendency syndrome, Prader-Labhart-Willi-Fanconi syndrome, H2O syndrome, hypotonia-hypopigmentia-hypogonadism-obesity (HHHO) syndrome, hypotonia-hypopigmentia-hypogonadism-obesity syndrome, hypotonia-obesity-hypogonadism-mental retardation syndrome, hypotonia-hypogonadism-obesity syndrome, Prader-Labhart-Willi (PLW) syndrome (PLWS), Prader-Labhart-Willi syndrome, Prader-Willi syndrome (PWS), Prader-Willi Syndrome [Disease/Finding], syndrome prader-willi, prader syndrome willy, prader willis syndrome, prader willi syndrome, prader syndrome willis, prader willi syndromes, syndrome willi prader, prader syndrome willi, prader willies syndrome, prader syndrome willies, prader willy syndrome, prader-willi syndrome, willi prader syndrome, Prader-Willi syndrome, Prader-Willi syndrome (disorder), Prader-Willi, Prader - Willi syndrome, Prader Willi Syndrome</FPU_LG_English><FPU_LG_French>SPW (Syndrome de Prader-Willi), Syndrome de Prader-Willi, Syndrome de Prader-Labhart-Willi</FPU_LG_French><FPU_SnomedCT>89392001, 205794007</FPU_SnomedCT><FPU_DefCSP>congenital neurobehavioral disorder characterized by rounded face, low forehead, almond shaped eyes, squinting, hypogonadism, hypotonia, insatiable appetite leading to obesity, and mental retardation; chromosomal disorder usually associated with a deletion of the proximal portion of the long arm of chromosome 15.</FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
</FPU_Concepts><FPU_Concepts_Codes>T019</FPU_Concepts_Codes><FPU_DefNCI>A genetic syndrome caused by deletions or disruptions of chromosome 15. It is characterized by reduced fetal activity, mental retardation, hypotonia, short stature, and hypogonadism.</FPU_DefNCI><FPU_Name>Prader-Willi Syndrome</FPU_Name><FPU_DefMSH>An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)</FPU_DefMSH><FPU_Code>C0032897</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Peds/PrdrWlSyndrm.htm</FPU_URL></item><item><FPU_Page>Anologue Basal Insulin</FPU_Page><FPU_LG_English>Basal insulin (product), Basal insulin</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>416303005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Basal insulin</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0650607</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnlgBslInsln.htm</FPU_URL></item><item><FPU_Page>Anologue Basal Insulin</FPU_Page><FPU_LG_English>A21-Gly-B31-Arg-B32-Arg-insulin, Insulin Glargine,Hum.Rec.Anlog, insulin, Gly(A21)-Arg(B31,B32)-, insulin, glycyl(A21)-arginyl(B31,B32)-, insulin glargine, Insulin Glargine, Insulin glargine preparation, Insulin Glargine Recombinant, INSULIN GLARGINE, glargine [Chemical/Ingredient], glargine insulin, insulin glargine human, insulin glargine recombinant, glargine, Insulin glargine product (product), Insulin glargine product, Insulin glargine (product), Insulin glargine preparation (substance), Insulin glargine, Insulin glargine (substance), INSULIN,GLARGINE,HUMAN/rDNA</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>126212009, 126207008, 411529005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A recombinant human insulin analog with long-acting, blood glucose-lowering activity. Insulin glargine, like regular types of human insulin, regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, thereby facilitating the cellular uptake of glucose. This lowers blood glucose levels. At the same time, insulin glargine inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. Insulin glargine also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. (NCI05) A drug used to control the amount of sugar in the blood of patients with diabetes. It is a form of the hormone insulin that is made in the laboratory. Insulin glargine controls blood sugar longer than insulin does. It is a type of therapeutic insulin.</FPU_DefNCI><FPU_Name>Insulin Glargine</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0907402</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnlgBslInsln.htm</FPU_URL></item><item><FPU_Page>Anologue Basal Insulin</FPU_Page><FPU_LG_English>Lantus, lantu, lantus</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Lantus</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0876064</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnlgBslInsln.htm</FPU_URL></item><item><FPU_Page>Anologue Basal Insulin</FPU_Page><FPU_LG_English>12C-Lys(B29)-DB30I, B29-tetradecanoyl-Lys-B30-des-Ala-insulin, Insulin Detemir, des-(B30)-insulin, Lys(B29)-tetradecanoyl-, insulin, tetradecanoyllysyl(B29)-desalanyl(B30)-, INSULIN DETEMIR, basal insulin detemir, insulin detemir (medication), Insulin detemir (substance), Insulin detemir product (product), Insulin detemir product, Insulin detemir, insulin detemir, insulin, tetradecanoyl-Lys(B29)-des-Ala(B30)-</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>414518007, 414515005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>insulin detemir</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0537270</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnlgBslInsln.htm</FPU_URL></item><item><FPU_Page>Anologue Basal Insulin</FPU_Page><FPU_LG_English>Levemir, levemir</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Levemir</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1314782</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Pharm/AnlgBslInsln.htm</FPU_URL></item><item><FPU_Page>Multiple Endocrine Neoplasia Type 2</FPU_Page><FPU_LG_English>Multiple endocrine adenomatosis, type IIa, MEA syndrome, type IIa, MEA II, MEN II, Sipple Syndrome, MEA 2a, MEA IIa, MEN 2, MEN 2a, MEN IIa, MEN2a, MULTIPLE ENDOCRINE NEOPLASIA TYPE II, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasms Type 2a, Neoplasia, Multiple Endocrine Type 2a, Neoplasms, Multiple Endocrine Type 2a, MEN syndrome type 2A, Multiple endoc neoplas type 2A, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA, MEN2A, PHEOCHROMOCYTOMA AND AMYLOID-PRODUCING MEDULLARY THYROID CARCINOMA, SIPPLE SYNDROME, PTC SYNDROME, MULTIPLE ENDOCRINE NEOPL TYPE 2A, MEN 002 A, NEOPLASIA MULTIPLE ENDOCRINE TYPE 002 A, NEOPLASMS MULTIPLE ENDOCRINE TYPE 002 A, MEN 002, NEOPL MULTIPLE ENDOCRINE TYPE 2A, type II multiple endocrine neoplasia, multiple endocrine neoplasia, type 2 (diagnosis), multiple endocrine neoplasia, type 2, type II multiple endocrine neoplasia (diagnosis), type IIa multiple endocrine neoplasia (diagnosis), type IIa multiple endocrine neoplasia, Multiple Endocrine Neoplasia Type 2A, MEN 2A, Multiple Endocrine Neoplasia, Type II, Multiple endocrine adenomatosis Type II, Multiple endocrine neoplasia Type II, MEN Type II, MEA Type II, Mult endo neop type IIA, Multiple endocrine neoplasia [MEN] type IIA, Multiple Endocrine Neoplasia Type 2a [Disease/Finding], MEN 2A Syndrome, MEN-2A Syndromes, MEN-2A Syndrome, sipple syndrome, multiple endocrine neoplasia type 2A (MEN 2A), men type 2, men type ii, sipple's syndrome, Multiple endocrine adenomatosis Type IIa, Sipple's syndrome, Familial chromaffinomatosis, MEA, type 2, MEN, type 2, Multiple endocrine adenomatosis, type 2, Multiple endocrine neoplasia, type 2, PTC syndrome, Sipple syndrome, MEN 2A - Multiple endocrine neoplasia syndrome type 2A, MEN 2A syndrome, Multiple endocrine neoplasia syndrome type 2A, Multiple endocrine neoplasia, type 2 (disorder), MEA Type 2a, MEN Type 2a, Multiple Endocrine Adenomatosis Type 2A, Multiple Endocrine Adenomatosis Type 2a, Multiple Endocrine Adenomatosis Type II, Multiple Endocrine Adenomatosis, Type II, Multiple Endocrine Neoplasia Type II, Multiple Endocrine Neoplasia Type 2</FPU_LG_English><FPU_LG_French>Polyadénomatose endocrinienne type IIa, AEM de type II, MEN (adénomatose polyendocrinienne) de type II, Adénomatose polyendocrinienne de type II, Apudomatose de type IIa, Adénomatose endocrine multiple type II, Syndrome de Sipple, Néoplasie endocrinienne multiple de type 2a, Polyadénomatose endocrinienne de type 2A, Adénomatose endocrinienne multiple de type 2a, NEM 2a, NEM IIa, NEM2a</FPU_LG_French><FPU_SnomedCT>61808009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Neoplastic Process (T191)
</FPU_Concepts><FPU_Concepts_Codes>T191</FPU_Concepts_Codes><FPU_DefNCI>Multiple endocrine neoplasia caused by mutation of the RET gene. Patients develop medullary thyroid carcinomas, and may also develop pheochromocytomas and parathyroid gland hyperplasia.</FPU_DefNCI><FPU_Name>Multiple Endocrine Neoplasia Type 2a</FPU_Name><FPU_DefMSH>A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease.</FPU_DefMSH><FPU_Code>C0025268</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Parathyroid/MltplEndcrnNplsTyp1.htm</FPU_URL></item><item><FPU_Page>Multiple Endocrine Neoplasia Type 1</FPU_Page><FPU_LG_English>Multiple endocrine adenomatosis, type I, Wermer's syndrome, MEA syndrome, type I, MEA I, MEN I, Wermer Syndrome, ADENOMATOSIS, POLYGLANDULAR, ENDOCRINE ADENOMA PEPTIC ULCER COMPLEX, MEA 1, MEN 1, MEN1, MULTIPLE ENDOCRINE NEOPLASIA TYPE 1, MULTIPLE ENDOCRINE NEOPLASIA TYPE I, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type I, Multiple Endocrine Neoplasms Type 1, Neoplasia, Multiple Endocrine Type 1, Neoplasms, Multiple Endocrine Type 1, Neoplasms, Multiple Endocrine Type I, MEN syndrome type 1, Multiple endoc neoplas type 1, Wermer's Syndrome, MULTIPLE ENDOCRINE NEOPLASIA, TYPE I, ENDOCRINE ADENOMATOSIS, MULTIPLE, WERMER SYNDROME, NEOPL MULTIPLE ENDOCRINE TYPE 1, MEN 001, NEOPLASIA MULTIPLE ENDOCRINE TYPE 001, NEOPLASMS MULTIPLE ENDOCRINE TYPE 001, MULTIPLE ENDOCRINE NEOPL TYPE 1, type I multiple endocrine neoplasia (diagnosis), type I multiple endocrine neoplasia, Multiple endocrine adenomatosis Type I, Multiple endocrine neoplasia Type I, MEN Type I, MEA Type I, Mult endo neoplas type I, Multiple endocrine neoplasia [MEN] type I, Multiple Endocrine Neoplasia Type 1 [Disease/Finding], wermer syndrome, men 1 syndrome, wermer's syndrome, men type 1, multiple endocrine neoplasia type 1 (MEN1), men type i, multiple endocrine neoplasia type 1 syndrome, MEN1 syndrome, MEA, type 1, MEN, type 1, Multiple endocrine adenomatosis, type 1, Multiple endocrine neoplasia, type 1, Wermer syndrome, MEN 1 - Multiple endocrine neoplasia syndrome type 1, MEN 1 syndrome, Multiple endocrine neoplasia syndrome type 1, Multiple endocrine neoplasia, type 1 (disorder), MEA Type 1, MEN Type 1, Multiple Endocrine Adenomatosis Type 1, Multiple Endocrine Adenomatosis Type I, Multiple Endocrine Adenomatosis, Type I, Multiple Endocrine Neoplasia, Type I</FPU_LG_English><FPU_LG_French>Adénomatose polyendocrinienne de type I, AEM de type I, Apudomatose de type I, Adénomatose endocrine multiple type I, Syndrome de Wermer, Néoplasie endocrinienne multiple de type 1, Polyadénomatose endocrinienne de type 1, Adénomatose endocrinienne multiple de type 1, NEM 1, NEM I, NEM1</FPU_LG_French><FPU_SnomedCT>30664006, 190566000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Neoplastic Process (T191)
</FPU_Concepts><FPU_Concepts_Codes>T191</FPU_Concepts_Codes><FPU_DefNCI>Multiple endocrine neoplasia caused by inactivation of the tumor suppressor gene MEN-1. Patients may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors. A rare, inherited disorder that affects the endocrine glands and can cause tumors in the parathyroid and pituitary glands and the pancreas. These tumors are usually benign (not cancer). They cause the glands to secrete high levels of hormones, which can lead to other medical problems, such as kidney stones, fertility problems, and severe ulcers. In some cases, tumors inside the pancreas can become malignant (cancer).</FPU_DefNCI><FPU_Name>Multiple Endocrine Neoplasia Type 1</FPU_Name><FPU_DefMSH>A form of multiple endocrine neoplasia that is characterized by the combined occurrence of tumors in the PARATHYROID GLANDS, the PITUITARY GLAND, and the PANCREATIC ISLETS. The resulting clinical signs include HYPERPARATHYROIDISM; HYPERCALCEMIA; HYPERPROLACTINEMIA; CUSHING DISEASE; GASTRINOMA; and ZOLLINGER-ELLISON SYNDROME. This disease is due to loss-of-function of the MEN1 gene, a tumor suppressor gene (GENES, TUMOR SUPPRESSOR) on CHROMOSOME 11 (Locus: 11q13).</FPU_DefMSH><FPU_Code>C0025267</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Parathyroid/MltplEndcrnNplsTyp.htm</FPU_URL></item><item><FPU_Page>Hyperparathyroidism</FPU_Page><FPU_LG_English>Hyperparathyroidism, HYPERPARATHYROIDISM, PARATHYROID, HYPERFUNCTION, Hyperparathyroidism, NOS, Hyperparathyroidism, unspecified, hyperparathyroidism (diagnosis), hyperparathyroidism, hyperpth, Hyperparathyroidism NOS, Hyperparathyroidism [Disease/Finding], HPTH - Hyperparathyroidism, Hyperparathyroidism (disorder), hyperfunction; parathyroid, parathyroid; hyperfunction</FPU_LG_English><FPU_LG_French>HYPERPARATHYROIDIE, Hyperparathyroïdie SAI, Hyperparathyroïdie, Hyperparathyroïdisme</FPU_LG_French><FPU_SnomedCT>154696001, 66999008, 190451000</FPU_SnomedCT><FPU_DefCSP>abnormally increased activity of the parathyroid glands, which may be primary or secondary; primary hyperparathyroidism is associated with neoplasia or hyperplasia; excess of parathyroid hormone leads to alteration in function of bone, renal tubules, and gastrointestinal mucosa.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes. A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood). A condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.</FPU_DefNCI><FPU_Name>Hyperparathyroidism</FPU_Name><FPU_DefMSH>A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.</FPU_DefMSH><FPU_Code>C0020502</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Parathyroid/Hyprprthyrdsm.htm</FPU_URL></item><item><FPU_Page>Hyperparathyroidism</FPU_Page><FPU_LG_English>HYPERPARATHYROIDISM, PRIMARY, Hyperparathyroidism, primary, HYPERPARATHYROIDISM PRIMARY, primary hyperparathyroidism, Hyperparathyroidism primary, HYPERPARATHYROID PRIMARY, Primary hyperparathyroid, Hyperparathyroidism, Primary [Disease/Finding], Primary hyperparathyroidism, Primary hyperparathyroidism (disorder), hyperparathyroidism; primary, primary; hyperparathyroidism, Hyperparathyroidism, Primary, Hyperparathyroidisms, Primary, Primary Hyperparathyroidisms, Primary Hyperparathyroidism</FPU_LG_English><FPU_LG_French>Hyperparathyroïdie primaire, Hyperparathyroïdie primitive, Hyperparathyroïdisme primaire, Hyperparathyroïdisme primitif</FPU_LG_French><FPU_SnomedCT>190452007, 36348003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones.</FPU_DefNCI><FPU_Name>Hyperparathyroidism, Primary</FPU_Name><FPU_DefMSH>A condition of abnormally elevated output of PARATHYROID HORMONE due to parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. It is characterized by the combination of HYPERCALCEMIA, phosphaturia, elevated renal 1,25-DIHYDROXYVITAMIN D3 synthesis, and increased BONE RESORPTION.</FPU_DefMSH><FPU_Code>C0221002</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Parathyroid/Hyprprthyrdsm.htm</FPU_URL></item><item><FPU_Page>Obesity Risk</FPU_Page><FPU_LG_English>Adiposity, Obesities, Obesity, OBESE, OBESITY, Obesity, NOS, Obesity, unspecified, obesity (diagnosis), obesity, Obesity NOS, Obesity [Disease/Finding], obese, adiposity, Obesity [Ambiguous], Obese, Obese (finding), Obesity (disorder)</FPU_LG_English><FPU_LG_French>OBESITE, Obésité, non précisée, Obésité</FPU_LG_French><FPU_SnomedCT>5476005, 154776002, 190963004, 414916001, 414915002</FPU_SnomedCT><FPU_DefCSP>excessively high accumulation of body fat or adipose tissue in relation to lean body mass; the amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits; individuals are usually at high clinical risk because of excess amount of body fat (BMI greater than 30).</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Having a high amount of body fat (body mass index [BMI] of 30 or more). A disorder characterized by having a high amount of body fat. A condition marked by an abnormally high, unhealthy amount of body fat.</FPU_DefNCI><FPU_Name>Obesity</FPU_Name><FPU_DefMSH>A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).</FPU_DefMSH><FPU_Code>C0028754</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyRsk.htm</FPU_URL></item><item><FPU_Page>Obesity Risk</FPU_Page><FPU_LG_English>Obesity, Obesity Adverse Event</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Obesity Adverse Event</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1963185</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyRsk.htm</FPU_URL></item><item><FPU_Page>Hypoparathyroidism</FPU_Page><FPU_LG_English>HYPOPARATHYROIDISM, Hypoparathyroidism, NOS, Hypoparathyroidism NOS, Hypoparathyroidism, unspecified, hypoparathyroidism (diagnosis), hypoparathyroidism, HYPOPARATHYROID, Hypoparathyroidism NOS (disorder), Hypoparathyroidism [Disease/Finding], hypoparathyroid, Deficiency of PTH, Deficiency of parathyrin, Deficiency of parathyroid hormone, Hypoparathyroidism (disorder), deficiency; parathyroid, insufficiency; parathyroid, parathyroid; deficiency, parathyroid; insufficiency, Hypoparathyroidism</FPU_LG_English><FPU_LG_French>HYPOPARATHYROIDIE, Hypoparathyroïdie, Insuffisance parathyroïdienne, Hypoparathyroïdisme</FPU_LG_French><FPU_SnomedCT>190457001, 36976004, 154697005, 267479004</FPU_SnomedCT><FPU_DefCSP>condition produced by greatly reduced function of the parathyroids possibly due to autoimmune disease or genetic factors, or by the removal of those bodies; lack of parathyroid hormone leads to a fall in plasma calcium level, which may result in increase neuromuscular excitability and ultimately tetany followed by a rise in plasma phosphate level.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>An endocrine disorder characterized by decreased production of parathyroid hormone by the parathyroid glands. It is usually caused by damage of the parathyroid glands during head and neck surgery. Signs and symptoms include muscle cramps, abdominal pain, dry skin, brittle nails, cataracts, tetany, and convulsions. A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.</FPU_DefNCI><FPU_Name>Hypoparathyroidism</FPU_Name><FPU_DefMSH>A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.</FPU_DefMSH><FPU_Code>C0020626</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Parathyroid/Hyprthyrdsm.htm</FPU_URL></item><item><FPU_Page>Dietary Supplements in Obesity</FPU_Page><FPU_LG_English>Supplement, Dietary, Supplements, Dietary, Dietary Supplement, Nutritional Supplement, Supplement, dietary supplements, dietary supplements (medication), Dietary supplement, nutritional supplementation, nutrient supplementation, dietary supplement, nutritional supplement, Nutrient supplementation, Nutritional supplementation, Nutrient supplementation (product), Nutritional supplement (product), Nutritional supplement (substance), Nutritional supplement, Dietary Supplements, Nutrient supplementation (substance), Nutritional Supplements, nutritional supplements</FPU_LG_English><FPU_LG_French>Compléments alimentaires</FPU_LG_French><FPU_SnomedCT>373689005, 226279009, 108961000, 373453009</FPU_SnomedCT><FPU_DefCSP>something that completes a diet, offsets a dietary deficiency or strengthens the diet.</FPU_DefCSP><FPU_Concepts>Food (T168)
</FPU_Concepts><FPU_Concepts_Codes>T168</FPU_Concepts_Codes><FPU_DefNCI>A product that is added to the diet. A dietary supplement is taken by mouth, and usually contains one or more dietary ingredient (such as vitamin, mineral, herb, amino acid, and enzyme). Oral preparations containing dietary ingredient(s) intended to supplement the diet. Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites.</FPU_DefNCI><FPU_Name>Dietary Supplements</FPU_Name><FPU_DefMSH>Products in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance. (FDA Backgrounder, June 15, 1993, p2)</FPU_DefMSH><FPU_Code>C0242295</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/DtrySplmntsInObsty.htm</FPU_URL></item><item><FPU_Page>Obesity Measurement</FPU_Page><FPU_LG_English>Obesity screen, Weight screen (&amp;amp; [obesity]) (procedure), screening obesity, obesity screening, Obesity screening (procedure), Obesity screening, Weight screen, Weight screen (&amp;amp; [obesity])</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>171192001, 148407009, 268551005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Therapeutic or Preventive Procedure (T061)
</FPU_Concepts><FPU_Concepts_Codes>T061</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Obesity screen</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0740216</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyMsrmnt.htm</FPU_URL></item><item><FPU_Page>Obesity Measurement</FPU_Page><FPU_LG_English>Adiposity, Obesities, Obesity, OBESE, OBESITY, Obesity, NOS, Obesity, unspecified, obesity (diagnosis), obesity, Obesity NOS, Obesity [Disease/Finding], obese, adiposity, Obesity [Ambiguous], Obese, Obese (finding), Obesity (disorder)</FPU_LG_English><FPU_LG_French>OBESITE, Obésité, non précisée, Obésité</FPU_LG_French><FPU_SnomedCT>5476005, 154776002, 190963004, 414916001, 414915002</FPU_SnomedCT><FPU_DefCSP>excessively high accumulation of body fat or adipose tissue in relation to lean body mass; the amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits; individuals are usually at high clinical risk because of excess amount of body fat (BMI greater than 30).</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Having a high amount of body fat (body mass index [BMI] of 30 or more). A disorder characterized by having a high amount of body fat. A condition marked by an abnormally high, unhealthy amount of body fat.</FPU_DefNCI><FPU_Name>Obesity</FPU_Name><FPU_DefMSH>A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).</FPU_DefMSH><FPU_Code>C0028754</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyMsrmnt.htm</FPU_URL></item><item><FPU_Page>Postpartum Thyroiditis</FPU_Page><FPU_LG_English>postpartum thyroiditis (diagnosis), postpartum thyroiditis, Postpartum Thyroiditis [Disease/Finding], thyroiditis postpartum, Postpartum thyroiditis, Postpartum thyroiditis (disorder), postpartum; thyroiditis, thyroiditis; postpartum, Post partum Thyroiditis, Post-partum Thyroiditides, Post-partum Thyroiditis, Postpartum Thyroiditides, Postpartum Thyroiditis, Thyroiditides, Post-partum, Thyroiditides, Postpartum, Thyroiditis, Post-partum, Thyroiditis, Postpartum</FPU_LG_English><FPU_LG_French>Thyroïdite du post-partum, Thyroïdite du postpartum</FPU_LG_French><FPU_SnomedCT>199241008, 52772002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Postpartum Thyroiditis</FPU_Name><FPU_DefMSH>Transient autoimmune thyroiditis occurring in the POSTPARTUM PERIOD. It is characterized by the presence of high titers of AUTOANTIBODIES against THYROID PEROXIDASE and THYROGLOBULIN. Clinical signs include the triphasic thyroid hormone pattern: beginning with THYROTOXICOSIS, followed with HYPOTHYROIDISM, then return to euthyroid state by 1 year postpartum.</FPU_DefMSH><FPU_Code>C0271815</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/OB/PstprtmThyrdts.htm</FPU_URL></item><item><FPU_Page>Obesity Medication</FPU_Page><FPU_LG_English>Anorectics, Appetite Depressants, Appetite Suppressants, Depressants, Appetite, Suppressants, Appetite, anorexic agent, Appetite depressants, Anorexigenic Drugs, Appetite-Depressing Drugs, Drugs, Anorexigenic, Drugs, Appetite-Depressing, APPETITE DEPRESS, APPETITE SUPPRESSANTS, Anorexic Agent, Anorexics, anorexigenic drug, appetite depressant, Anorexic Drugs, Drugs, Anorexic, Appetite Suppressant Drugs, Appetite-Suppressant Drugs, Drugs, Appetite-Suppressant, anorectic agents, anorexiants, appetite depressants, appetite suppressants, anorexics (medication), anorexics, Anorexiant product, Appetite Suppressant, [GA750] APPETITE SUPPRESSANTS, Anorexic drugs, Anorectic Agents, Agents, Anorectic, anorectics, anorexiant, agents anorexic, appetite suppressant, appetite drugs suppressants, anorexic drugs, anorectic agent, appetite suppressant drugs, Anorexiant (substance), Anorexiant product (product), Anorexiant, Appetite Depressing Drugs</FPU_LG_English><FPU_LG_French>Anorexigènes, Agents anorexigènes, Suppresseurs de l'appétit, Médicaments anorexigènes, Coupe-faim, Modérateurs de l'appétit</FPU_LG_French><FPU_SnomedCT>371141007, 108374003</FPU_SnomedCT><FPU_DefCSP>class of drugs which suppress appetite, used for weight control.</FPU_DefCSP><FPU_Concepts>Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T121</FPU_Concepts_Codes><FPU_DefNCI>Any substance that induces loss of appetite to prevent weight gain and achieve weight loss.</FPU_DefNCI><FPU_Name>Appetite Depressants</FPU_Name><FPU_DefMSH>Agents that are used to suppress appetite.</FPU_DefMSH><FPU_Code>C0003620</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyMdctn.htm</FPU_URL></item><item><FPU_Page>Obesity Medication</FPU_Page><FPU_LG_English>Agents, Anti-Obesity, Agents, Antiobesity, Anti Obesity Agents, Anti Obesity Drugs, Anti-Obesity Agents, Anti-Obesity Drugs, Antiobesity Agents, Antiobesity Drugs, Drugs, Anti-Obesity, Drugs, Antiobesity, ANTIOBESITY AGENTS, anti-obesity agents (medication), anti-obesity agents, anti obesity drug, antiobesity drug, anti obesity drugs, antiobesity drugs, anti-obesity drugs</FPU_LG_English><FPU_LG_French>Pilules antiobésité, Médicaments anti-obésité, Médicaments antiobésité, Pilules anti-obésité, Médicaments contre l'obésité, Agents antiobésité, Agents anti-obésité</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Pharmacologic Substance (T121)
</FPU_Concepts><FPU_Concepts_Codes>T121</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Anti-Obesity Agents</FPU_Name><FPU_DefMSH>Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.</FPU_DefMSH><FPU_Code>C0376607</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyMdctn.htm</FPU_URL></item><item><FPU_Page>Obesity Management</FPU_Page><FPU_LG_English>Obesity monitoring status, Obesity monitoring status (finding)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>243862009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Obesity monitoring status</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0421268</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyMngmnt.htm</FPU_URL></item><item><FPU_Page>Obesity Management</FPU_Page><FPU_LG_English>Weight Control, Weight maintenance diet, Weight Management, Weight maintenance regimen or diet, weight control (history), weight control, rnrx weight control, rnrx weight control (treatment), controling weight, Weight control, Weight maintenance regimen (regime/therapy), Weight management, Weight maintenance regimen, weight management</FPU_LG_English><FPU_LG_French>Contrôle du poids</FPU_LG_French><FPU_SnomedCT>388962008</FPU_SnomedCT><FPU_DefCSP>therapy to regulate body weight.</FPU_DefCSP><FPU_Concepts>Therapeutic or Preventive Procedure (T061)
</FPU_Concepts><FPU_Concepts_Codes>T061</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Weight maintenance regimen</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0920298</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyMngmnt.htm</FPU_URL></item><item><FPU_Page>Obesity Management</FPU_Page><FPU_LG_English>Obesity, Obesity Adverse Event</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Obesity Adverse Event</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1963185</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyMngmnt.htm</FPU_URL></item><item><FPU_Page>Obesity</FPU_Page><FPU_LG_English>OVERWEIGHT, OVER WEIGHT, Overweight (BMI &amp;lt;30), overweight (diagnosis), overweight (physical finding), overweight, Overweight [Disease/Finding], clinical overweight, Patient overweight, Overweight (finding), Overweight, overweight (BMI&amp;lt;30), Overweight (BMI 25-30)</FPU_LG_English><FPU_LG_French>Surplus de poids, Excédent de poids, Excès de poids, Exces de poids (IMC &amp;lt;30), Surcharge pondérale, Surpoids</FPU_LG_French><FPU_SnomedCT>238131007, 23495001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Sign or Symptom (T184)
</FPU_Concepts><FPU_Concepts_Codes>T184</FPU_Concepts_Codes><FPU_DefNCI>Being too heavy for one's height. Excess body weight can come from fat, muscle, bone, and/or water retention. Being overweight does not always mean being obese.</FPU_DefNCI><FPU_Name>Overweight</FPU_Name><FPU_DefMSH>A status with BODY WEIGHT that is above certain standard of acceptable or desirable weight. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal "over fat".</FPU_DefMSH><FPU_Code>C0497406</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/Obsty.htm</FPU_URL></item><item><FPU_Page>Obesity</FPU_Page><FPU_LG_English>Adiposity, Obesities, Obesity, OBESE, OBESITY, Obesity, NOS, Obesity, unspecified, obesity (diagnosis), obesity, Obesity NOS, Obesity [Disease/Finding], obese, adiposity, Obesity [Ambiguous], Obese, Obese (finding), Obesity (disorder)</FPU_LG_English><FPU_LG_French>OBESITE, Obésité, non précisée, Obésité</FPU_LG_French><FPU_SnomedCT>5476005, 154776002, 190963004, 414916001, 414915002</FPU_SnomedCT><FPU_DefCSP>excessively high accumulation of body fat or adipose tissue in relation to lean body mass; the amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits; individuals are usually at high clinical risk because of excess amount of body fat (BMI greater than 30).</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Having a high amount of body fat (body mass index [BMI] of 30 or more). A disorder characterized by having a high amount of body fat. A condition marked by an abnormally high, unhealthy amount of body fat.</FPU_DefNCI><FPU_Name>Obesity</FPU_Name><FPU_DefMSH>A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).</FPU_DefMSH><FPU_Code>C0028754</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/Obsty.htm</FPU_URL></item><item><FPU_Page>Obesity Evaluation</FPU_Page><FPU_LG_English>Adiposity, Obesities, Obesity, OBESE, OBESITY, Obesity, NOS, Obesity, unspecified, obesity (diagnosis), obesity, Obesity NOS, Obesity [Disease/Finding], obese, adiposity, Obesity [Ambiguous], Obese, Obese (finding), Obesity (disorder)</FPU_LG_English><FPU_LG_French>OBESITE, Obésité, non précisée, Obésité</FPU_LG_French><FPU_SnomedCT>5476005, 154776002, 190963004, 414916001, 414915002</FPU_SnomedCT><FPU_DefCSP>excessively high accumulation of body fat or adipose tissue in relation to lean body mass; the amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits; individuals are usually at high clinical risk because of excess amount of body fat (BMI greater than 30).</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Having a high amount of body fat (body mass index [BMI] of 30 or more). A disorder characterized by having a high amount of body fat. A condition marked by an abnormally high, unhealthy amount of body fat.</FPU_DefNCI><FPU_Name>Obesity</FPU_Name><FPU_DefMSH>A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).</FPU_DefMSH><FPU_Code>C0028754</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Obesity/ObstyEvltn.htm</FPU_URL></item><item><FPU_Page>Infantile Hypothyroidism</FPU_Page><FPU_LG_English>CRETINISM, CRETINISM, INFANTILE, HYPOTHYROIDISM CONGENITAL, HYPOTHYROIDISM, CONGENITAL, HYPOTHYROIDISM, INFANTILE, Cretinism, NOS, Congen hypothy not iodine def, Congenital hypothyroidism NOS, CONGEN HYPOTHYROIDISM, CHT - Congenit hypothyroidism, Hypothyroidism, congenital, congenital hypothyroidism (diagnosis), congenital hypothyroidism, Cretinism (disorder), Congenital hypothyroidism: [cretinism] or [NOS] (disorder), Hypothyroidism congenital, Congenital hypothyroidsm, Congenital hypothyroidism NOS (disorder), Congenital Hypothyroidism [Disease/Finding], infantile hypothyroidism, Hypothyroidism;congenital, hypothyroidism congenital, Congenital Hypothyroidism, Congenital hypothyroidism, Infantile hypothyroidism, Congenital hypothyroidism not due to iodine deficiency, Congenital goiter, Congenital goitre, CHT - Congenital hypothyroidism, Congenital hypothyroidism (disorder), congenital; hypothyroidism, cretin; type hypothyroid, cretin, hypothyroid; cretin (type), hypothyroidism; congenital, insufficiency; thyroid, congenital, thyroid; insufficiency, congenital, Congenital hypothyroidism: [cretinism] or [NOS], Cretinism (disorder) [Ambiguous], Congenital thyroid insufficiency, Goitrous cretinism, Cretinism, Hypothyroidism, Congenital, cretinism</FPU_LG_English><FPU_LG_French>Hypothyroïdisme congénital, HYPOTHYROIDIE CONGENITALE, Crétinisme, Hypothyroïdie congénitale</FPU_LG_French><FPU_SnomedCT>3614006, 190273009, 154661001, 75065003, 267376007, 190268003, 217710005, 154660000, 267465007</FPU_SnomedCT><FPU_DefCSP>condition due to congenital lack of thyroid hormone, marked by arrested physical and mental development, dystrophy of the bones and soft parts, and lowered basal metabolism; it is the congenital form of thyroid deficiency, while myxedema is the acquired form.</FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI>A deficiency of thyroid hormone present at birth. The etiology can be genetic or environmental, or a combination of both; treatment is based on severity and causality.</FPU_DefNCI><FPU_Name>Congenital Hypothyroidism</FPU_Name><FPU_DefMSH>A condition in infancy or early childhood due to an in-utero deficiency of THYROID HORMONES that can be caused by genetic or environmental factors, such as thyroid dysgenesis or HYPOTHYROIDISM in infants of mothers treated with THIOURACIL during pregnancy. Endemic cretinism is the result of iodine deficiency. Clinical symptoms include severe MENTAL RETARDATION, impaired skeletal development, short stature, and MYXEDEMA.</FPU_DefMSH><FPU_Code>C0010308</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/NICU/InfntlHypthyrdsm.htm</FPU_URL></item><item><FPU_Page>Ornithine Transcarbamylase Deficiency</FPU_Page><FPU_LG_English>Ornithine carbamoyltransferase deficiency, OCT-Ornith carbamoyltransf def, OTC-Ornith transcarbamyl defic, Ornith carbamoyltransferas def, Ornithin transcarbamoylase def, ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO, ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY, OTC DEFICIENCY, ORNITHINE CARBAMOYLTRANSFERASE DEFIC DIS, ORNITHINE TRANSCARBAMYLASE DEFIC DIS, DEFIC DIS ORNITHINE CARBAMOYLTRANSFERASE, DEFIC DIS ORNITHINE TRANSCARBAMYLASE, ornithine carbamoyltransferase deficiency, ornithine transcarbamylase deficiency, ornithine transcarbamylase deficiency (diagnosis), Deficiency of ornithine carbamoyltransferase (disorder), Deficiency Disease, Ornithine Carbamoyltransferase, Ornithine Carbamoyltransferase Deficiency Disease, Deficiency Disease, Ornithine Transcarbamylase, Ornithine Transcarbamylase Deficiency Disease, Ornithine Transcarbamylase Deficiency, Deficiency, Ornithine Transcarbamylase, Deficiencies, OTC, OTC Deficiencies, Deficiencies, Ornithine Transcarbamylase, Deficiency, OTC, Ornithine Transcarbamylase Deficiencies, OTC Deficiency, ornithine carbomoyltransferase (OCT) deficiency, ornithine carbomoyltransferase deficiency, hyperammonemia due to ornithine transcarbamylase deficiency, ornithine transcarbamylase (OTC) deficiency (OTCD), hyperammonemic syndrome, Ornithine Carbamoyltransferase Deficiency Disease [Disease/Finding], octd, ornithine carbamoyltransferase deficiency (OCTD), OCT deficiency, OCTD, Ornithine transcarbamylase deficiency, OCT - Ornithine carbamoyltransferase deficiency, OTC - Ornithine transcarbamylase deficiency, Ornithine transcarbamoylase deficiency, Deficiency of citrulline phosphorylase, Deficiency of ornithine carbamoyltransferase, Deficiency of ornithine transcarbamylase, Ornithine carbamoyltransferase deficiency (disorder), deficiency; ornithine transcarbamylase, ornithine transcarbamylase; deficiency</FPU_LG_English><FPU_LG_French>Carence en ornithine carbamoyltransférase, Déficit en ornithine transcarbamylase, Carence en ornithine transcarbamylase, Déficience en ornithine-transcarbamylase, Déficit en OTC, Déficit en ornithine carbamyl transférase, Déficit en ornithine carbamyltransférase</FPU_LG_French><FPU_SnomedCT>124249000, 80908008</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine transcarbamylase, resulting in the accumulation of ammonia in the serum. Symptoms include vomiting, lethargy, and coma. An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine carbamoyltransferase, resulting in the accumulation of amino acids and ammonia in the serum. Signs and symptoms include seizures, delayed growth, behavioral changes, ataxia, lethargy, and coma.</FPU_DefNCI><FPU_Name>Ornithine carbamoyltransferase deficiency</FPU_Name><FPU_DefMSH>An inherited urea cycle disorder associated with deficiency of the enzyme ORNITHINE CARBAMOYLTRANSFERASE, transmitted as an X-linked trait and featuring elevations of amino acids and ammonia in the serum. Clinical features, which are more prominent in males, include seizures, behavioral alterations, episodic vomiting, lethargy, and coma. (Menkes, Textbook of Child Neurology, 5th ed, pp49-50)</FPU_DefMSH><FPU_Code>C0268542</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/OrnthnTrnscrbmylsDfcncy.htm</FPU_URL></item><item><FPU_Page>Ornithine Transcarbamylase Deficiency</FPU_Page><FPU_LG_English>Hyperornithinemia, NOS, Ornithinemia, OAT-Ornth ox-acd amno trns def, Ornith ketoacid transamin def, Ornith oxo-acid aminotrans def, Ornith oxoacidaminotrans def, Ornithine oxoacidaminotransferase deficiency, Hyperornithinaemia, NOS, Hyperornithinemia, Ornithine oxo-acid aminotransferase deficiency, ornithine aminotransferase deficiency, hyperornithinemia (diagnosis), hyperornithinemia, Hyperornithinemia with gyrate atrophy of choroid and retina, Ornithine ketoacid aminotransferase deficiency, Ornithine aminotransferase deficiency, Gyrate atrophy of choroid and retina, OAT deficiency, OKT deficiency, Ornithine ketoacid transaminase deficiency, Ornithine-delta-aminotransferase deficiency, Ornithine-oxo-acid amino acid transferase deficiency, Hyperornithinaemia, OAT - Ornithine oxo-acid aminotransferase deficiency, Hyperornithinemia (disorder), Ornithine oxo-acid aminotransferase deficiency (disorder), ornithinemia, Ornithine oxo-acid aminotransferase deficiency [Ambiguous], Deficiency of ornithine-oxo-acid aminotransferase (disorder), Deficiency of ornithine-oxo-acid aminotransferase</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>276426004, 190716009, 193471005, 33985005, 87126009, 124292005</FPU_SnomedCT><FPU_DefCSP>excess of ornithine in the plasma, such as occurs in the genetic disorders gyrate atrophy of choroid and retina and hyperornithinemia-hyperamonemia-homocitrullinuria syndrome.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hyperornithinemia</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0599035</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/OrnthnTrnscrbmylsDfcncy.htm</FPU_URL></item><item><FPU_Page>Diabetic Neuropathy</FPU_Page><FPU_LG_English>Neuropathy, diabetic, DIABETIC NEUROPATHY, Neuropathies, Diabetic, Diabetic neuropathies, NEUROPATHY, DIABETIC, Neuropathy, Diabetic, Diab.mell. with neuropathy, NEUROPATHY DIABETIC, Diabetes mellitus NOS with neurological manifestation (disorder), Diabetes mellitus NOS with neurological manifestation, Diabetic Neuropathies [Disease/Finding], Neuropathy;diabetic, diabetic nerve damage, diabetic neuropathies, Diabetic neuropathy, Diabetes mellitus with neuropathy, Diabetic neuropathy (disorder), neuropathy; diabetes (manifestation), Diabetes mellitus with neurological manifestation, Diabetes + neuropathy, Diabetic neuropathy (disorder) [Ambiguous], Neuropathy - diabetic, Diabetic Neuropathies, Diabetic Neuropathy, Diabetes with neurological manifestations, diabetic neuropathy</FPU_LG_English><FPU_LG_French>Neuropathie diabétique, Neuropathies diabétiques</FPU_LG_French><FPU_SnomedCT>866003, 190353001, 230572002, 154683002, 193182005, 267472008, 190349003</FPU_SnomedCT><FPU_DefCSP>common complication of diabetes mellitus in which nerves are damaged as a result of hyperglycemia (high blood sugar levels).</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Diabetic Neuropathies</FPU_Name><FPU_DefMSH>Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)</FPU_DefMSH><FPU_Code>C0011882</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Neuro/DbtcNrpthy.htm</FPU_URL></item><item><FPU_Page>Phenylketonuria</FPU_Page><FPU_LG_English>Phenylketonuria, Phenylketonuria (PKU), PHENYLKETONURIA, PKU, PHENYLKETOURIA, PKU - Phenylketonuria, Phenylketonuria, NOS, phenylalaninemia, phenylketonuria (diagnosis), phenylketonuria, Phenylketonuria (disorder), Phenylalaninemia, Phenylketouria, Phenylketonuria - pku, Phenylketonurias [Disease/Finding], phenylketonurias, phenylketonuria (PKU), phenylketouria, pku phenylketonuria, Phenylalaninaemia, Phenylketonurias, PKU (Hereditary Disorder), Phenylketonuria [PKU]</FPU_LG_English><FPU_LG_French>PHENYLCETONURIE, Phénylalaninémie, Phénylkétonurie (PKU), PKU, Phénylcétonuries, Phénylcétonurie</FPU_LG_French><FPU_SnomedCT>190687004, 154735006</FPU_SnomedCT><FPU_DefCSP>group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme phenylaline hydroxylase or less frequently by reduced activity of dihydropteridine reductase.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A disorder characterized by the body's inability to break down and utilize the essential amino acid phenylalanine. An inherited disorder that causes a build-up of phenylalanine (an amino acid) in the blood. This can cause mental retardation, behavioral and movement problems, seizures, and delayed development. Using a blood test, PKU can easily be found in newborns, and treatment is a diet low in phenylalanine.</FPU_DefNCI><FPU_Name>Phenylketonurias</FPU_Name><FPU_DefMSH>A group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme PHENYLALANINE HYDROXYLASE or less frequently by reduced activity of DIHYDROPTERIDINE REDUCTASE (i.e., atypical phenylketonuria). Classical phenylketonuria is caused by a severe deficiency of phenylalanine hydroxylase and presents in infancy with developmental delay; SEIZURES; skin HYPOPIGMENTATION; ECZEMA; and demyelination in the central nervous system. (From Adams et al., Principles of Neurology, 6th ed, p952).</FPU_DefMSH><FPU_Code>C0031485</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/Phnylktnr.htm</FPU_URL></item><item><FPU_Page>Methylmalonic acidemia</FPU_Page><FPU_LG_English>Methylmalonic acidemia, NOS, Methylmalonic aciduria, methylmalonic aciduria, methylmalonic acidemia (diagnosis), methylmalonic aciduria (diagnosis), methylmalonic acidemia, Methylmalonic acidemias, Acidemia, methylmalonic, Methylmalonic acidemia, methylmalonic acidaemia, acidemias methylmalonic, MMA - Methylmalonic aciduria, Methylmalonic acidaemia, Methylmalonic acidemia (disorder), disorder; methylmalonic acidemia, acidemia; methylmalonic, methylmalonic acidemia; disorder, methylmalonic; acidemia</FPU_LG_English><FPU_LG_French>Acidurie méthylmalonique</FPU_LG_French><FPU_SnomedCT>42393006, 190727006</FPU_SnomedCT><FPU_DefCSP>autosomal recessive aminoacidopathy characterized by an excess of methylmalonic acid in the blood and urine, with metabolic ketoacidosis, hyperglycinemia, hyperglycinuria and hyperammonemia; results from defects that cause deficiencies of methylmalonyl-CoA mutase.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Methylmalonic acidemia</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0268583</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/MthylmlncAcdm.htm</FPU_URL></item><item><FPU_Page>Inborn Errors of Metabolism</FPU_Page><FPU_LG_English>Metabolism, Inborn errors of, Error, Inborn Metabolism, Errors Metabolism, Inborn, Errors Metabolisms, Inborn, Errors, Inborn Metabolism, Inborn Errors Metabolism, Inborn Errors Metabolisms, Inborn Metabolism Error, Inborn Metabolism Errors, Metabolism Error, Inborn, Metabolism Errors, Inborn, Metabolism Inborn Error, Metabolism Inborn Errors, Metabolism, Inborn Errors, Metabolisms, Inborn Errors, inborn metabolism disorder, Inborn error of metabolism, NOS, METAB ERR INBORN, INBORN ERR METAB, METAB INBORN ERR, IBEM - Inborn error of metabol, IEM - Inborn error metabolism, Congenital Metabolic Disorder, Inborn Errors of Metabolism, Inborn error of metabolism NOS, Metabolism, Inborn Errors [Disease/Finding], inborn error of metabolism, inborn error metabolism, errors inborn metabolism, inborn errors metabolism, inborn errors of metabolism, Inborn errors of metabolism, Inborn error of metabolism, IBEM - Inborn error of metabolism, IEM - Inborn error of metabolism, Inborn error of metabolism (disorder), Metabolic hereditary disorder (disorder), Metabolic hereditary disorder</FPU_LG_English><FPU_LG_French>Erreur innée du métabolisme SAI, Erreur innée du métabolisme, Erreurs innées du métabolisme, Maladies métaboliques congénitales</FPU_LG_French><FPU_SnomedCT>86095007, 363205007</FPU_SnomedCT><FPU_DefCSP>errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.</FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI>A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.</FPU_DefNCI><FPU_Name>Inborn Errors of Metabolism</FPU_Name><FPU_DefMSH>Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.</FPU_DefMSH><FPU_Code>C0025521</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/InbrnErrsOfMtblsm.htm</FPU_URL></item><item><FPU_Page>Hereditary Fructose Intolerance</FPU_Page><FPU_LG_English>Fructose Intolerance, Fructose Intolerances, Intolerances, Fructose, FRUCTOSE INTOLERANCE, Intolerance, Fructose, hereditary fructose intolerance, Fructose intolerance, NOS, Hereditary fructose intolerance syndrome, ALDB - aldolose B deficiency, Fructo-16-bisphosph aldolB def, Hereditary fructose intoleran., ALDB - aldolase B deficiency, FRUCTOSEMIA, FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE B DEFICIENCY, ALDOLASE B DEFICIENCY, FRUCTOSE INTOLERANCE, HEREDITARY, FRUCTOSE-1-PHOSPHATE ALDOLASE DEFICIENCY, fructose 1 phosphate aldolase deficiency, fructose intolerance (diagnosis), fructose intolerance, Fructosemia (disorder), Fructose intolerance hereditary, ALDOB DEFICIENCY, Hered fructose intoleran, Hereditary Fructose Intolerance, Intolerance, Hereditary Fructose, Hereditary Fructose Intolerances, Aldolase Deficiency, Fructose-1-Phosphate, Fructose 1 Phosphate Aldolase Deficiency, Deficiencies, Fructose-1-Phosphate Aldolase, Fructose-1,6-Biphosphate Aldolase Deficiency, Aldolase Deficiencies, Fructose-1,6-Biphosphate, Intolerances, Hereditary Fructose, Fructose-1-Phosphate Aldolase Deficiency, Aldolase Deficiencies, Fructose-1-Phosphate, Fructose-1,6-Biphosphate Aldolase Deficiencies, Fructose Aldolase B Deficiency, Aldolase Deficiency, Fructose-1,6-Biphosphate, Fructose-1-Phosphate Aldolase Deficiencies, Fructose 1,6 Biphosphate Aldolase Deficiency, Fructose Intolerance, Hereditary, Fructose Intolerances, Hereditary, Deficiency, Fructose-1-Phosphate Aldolase, Deficiencies, Fructose-1,6-Biphosphate Aldolase, Deficiency, Fructose-1,6-Biphosphate Aldolase, Fructose Intolerance [Disease/Finding], fructose hereditary intolerance, fructose intolerance hereditary, Hereditary fructose intolerance, Fructosemia, ALDB deficiency, Aldolase B deficiency, Fructose-1-phosphate aldolase deficiency, Fructose-biphosphate aldolase B deficiency, Hereditary fructosuria, Fructosaemia, Fructose-1,6-bisphosphate aldolase B deficiency, Fructose intolerance, Fructose-1,6-bisphosphate aldolase B deficiency (disorder), fructose; intolerance, fructosemia, intolerance; fructose, Hereditary fructosuria (disorder)</FPU_LG_English><FPU_LG_French>Intolérance au fructose héréditaire, Intolérance héréditaire au fructose, Déficit héréditaire en fructose-1-phosphate aldolase, Fructosémie congénitale, Intolérance au fructose</FPU_LG_French><FPU_SnomedCT>20052008, 20290005, 237962008</FPU_SnomedCT><FPU_DefCSP>autosomal recessive fructose metabolism disorder due to deficient fructose-1-phosphate aldolase (EC 2.1.2.13) activity, resulting in accumulation of fructose-1-phosphate; accumulated fructose-1-phosphate inhibits glycogenolysis and gluconeogenesis, causing severe hypoglycemia following ingestion of fructose; prolonged fructose ingestion in infants leads ultimately to hepatic failure and death; patients develop a strong distaste for sweet food, and avoid a chronic course of the disease by remaining on a fructose- and sucrose-free diet.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A genetic disorder characterized by the absence of the enzyme aldolase-B from the liver. This enzyme is essential for the metabolism of fructose. Signs and symptoms from fructose ingestion are evident in infancy and include vomiting, abdominal pain and hypoglycemia. Long term complications include hepatic and renal failure.</FPU_DefNCI><FPU_Name>Hereditary fructose intolerance syndrome</FPU_Name><FPU_DefMSH>An autosomal recessive fructose metabolism disorder due to deficient fructose-1-phosphate aldolase (EC 2.1.2.13) activity, resulting in accumulation of fructose-1-phosphate. The accumulated fructose-1-phosphate inhibits glycogenolysis and gluconeogenesis, causing severe hypoglycemia following ingestion of fructose. Prolonged fructose ingestion in infants leads ultimately to hepatic failure and death. Patients develop a strong distaste for sweet food, and avoid a chronic course of the disease by remaining on a fructose- and sucrose-free diet.</FPU_DefMSH><FPU_Code>C0016751</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/HrdtryFrctsIntlrnc.htm</FPU_URL></item><item><FPU_Page>MCAD Deficiency</FPU_Page><FPU_LG_English>Deficiency of medium-chain acyl-CoA dehydrogenase, MCAD DEFICIENCY, MCADH DEFICIENCY, CARNITINE DEFICIENCY SECONDARY TO MEDIUM-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY, ACADM DEFICIENCY, ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF, Medium-chain acyl-coenzyme A dehydrogenase deficiency, medium-chain acyl-CoA dehydrogenase deficiency, medium-chain acyl-CoA dehydrogenase deficiency (diagnosis), Medium chain acyl-CoA dehydrogenase deficiency (disorder), MCAD-Med ch acyl-CoA dehyd def, Med ch acyl-CoA dehydrog defic, MCAD, Acyl-CoA Dehydrogenase, Medium-Chain Deficiency, Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency (MCAD), Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Medium-chain Acyl-CoA dehydrogenase deficiency, Medium chain acyl CoA dehydrogenase deficiency, Acyl-CoA dehydrogenase, medium chain, deficiency of, mcad deficiency, ACADMD, MCAD deficiency, MCAD - Medium chain acyl-CoA dehydrogenase deficiency, Medium chain acyl-CoA dehydrogenase deficiency, Medium-chain acyl-coenzyme A dehydrogenase deficiency (disorder), Medium chain acyl CoA dehydrogenase deficiency (MCAD)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>393571006, 394513008, 128596003, 74351001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A genetic disorder characterized by deficiency of the enzyme medium-chain acyl-coenzyme A dehydrogenase that metabolizes medium-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia and lethargy.</FPU_DefNCI><FPU_Name>Medium-chain acyl-coenzyme A dehydrogenase deficiency</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0220710</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/McdDfcncy.htm</FPU_URL></item><item><FPU_Page>Homocystinuria</FPU_Page><FPU_LG_English>HOMOCYSTINURIA, Homocystinuria, NOS, Homocystinuria, cystathionine synthase deficiency, homocystinuria, homocystinuria (diagnosis), Cystathionine synthase deficiency, Homocystinuria [Disease/Finding], homocystinurias, Homocystinuria (disorder), Homocystinuria [Ambiguous]</FPU_LG_English><FPU_LG_French>Homocystinurie</FPU_LG_French><FPU_SnomedCT>190709008, 11282001</FPU_SnomedCT><FPU_DefCSP>autosomal recessive inborn error of methionine metabolism usually caused by a deficiency of cystathionine beta-synthase and associated with elevations of homocysteine in plasma and urine; clinical features include a tall, slender habitus, scoliosis, arachnodactyly, muscle weakness, genu varis, thin blond hair, malar flush, lens dislocations, an increased incidence of mental retardation, and a tendency to develop fibrosis of arteries, frequently complicated by cerebrovascular accidents and myocardial infarction.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>An autosomal recessive inherited metabolic disorder caused by mutations in the CBS, MTHFR, MTR, and MTRR genes. It is characterized by abnormalities in the methionine metabolism and is associated with deficiency of cystathionine synthase. It results in the accumulation of homocysteine in the serum. It may affect the cardiovascular, musculoskeletal and the central nervous systems.</FPU_DefNCI><FPU_Name>Homocystinuria</FPU_Name><FPU_DefMSH>Autosomal recessive inborn error of methionine metabolism usually caused by a deficiency of CYSTATHIONINE BETA-SYNTHASE and associated with elevations of homocysteine in plasma and urine. Clinical features include a tall slender habitus, SCOLIOSIS, arachnodactyly, MUSCLE WEAKNESS, genu varus, thin blond hair, malar flush, lens dislocations, an increased incidence of MENTAL RETARDATION, and a tendency to develop fibrosis of arteries, frequently complicated by CEREBROVASCULAR ACCIDENTS and MYOCARDIAL INFARCTION. (From Adams et al., Principles of Neurology, 6th ed, p979)</FPU_DefMSH><FPU_Code>C0019880</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/Hmcystnr.htm</FPU_URL></item><item><FPU_Page>Galactosemia</FPU_Page><FPU_LG_English>GALACTOSE INTOLERANCE, GALACTOSEMIA, Galactosemia, NOS, Galactosaemia NOS, Galactosemia NOS, Galactosaemia, NOS, Galactose intolerance, NOS, Galactosemias, galactosemia (diagnosis), galactosemia, Galactosemia NOS (disorder), Galactosemias [Disease/Finding], disorder galactosemia, galactosemias, galactosaemia, galactose intolerance, Galactosemia, Galactosaemia, Galactose intolerance, Galactosemia (disorder), Galactosemia (disorder) [Ambiguous]</FPU_LG_English><FPU_LG_French>Galactosémie, Intolérance au galactose, Galactosémies</FPU_LG_French><FPU_SnomedCT>38177000, 190747003, 190745006, 190749000, 154738008, 267498002</FPU_SnomedCT><FPU_DefCSP>group of inherited enzyme deficiencies which feature elevations of galactose in the blood; this condition may be associated with deficiencies of galactokinase, UDP glucose-hexose-1-phosphate uridylyltransferase (classic form), or UDP glucose 4-epimerase; the classic form presents in infancy with failure to thrive, vomiting, and intracranial hypertension; affected individuals also may develop mental retardation, jaundice, hepatosplenomegaly, ovarian failure and cataracts.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>An autosomal recessive inherited metabolic disorder caused by mutations in the GALE, GALK1, and GALT genes. It is characterized by deficiency of the enzymes responsible for the metabolism of galactose. Signs and symptoms include intellectual disability, hepatomegaly, hepatic failure, and renal failure.</FPU_DefNCI><FPU_Name>Galactosemias</FPU_Name><FPU_DefMSH>A group of inherited enzyme deficiencies which feature elevations of GALACTOSE in the blood. This condition may be associated with deficiencies of GALACTOKINASE; UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; or UDPGLUCOSE 4-EPIMERASE. The classic form is caused by UDPglucose-Hexose-1-Phosphate Uridylyltransferase deficiency, and presents in infancy with FAILURE TO THRIVE; VOMITING; and INTRACRANIAL HYPERTENSION. Affected individuals also may develop MENTAL RETARDATION; JAUNDICE; hepatosplenomegaly; ovarian failure (PRIMARY OVARIAN INSUFFICIENCY); and cataracts. (From Menkes, Textbook of Child Neurology, 5th ed, pp61-3)</FPU_DefMSH><FPU_Code>C0016952</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/Glctsm.htm</FPU_URL></item><item><FPU_Page>Tay-Sachs Disease</FPU_Page><FPU_LG_English>INFANTILE AMAUROTIC FAMILIAL IDIOCY, Amaurotic Idiocy, Familial, Familial Amaurotic Idiocy, Idiocies, Familial Amaurotic, amaurotic familial idiocy, familial amaurotic idiocy (diagnosis), familial amaurotic idiocy, Amaurotic familial idiocy, Infantile amaurotic familial disease, Amaurotic Familial Idiocy, Familial Idiocy (Amaurotic)</FPU_LG_English><FPU_LG_French>Idiotie amaurotique familiale, Idiotie familiale amaurotique</FPU_LG_French><FPU_SnomedCT>111385000, 192786008</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Amaurotic Familial Idiocy</FPU_Name><FPU_DefMSH>An outdated term for Tay-Sachs disease.</FPU_DefMSH><FPU_Code>C0282220</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/TySchsDs.htm</FPU_URL></item><item><FPU_Page>Tay-Sachs Disease</FPU_Page><FPU_LG_English>GM2 gangliosidosis, type I, G(M2) Gangliosidosis, Type I, Gangliosidosis G(M2), Type I, GANGLIOSIDOSIS GM2 TYPE 1, INFANTILE GANGLIOSIDE LIPIDOSIS, LIPIDOSIS, GANGLIOSIDE, INFANTILE, TAY SACHS DISEASE, Tay Sachs disease, TAY SACH'S DISEASE, GM2 gangliosidosis, type 1, GM&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt; gangliosidosis, type 1, Gangliosidosis GM2, Type I, GM2 Gangliosidosis, Type I, GM2 Gangliosidosis, B Variant, Gangliosidosis GM2, B Variant, Tay Sachs Disease, B Variant, Tay-Sachs Disease, B Variant, TAY-SACHS DISEASE, HEXA DEFICIENCY, GM2-GANGLIOSIDOSIS, TYPE I, HEXOSAMINIDASE A DEFICIENCY, GANGLIOSIDOSIS GM 02 B VARIANT, TAY SACHS DIS, GM2 GANGLIOSIDOSIS TYPE I, GM GANGLIOSIDOSIS 02 TYPE I, GANGLIOSIDOSIS GM 02 TYPE I, GANGLIOSIDOSIS GM2 TYPE I, DEFIC DIS HEXOSAMINIDASE A, HEXOSAMINIDASE A DEFIC DIS, hexosaminidase A deficiency, gangliosidosis GM2 type I, B VARIANT GM2-GANGLIOSIDOSIS, Tay-Sachs disease (diagnosis), GM2 gangliosidosis, Deficiency Disease Hexosaminidase A, Hexosaminidase A Deficiency Disease, B Variant GM2 Gangliosidosis, Gangliosidosis GM2 , Type 1, Sphingolipidosis, Tay-Sachs, GM2 Gangliosidosis, Type 1, Sphingolipidosis, Tay Sachs, Tay-Sachs Sphingolipidosis, Tay-Sachs Disease [Disease/Finding], tsd, deficiency hexosaminidase, disease sach tay, disease tay sachs, disease sachs tay, tay sach's disease, diseases sachs tay, diseases tay sachs, disease sach's tay, disease tay sach, tay sachs disease, diseases sachs tays, tay-sachs disease, disease tay-sachs, Tay-Sachs disease, Severe hexosaminidase A deficiency, TSD, Hexosaminidase A deficiency, GM&amp;gt;2&amp;lt; gangliosidosis, type 1, Tay-Sachs disease (disorder), Sachs-Tay, Sachs, Tay-Sachs, Tay-Sachs Disease, Tay Sachs Disease, Disease, Tay-Sachs</FPU_LG_English><FPU_LG_French>Maladie de Tay-Sachs, Déficit en hexosaminidase A, Gangliosidose à GM2 de type 1, Gangliosidose à GM2 de type I, Gangliosidose à GM2 variante B</FPU_LG_French><FPU_SnomedCT>111385000</FPU_SnomedCT><FPU_DefCSP>autosomal recessive inherited gangliosidosis characterized by the onset in the first 6 months of life of an exaggerated startle response, delay in psychomotor development, hypotonia (followed by spasticity), visual loss, and a macular cherry red spot; hexosaminidase A is deficient, leading to the accumulation of GM2 ganglioside in neurons of the central nervous system and retina; this condition is strongly associated with Ashkenazic Jewish ancestry.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A rare, fatal, autosomal recessive lipid storage disorder caused by mutations in the HEXA gene. It is characterized by deficiency of beta-hexosaminidase A, resulting in accumulation of gangliosides in the neurons of the brain and spinal cord. Signs and symptoms include progressive deterioration of the mental and physical abilities early in life, accompanied by blindness, deafness, muscle atrophy, and paralysis.</FPU_DefNCI><FPU_Name>Tay-Sachs Disease</FPU_Name><FPU_DefMSH>An autosomal recessive neurodegenerative disorder characterized by the onset in infancy of an exaggerated startle response, followed by paralysis, dementia, and blindness. It is caused by mutation in the alpha subunit of the HEXOSAMINIDASE A resulting in lipid-laden ganglion cells. It is also known as the B variant (with increased HEXOSAMINIDASE B but absence of hexosaminidase A) and is strongly associated with Ashkenazic Jewish ancestry.</FPU_DefMSH><FPU_Code>C0039373</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/TySchsDs.htm</FPU_URL></item><item><FPU_Page>Thyroxine Binding Globulin</FPU_Page><FPU_LG_English>Thyroxine-Binding Globulin, TBG - Thyroxine binding globulin, TBG-Thyroxine binding globulin, Thyroxin binding globulin (TBG), Serpin A7, Thyroxine Binding Globulin, Thyropexin, Thyroxine-Binding Globulin [Chemical/Ingredient], tbg, thyroxine binding globulin (TBG), thyroxine binding globulin, Thyroxine binding glob., Thyroxine binding globulin -RETIRED-, Thyroxine binding globulin-TBG, TBG, Thyroxine binding globulin, Thyroxin-binding globulin, Thyroxine binding globulin (substance)</FPU_LG_English><FPU_LG_French>Globuline liant la thyroxine, Globuline fixant la thyroxine, Globuline se liant à la thyroxine, TBG (Thyroxine-Binding Globulin), Globuline de liaison à la thyroxine</FPU_LG_French><FPU_SnomedCT>123338002, 143682007, 166320009, 166334009, 415720002, 88181004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Immunologic Factor (T129)
</FPU_Concepts><FPU_Concepts_Codes>T116 T129</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Thyroxine-Binding Globulin</FPU_Name><FPU_DefMSH>A thyroid hormone transport protein found in serum. It binds about 75% of circulating THYROXINE and 70% of circulating TRIIODOTHYRONINE.</FPU_DefMSH><FPU_Code>C0087090</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/ThyrxnBndngGlbln.htm</FPU_URL></item><item><FPU_Page>Urine Vanillylmandelic Acid</FPU_Page><FPU_LG_English>Vanillylmandelic acid (VMA), urine, VANILLYLMANDELIC ACID (VMA), URINE, urine vanillylmandelic acid measurement (lab test), urine vanillylmandelic acid, urine vanillylmandelic acid measurement, Urine VMA (&amp;amp; level) (procedure), urine VMA measurement, Measurement of vanillylmandelic acid in urine specimen (procedure), Measurement of vanillylmandelic acid in urine specimen, Urine VMA level, Urine VMA measurement (procedure), Urine VMA, ASSAY OF URINE VMA, Assay of urine vma, Urine VMA (&amp;amp; level), VMA - urine, Urine VMA measurement, VANILLYLMANDELIC ACID URINE</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>144639000, 167410009, 271253003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Laboratory Procedure (T059)
</FPU_Concepts><FPU_Concepts_Codes>T059</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Urine VMA measurement</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0428375</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/UrnVnlylmndlcAcd.htm</FPU_URL></item><item><FPU_Page>Lysosomal Storage Disease</FPU_Page><FPU_LG_English>Mucopolysaccharidoses, Mucopolysaccharidosis, Mucopolysaccharidosis, NOS, Mucopolysaccharidosis NOS, Mucopolysaccharidosis, unspecified, mucopolysaccharidosis, mucopolysaccharidosis (diagnosis), Mucopolysaccharidosis NOS (disorder), Mucopolysaccharidoses [Disease/Finding], mucopolysaccharidose, mucopolysaccharidoses, MPS - Mucopolysaccharidosis, Mucopolysaccharidosis (disorder), Mucopolysaccharidosis [Ambiguous]</FPU_LG_English><FPU_LG_French>Mucopolysaccharidose SAI, Mucopolysaccharidose, Mucopolysaccharidoses</FPU_LG_French><FPU_SnomedCT>267452003, 190942001, 11380006, 190936000</FPU_SnomedCT><FPU_DefCSP>any of a group of lysosomal storage diseases resulting from defects in degradation of glycosaminoglycans, which are excreted in urine and accumulate in tissue.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, mental retardation, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.</FPU_DefNCI><FPU_Name>Mucopolysaccharidoses</FPU_Name><FPU_DefMSH>Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency.</FPU_DefMSH><FPU_Code>C0026703</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/LysmlStrgDs.htm</FPU_URL></item><item><FPU_Page>Lysosomal Storage Disease</FPU_Page><FPU_LG_English>Mucolipidoses, Mucolipidosis, Mucolipidosis, NOS, mucolipidosis (diagnosis), mucolipidosis, Mucolipidoses [Disease/Finding], mucolipidoses, Mucolipidosis (disorder)</FPU_LG_English><FPU_LG_French>Mucolipidoses</FPU_LG_French><FPU_SnomedCT>70528007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.</FPU_DefNCI><FPU_Name>Mucolipidoses</FPU_Name><FPU_DefMSH>A group of inherited metabolic diseases characterized by the accumulation of excessive amounts of acid mucopolysaccharides, sphingolipids, and/or glycolipids in visceral and mesenchymal cells. Abnormal amounts of sphingolipids or glycolipids are present in neural tissue. INTELLECTUAL DISABILITY and skeletal changes, most notably dysostosis multiplex, occur frequently. (From Joynt, Clinical Neurology, 1992, Ch56, pp36-7)</FPU_DefMSH><FPU_Code>C0026697</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/LysmlStrgDs.htm</FPU_URL></item><item><FPU_Page>Lysosomal Storage Disease</FPU_Page><FPU_LG_English>Gangliosidoses, Gangliosidosis, Ganglioside storage disease, NOS, Gangliosidosis, NOS, GANGLIOSIDE STORAGE DIS, Ganglioside Storage Disease, Ganglioside Storage Diseases, Storage Disease, Ganglioside, Storage Diseases, Ganglioside, Ganglioside Storage Disorder, Ganglioside Storage Disorders, Storage Disorder, Ganglioside, Storage Disorders, Ganglioside, Gangliosidosis NOS, Unspecified gangliosidosis, Gangliosidoses [Disease/Finding], ganglioside storage diseases, ganglioside storage disease, gangliosidoses, Ganglioside accumulation in nervous tissue lysosomes, Ganglioside storage disease, Gangliosidosis (disorder), gangliosidosis, Disease, Gangliosidosis</FPU_LG_English><FPU_LG_French>Gangliosidoses</FPU_LG_French><FPU_SnomedCT>50967008</FPU_SnomedCT><FPU_DefCSP>group of often fatal inherited diseases marked by the accumulation of gangliosides in lysosomes secondary to enzymatic deficiency states; gangliosidoses include Tay-Sachs disease, gangliosidosis GM1, gangliosidoses GM2, and Sandhoff disease; which share the infantile or childhood onset of central nervous system deterioration.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Gangliosidoses</FPU_Name><FPU_DefMSH>A group of autosomal recessive lysosomal storage disorders marked by the accumulation of GANGLIOSIDES. They are caused by impaired enzymes or defective cofactors required for normal ganglioside degradation in the LYSOSOMES. Gangliosidoses are classified by the specific ganglioside accumulated in the defective degradation pathway.</FPU_DefMSH><FPU_Code>C0017083</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/LysmlStrgDs.htm</FPU_URL></item><item><FPU_Page>Lysosomal Storage Disease</FPU_Page><FPU_LG_English>Disease, Lysosomal Storage, Diseases, Lysosomal Storage, Disorder, Lysosomal Enzyme, Disorders, Lysosomal Enzyme, Enzyme Disorder, Lysosomal, Enzyme Disorders, Lysosomal, Lysosomal Enzyme Disorder, Lysosomal Enzyme Disorders, Lysosomal Storage Diseases, inborn lysosomal enzyme disorder, DISORDERS OF LYSOSOMAL ENZYMES, Disorder of lysosomal enzyme, NOS, lysosomal storage disease, LYSOSOMAL STORAGE DIS, LYSOSOMAL ENZYME DIS, Lysosomal Storage Disease, SECTION 6-7 DISORDERS OF LYSOSOMAL ENZYMES, Lysosomal Storage Diseases [Disease/Finding], lysosomal storage disorders, lysosomal storage diseases, lysosomal storage disorder, Lysosomal storage disorders, Disorder of lysosomal enzyme (disorder), Disorder of lysosomal enzyme, defect; lysosomal enzyme, lysosomal enzyme; defect</FPU_LG_English><FPU_LG_French>Troubles lysosomaux, Maladies lysosomiales, Maladies lysosomales</FPU_LG_French><FPU_SnomedCT>23585005</FPU_SnomedCT><FPU_DefCSP>inborn errors of metabolism characterized by defects in specific lysosomal hydrolases and resulting in intracellular accumulation of unmetabolized substrates.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A group of autosomal recessive or X-linked inherited metabolic disorders caused by defects in the function of the lysosomes. Signs and symptoms include hepatomegaly, splenomegaly, nervous system manifestations, skeletal abnormalities, and mental deterioration. Representative examples include Gaucher disease, Niemann-Pick disease, Wolman disease, and Fabry disease.</FPU_DefNCI><FPU_Name>Lysosomal Storage Diseases</FPU_Name><FPU_DefMSH>Inborn errors of metabolism characterized by defects in specific lysosomal hydrolases and resulting in intracellular accumulation of unmetabolized substrates.</FPU_DefMSH><FPU_Code>C0085078</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/LysmlStrgDs.htm</FPU_URL></item><item><FPU_Page>Lysosomal Storage Disease</FPU_Page><FPU_LG_English>Glycoprotein storage disorder, NOS, Glycoprotein storage disorder (disorder), Glycoprotein storage disorder</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>7810004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Glycoprotein storage disorder</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0268220</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/LysmlStrgDs.htm</FPU_URL></item><item><FPU_Page>Lysosomal Storage Disease</FPU_Page><FPU_LG_English>Sphingolipidoses, Sphingolipidosis, Sphingolipidosis, NOS, Sphingolipidosis, unspecified, SPHINGOLIPID STORAGE DIS, sphingolipidosis (diagnosis), sphingolipidosis, Sphingolipid Storage Disease, Sphingolipid Storage Diseases, Storage Disease, Sphingolipid, Storage Diseases, Sphingolipid, Sphingolipidoses [Disease/Finding], sphingolipidose, sphingolipidoses, Sphingolipidosis (disorder)</FPU_LG_English><FPU_LG_French>Sphingolipidoses, Maladies de surcharge en sphingolipides</FPU_LG_French><FPU_SnomedCT>238028008, 58459009</FPU_SnomedCT><FPU_DefCSP>lysosomal storage diseases characterized by abnormal storage of spingolipids.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Sphingolipidoses</FPU_Name><FPU_DefMSH>A group of inherited metabolic disorders characterized by the intralysosomal accumulation of SPHINGOLIPIDS primarily in the CENTRAL NERVOUS SYSTEM and to a variable degree in the visceral organs. They are classified by the enzyme defect in the degradation pathway and the substrate accumulation (or storage). Clinical features vary in subtypes but neurodegeneration is a common sign.</FPU_DefMSH><FPU_Code>C0037899</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/LysmlStrgDs.htm</FPU_URL></item><item><FPU_Page>Disorders of Energy Metabolism</FPU_Page><FPU_LG_English>Diseases, Glycogen Storage, Glycogen Storage Disease, Glycogen Storage Diseases, Glycogenoses, Glycogenosis, Storage Disease, Glycogen, Storage Diseases, Glycogen, Disease, Glycogen Storage, Glycogen storage disease, NOS, Glycogenosis, NOS, Glycogenosis NOS, GLYCOGEN STORAGE DIS, glycogen storage disease, glycogen storage disease (diagnosis), Glycogen storage disorder NOS, Glycogenosis NOS (disorder), Glycogen storage disease, unspecified, Glycogen Storage Disease [Disease/Finding], disorders glycogen storage, glycogen storage disorder, glycogen storage diseases, disease glycogen storage, diseases glycogen storage, glycogenoses, glycogenose, Glycogen storage disorder, Glycogen storage disease, GSD - Glycogen storage disease, Glycogen storage disease (disorder), glycogenosis, Gierke, glycogen storage; disease, liver; disease, glycogen storage (etiology), liver; disease, glycogen storage (manifestation), storage disease; glycogen, thesaurismosis; glycogen</FPU_LG_English><FPU_LG_French>Glycogénoses, Glycogénose SAI, Glycogénose, Maladie glycogénique</FPU_LG_French><FPU_SnomedCT>190744005, 29633007, 154738008, 267498002</FPU_SnomedCT><FPU_DefCSP>any of a group of metabolic disorders characterized by excessive storage of glycogen.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.</FPU_DefNCI><FPU_Name>Glycogen Storage Disease</FPU_Name><FPU_DefMSH>A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalized storage of glycogen occurs, sometimes with prominent cardiac involvement.</FPU_DefMSH><FPU_Code>C0017919</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm</FPU_URL></item><item><FPU_Page>Disorders of Energy Metabolism</FPU_Page><FPU_LG_English>Unspecified disorder of lipoid metabolism, FAT DISORDER, LIPID METABOLISM DISORDER NOS, Disorder of Lipid Metabolism, Disorder of lipoid metabolism NOS, Lipoid metabolism disorder NOS, Lipid Metabolism Disorders, Lipid Metabolism Disorder, Metabolism Disorder, Lipid, Metabolism Disorders, Lipid, Disease of lipid metabolism, lipid disorder, Lipid Disorders, lipoid metabolism disorder (diagnosis), lipoid metabolism disorder, disorders of lipid metabolism, lipid metabolism disorder, Fat disorder, Disorders of lipid metabolism, Lipid metabolism disorder NOS, Unspecified disorders of lipoid metabolism, Lipoid metabol dis NOS, Disorder of lipoid metabolism NOS (disorder), Lipid Metabolism Disorders [Disease/Finding], disorders fat, lipid disorders, Disease;lipid metabolism, Disorder;lipid metabolism, fat disorder, lipid metabolism disorders, disorder lipid metabolism, disorders lipid, disorders fats, disorders lipids, Lipid metabolism disorders, Lipid metabolism disorder, Disorders of lipoid metabolism, Disorder of lipid metabolism, Disorder of lipid metabolism (disorder), Lipid disorder, disorder; lipid metabolism, lipid; metabolic disorder, metabolic disorder; lipid, Lipid metabol. disorder, disorder of lipid metabolism, lipid metabolism disease</FPU_LG_English><FPU_LG_French>Troubles non précisés du métabolisme des lipoïdes, Trouble lipidique, Troubles du métabolisme des lipoïdes, Trouble du métabolisme lipidique SAI, Trouble du métabolisme des lipoïdes non précisé, Troubles du métabolisme des lipides, Troubles du métabolisme lipidique, ANOMALIE DU TISSU GRAISSEUX, Dyslipidemies, TROUBLE DU METABOL. LIPIDIQUE SAI, Trouble du métabolisme lipidique</FPU_LG_French><FPU_SnomedCT>190806008, 267431006, 190771005, 154739000, 267499005</FPU_SnomedCT><FPU_DefCSP>condition in which there is a deviation or interruption in the processing of lipids in the body: synthesis, absorption, transport, storage, and utilization.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Lipid Metabolism Disorders</FPU_Name><FPU_DefMSH>Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.</FPU_DefMSH><FPU_Code>C0154251</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm</FPU_URL></item><item><FPU_Page>Disorders of Energy Metabolism</FPU_Page><FPU_LG_English>DISORDER OF CARBOHYDRATE METABOLISM, DISORDERS OF CARBOHYDRATE METABOLISM, Disorder of carbohydrate metabolism, NOS, Disord of carbohydrate metabol, Disorder of carbohydrate metabolism, unspecified, Disease of carbohydrate metabolism, Diseases of Carbohydrate Metabolism, carbohydrate metabolism disorder, disorders of carbohydrate metabolism, 6-50 DISORDERS OF CARBOHYDRATE METABOLISM, carbohydrate disorders metabolism, Carbohydrate metabolism disorder, Disorder of carbohydrate metabolism, Disorder of carbohydrate metabolism (disorder), carbohydrate; metabolic disorder, disorder; carbohydrate metabolism, metabolic disorder; carbohydrate, Disorder;carbohydrate metabol, disorder of carbohydrate metabolism</FPU_LG_English><FPU_LG_French>Trouble du métabolisme des hydrates de carbone</FPU_LG_French><FPU_SnomedCT>20957000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Disorder of carbohydrate metabolism</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0149670</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm</FPU_URL></item><item><FPU_Page>Thyroid Releasing Hormone</FPU_Page><FPU_LG_English>Thyrotropin-Releasing Hormone, Protirelin preparation, TRF - Protirelin, TRH - Protirelin, Thyrotropin Releasing Factor, Thyrotropin-Releasing Factor, pyroGlu-His-Pro-NH2 (or 5-oxo-L-prolyl-L-histidyl-L-prolinamide), TRH-Thyrotrophin rel horm, Thyrotropin releasing factor (TRF), thyrotropin releasing hormone, protirelin, protirelin (discontinued) (medication), protirelin (discontinued), thyrotropin-releasing hormone, thyrotropin RH, hormones protirelin (discontinued), Protirelin preparation (product), Thyrotropin-releasing factor, Thyrotropin-Releasing Hormone [Chemical/Ingredient], thyrotrophin releasing hormone, trh, thyrotropin releasing hormone (TRH), Thyrotropin releasing hormone preparation, TRF, TRH, Thyrotrophin-releasing hormone, Thyrotropin releasing factor, Thyrotropin releasing hormone, TRH - Thyrotrophin releasing hormone, Thyrotrophin releasing hormone, Thyrotropin releasing factor (substance), Thyrotropin releasing hormone preparation (product), Protirelin preparation -RETIRED-, Thyrotropin releasing hormone preparation (substance), Protirelin (product), Protirelin (substance), Thyrotropin releasing factor agent (substance), Thyrotropin releasing factor agent, Thyrotropin Releasing Hormone, Protirelin, PROTIRELIN</FPU_LG_English><FPU_LG_French>Thyrolibérine, Hormone de libération de la thyrotropine, Hormone de libération de la thyréostimuline, Facteur de libération de la thyrotropine, Facteur de libération de la thyréostimuline, Hormone de libération de la thyréotropine, TRF (Thyrotropin-Releasing Factor), Thyréolibérine, Protireline, Protyreline, Pyr-His-ProNH2, TRH (Thyrotropin-Releasing Hormone)</FPU_LG_French><FPU_SnomedCT>29361008, 73805002, 10534002, 412495007, 412496008, 412494006</FPU_SnomedCT><FPU_DefCSP>tripeptide hormone elaborated by the median eminence of the hypothalamus which stimulates release of thyrotropin from the anterior pituitary gland.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>Expressed (highest) in the medial hypothalamic paraventricular nuclei and median eminence by human TRH Gene, 242-aa 27-kDa (precursor) (prepro-)Thyrotropin-Releasing Hormone is a major regulator of TSH biosynthesis and release in the anterior pituitary gland and neurotransmitter/neuromodulator in the central and peripheral nervous systems. (NCI)</FPU_DefNCI><FPU_Name>Thyrotropin-Releasing Hormone</FPU_Name><FPU_DefMSH>A tripeptide that stimulates the release of THYROTROPIN and PROLACTIN. It is synthesized by the neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, TRH (was called TRF) stimulates the release of TSH and PRL from the ANTERIOR PITUITARY GLAND.</FPU_DefMSH><FPU_Code>C0040162</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/ThyrdRlsngHrmn.htm</FPU_URL></item><item><FPU_Page>Triiodothyronine</FPU_Page><FPU_LG_English>Liothyronine, Triiodothyronine, L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, liothyronine, Triiodothyronine preparation, triiodothyronine, T-3, 3,3',5-triiodo-L-thyronine, T3, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, Triiodothyronine (T3), L-triiodothyronine preparation, T&amp;gt;3&amp;lt; preparation, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; preparation, T3 preparation, Triiodothyronine preparation (product), therapeutic triiodothyronine, L-Triiodothyronine, T AAA THYROID HORMONE 003, Triiodothyronine [Chemical/Ingredient], t3 thyroid hormone, t3, LIOTHYRONINE, T3 Thyroid Hormone, Thyroid Hormone, T3, 3,5,3' Triiodothyronine, T3 - Liothyronine, Tri-iodothyronine product, T3 - Triiodothyronine, Total triiodothyronine, T&amp;gt;3&amp;lt;, Liothyronine (product), Triiodothyronine (substance), Liothyronine (substance), Triiodothyronine preparation (substance), Therapeutic T3</FPU_LG_English><FPU_LG_French>T3 (Hormone thyroïdienne), Tri-iodothyronine, Hormone thyroïdienne T3, Triiodothyronine, 3,5,3'-triiodothyronine, Liothyronine</FPU_LG_French><FPU_SnomedCT>61275002, 350358003, 74495008, 36437009</FPU_SnomedCT><FPU_DefCSP>one of the thyroid hormones; an organic iodine containing compound secreted in small amounts by the thyroid gland; most circulating triiodothyroinine is produced by the deiodination of thyroxine in the peripheral tissues.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A thyroid hormone. A thyroid hormone containing 3 iodine atoms generally synthesized from levothyroxine, and has greater biological activity. A thyroid hormone. Also called triiodothyronine or liothyronine sodium. A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)</FPU_DefNCI><FPU_Name>Triiodothyronine</FPU_Name><FPU_DefMSH>A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.</FPU_DefMSH><FPU_Code>C0041014</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/Trdthyrn.htm</FPU_URL></item><item><FPU_Page>T3 Resin Uptake</FPU_Page><FPU_LG_English>T3RU, Triiodothyronine uptake (procedure), Tri-iodothyronine uptake, T3 uptake, T3U, Triiodothyronine Uptake Measurement, T3UP, Triiodothyronine Uptake, triiodothyronine uptake measurement (lab test), triiodothyronine uptake measurement, T3 resin uptake, resin t3 uptake, t3 uptake, t3u, t3 uptake test, t3 resin uptake, Tri-iodothyronine resin uptake measurement, T3U measurement, T3 - Triiodothyronine uptake, T3 uptake test, T3 uptake measurement (procedure), T3 uptake test (procedure), Triiodothyronine uptake, T3 uptake measurement</FPU_LG_English><FPU_LG_French>Test d'Hamolsky, Test d'Ham, Fixation de tri-iodothyronine</FPU_LG_French><FPU_SnomedCT>143695002, 166340002, 250669007, 17130003, 275756004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Laboratory Procedure (T059)
</FPU_Concepts><FPU_Concepts_Codes>T059</FPU_Concepts_Codes><FPU_DefNCI>The determination of the binding of triiodothyonine to thyroxine binding globulin protein in a sample. A measurement of the binding of triiodothyonine to thyroxine binding globulin protein in a biological specimen.</FPU_DefNCI><FPU_Name>T3 uptake measurement</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0202224</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/T3RsnUptk.htm</FPU_URL></item><item><FPU_Page>Sex Hormone Binding Globulin</FPU_Page><FPU_LG_English>Binding Globulin, Testosterone-Estradiol, Globulin, Sex Hormone-Binding, Globulin, Testosterone-Estradiol Binding, Hormone-Binding Globulin, Sex, Sex Hormone Binding Globulin, Sex Hormone-Binding Globulin, Sex Steroid Binding Protein, Sex Steroid-Binding Protein, Steroid-Binding Protein, Sex, Testosterone-Estradiol Binding Globulin, SHBG- Sex horm bind globulin, Sex Hormone-Binding Globulin [Chemical/Ingredient], sex hormone binding globulin, sex hormone-binding globulin, sex hormone binding globulin (SHBG), shbg, GBG, Sex hormone binding globulin, Sex steroid binding globulin, SHBG - Sex hormone binding globulin, Sex steroid binding globulin (substance), Testosterone Estradiol Binding Globulin, SHBG, Testis-Specific Androgen-Binding Protein</FPU_LG_English><FPU_LG_French>Globuline fixant les hormones sexuelles, Globuline de transport des hormones sexuelles, SBP (Sex Steroid-Binding Protein), Globuline de fixation des hormones sexuelles, Globuline de liaison des hormones sexuelles, Globuline liant les hormones sexuelles, Globuline se liant aux hormones sexuelles, Protéine de transport des hormones sexuelles, Globuline de liaison aux hormones sexuelles, Protéine de liaison aux hormones stéroïdes sexuelles</FPU_LG_French><FPU_SnomedCT>55503002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Biologically Active Substance (T123)
</FPU_Concepts><FPU_Concepts_Codes>T116 T123</FPU_Concepts_Codes><FPU_DefNCI>Expressed as 2 alternative isoforms in Sertoli cells and liver by human SHBG Gene, 402-aa 44-kDa (precursor) homodimeric Sex Hormone-Binding Globulin is a secreted beta-globulin plasma glycoprotein containing 2 laminin G-like domains that specifically bind 5-alpha-dihydrotestosterone, testosterone, or 17-beta-estradiol. An androgen transport protein, SHBG regulates the plasma metabolic clearance rate of steroid hormones by controlling plasma concentration and may be involved in receptor-mediated processes as well. (NCI)</FPU_DefNCI><FPU_Name>Sex Hormone-Binding Globulin</FPU_Name><FPU_DefMSH>A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Sex hormone-binding protein has the same amino acid sequence as ANDROGEN-BINDING PROTEIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications.</FPU_DefMSH><FPU_Code>C0036883</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/SxHrmnBndngGlbln.htm</FPU_URL></item><item><FPU_Page>Thyroxine</FPU_Page><FPU_LG_English>3,5,3',5'-Tetraiodothyronine, L Thyroxine, L-3,5,3',5'-Tetraiodothyronine, L-Thyroxine, Levothyroxine, Thyroxin, Thyroxine, O-(4-Hydroxy-3,5-diiodophenyl) 3,5-diiodo-L-tyrosine, O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine, Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, levothyroxine, T4, T4 preparation, T&amp;lt;sub&amp;gt;4&amp;lt;/sub&amp;gt; preparation, T&amp;lt;sub&amp;gt;4&amp;lt;/sub&amp;gt;, thyroxine, T AAB THYROID HORMONE 004, THROXINE L, Thyroxine [Chemical/Ingredient], l-thyroxine, thyroxine (T4), l thyroxine, LEVOTHYROXINE, thyroxin, L-3,5,5'-tetraiodothyronine, T4 Thyroid Hormone, Thyroid Hormone, T4, 3,5,3'5' Tetraiodothyronine, Tetraiodothyronine preparation, Thyroxine preparation, Thyroxine product, T4 - Thyroxine, Total thyroxine, TT4 - Total thyroxine, T&amp;gt;4&amp;lt; preparation, T&amp;gt;4&amp;lt;, Tetraiodothyronine preparation (product), Thyroxine (substance), Tetraiodothyronine preparation (substance)</FPU_LG_English><FPU_LG_French>T4 (Hormone thyroïdienne), Lévothyroxine, L-Thyroxine, 3,5,3',5'-Tétraiodothyronine, Hormone thyroïdienne T4, Tétra-iodothyronine, Tétraiodothyronine, Thyroxine</FPU_LG_French><FPU_SnomedCT>73187006, 38076006</FPU_SnomedCT><FPU_DefCSP>tetraiodothyronine (T4); major hormone elaborated by the thyroid gland follicular cells; increases the rate of cell metabolism, essential for central nervous system maturation, and regulates a number of other functions.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A hormone that is made by the thyroid gland and contains iodine. T4 increases the rate of chemical reactions in cells and helps control growth and development. T4 can also be made in the laboratory and is used to treat thyroid disorders. A hormone synthesized and secreted by the thyroid gland containing four iodine atoms and is converted to triiodothyronine (T3) in the body, influencing metabolism and organ function.</FPU_DefNCI><FPU_Name>Thyroxine</FPU_Name><FPU_DefMSH>The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.</FPU_DefMSH><FPU_Code>C0040165</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/Thyrxn.htm</FPU_URL></item><item><FPU_Page>Thyroid Stimulating Hormone</FPU_Page><FPU_LG_English>Thyroid stimulating hormone (TSH), Hormone, Thyroid-Stimulating, Thyreotropin, Thyroid-Stimulating Hormone, Thyrotrophin, Thyrotropin, thyrotropin, TSH preparation, Thyrotrophic hormone product, Thyrotropic hormone preparation, thyroid-stimulating hormone, TSH - Thyroid stimulating hormone, TSH-Thyroid stim horm, Thyroid Stimulating Hormone [EPC], Thyrotropin [Chemical/Ingredient], Thyroid Stimulating Hormone, thyroid stimulating hormone (TSH), thyrotropic hormone, thyroid stimulating hormone, TSH (Thyroid Stimulating Hormone), TSH, Thyroid stimulating hormone, Thyrotrophin product, Thyroid stimulating hormone (substance), Thyrotrophin product (product), Thyrotrophin product (substance), Thyrotropic hormone preparation (product), Thyrotropic hormone preparation (substance), Thyrotropic Hormone</FPU_LG_English><FPU_LG_French>TSH (Thyroid-stimulating hormone), Thyréotrophine, Thyréostimuline, Thyréotropine, Thyrotropine, Thyrotrophine, Hormone thyréotrope</FPU_LG_French><FPU_SnomedCT>65428006, 326013007, 24096000</FPU_SnomedCT><FPU_DefCSP>glycoprotein hormone of the anterior pituitary that promotes the growth of, sustains, and stimulates hormonal secretion of the thyroid gland.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A peptide hormone secreted by the anterior pituitary. It promotes the growth of the thyroid gland and stimulates the synthesis of thyroid hormones and the release of thyroxine by the thyroid gland. A hormone produced by the pituitary gland. TSH stimulates the release of thyroid hormone from thyroglobulin. It also stimulates the growth of thyroid follicular cells. An abnormal TSH level may mean that the thyroid hormonal regulation system is out of control, usually as a result of a benign condition (hyperthyroidism or hypothyroidism).</FPU_DefNCI><FPU_Name>Thyrotropin</FPU_Name><FPU_DefMSH>A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity.</FPU_DefMSH><FPU_Code>C0040160</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/ThyrdStmltngHrmn.htm</FPU_URL></item><item><FPU_Page>Reverse T3</FPU_Page><FPU_LG_English>3,3',5'-Triiodothyronine, 3,3,5 Triiodothyronine, 3,3,5-Triiodothyronine, Triiodothyronine, Reverse, L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3-iodo-, Reverse T3, r T3, Reverse T3 (substance), Reverse T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; (substance), Reverse T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, r T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, TRIIODOTHYRONINE A 03 03 05, REVERSE T 03 THYROID HORMONE, REVERSE T3, RT3 - Reverse triiodothyronine, Triiodothyronine, Reverse [Chemical/Ingredient], Triiodothyronine.reverse, reverse triiodothyronine, reverse t3, Reverse T3 Thyroid hormone, Reverse Triiodothyronine, 3,3' 5 Triiodothyronine, Reverse triiodothyronine, rT3 - Reverse triiodothyronine, r T&amp;gt;3&amp;lt;, Reverse T&amp;gt;3&amp;lt;, Reverse T&amp;gt;3&amp;lt; (substance)</FPU_LG_English><FPU_LG_French>rT3 (reverse Triiodothyronine), Triiodothyronine inverse, Tri-iodothyronine inverse, 3,3',5'-triiodothyronine</FPU_LG_French><FPU_SnomedCT>60760000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Reverse Triiodothyronine</FPU_Name><FPU_DefMSH>A metabolite of THYROXINE, formed by the peripheral enzymatic monodeiodination of T4 at the 5 position of the inner ring of the iodothyronine nucleus.</FPU_DefMSH><FPU_Code>C0041017</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/RvrsT3.htm</FPU_URL></item><item><FPU_Page>Prolactin</FPU_Page><FPU_LG_English>Hormone, Pituitary Lactogenic, Hormone, Pituitary Mammotropic, Lactogenic Hormone, Pituitary, Luteotropin, Mammotropic Hormone, Pituitary, Mammotropin, Pituitary Lactogenic Hormone, Pituitary Mammotropic Hormone, Prolactin, luteotropin, LTH (luteotropic hormone), lactogenic hormone, luteotropic hormone, mammary stimulating hormone, Lactogenic hormone, PROLACTIN, Prolactin [Chemical/Ingredient], lth, prolactins, prolactine, prolactin, LTH, PRL (Prolactin), Prl - Prolactin, Prolactin preparation, Prolactin (substance), Prolactin preparation (product), Prolactin preparation (substance), PRL</FPU_LG_English><FPU_LG_French>Lactostimuline, Mammotropine, Mammotrophine, PRL (Prolactin), Hormone galactogène, Prolactine</FPU_LG_French><FPU_SnomedCT>70454002, 82166002</FPU_SnomedCT><FPU_DefCSP>glycoprotein hormone secreted by the anterior pituitary; in mammals it stimulates the production of milk and assists in maintaining the corpus luteum.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI>A hormone that is made by the pituitary gland (a pea-sized organ in the center of the brain). Prolactin causes a woman's breasts to make milk during and after pregnancy, and has many other effects in the body. Human prolactin (227 aa, 26 kDa precursor) is encoded by the human prolactin (PIT1) gene. This secreted lactogenic glycoprotein is expressed in both anterior pituitary lactotropes and the decidual endometrium. It acts primarily on the mammary gland and, in synergy with estrogen, induces progesterone release by corpus luteum cells to render the uterine mucosa suitable for implantation.</FPU_DefNCI><FPU_Name>Prolactin</FPU_Name><FPU_DefMSH>A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate.</FPU_DefMSH><FPU_Code>C0033371</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/Prlctn.htm</FPU_URL></item><item><FPU_Page>Hemoglobin A1C</FPU_Page><FPU_LG_English>Glycohemoglobin A, Glycosylated Hemoglobin A, Hb A1, Hb A1a+b, Hb A1c, HbA1, Hemoglobin A(1), Hemoglobin A, Glycosylated, Glycosylated hemoglobin A, HBA GLYCOSYLATED, HBA 01, HEMOGLOBIN AA 01, HB AC 01, HbA&amp;lt;sub&amp;gt;1c&amp;lt;/sub&amp;gt; (substance), Haemoglobin A1c, HbA&amp;gt;1c&amp;lt; (substance), HbA1c, HbA1c (substance), HbA&amp;gt;1c&amp;lt;, Hemoglobin A1c, HbA&amp;lt;sub&amp;gt;1c&amp;lt;/sub&amp;gt;, Hemoglobin A, Glycosylated [Chemical/Ingredient], hemoglobin a1c, hba1, hemoglobin a 1, glycosylated hemoglobin a, hb a1, hba1c, haemoglobin a1c, HbA1 - Glycated haemoglobin, HbA1 - Glycated hemoglobin, Glycosylated haemoglobin A, Glycosylated hemoglobin A (substance)</FPU_LG_English><FPU_LG_French>Hb A1, HbA1, Hémoglobine A(1), Hémoglobine A1c, Hb A1c, Hb A1a+b, Hémoglobine A glycosylée, Glycohémoglobine A, Hémoglobine glycosylée A1c, Hémoglobine A1</FPU_LG_French><FPU_SnomedCT>103232008, 33601001, 259689004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Biologically Active Substance (T123)
</FPU_Concepts><FPU_Concepts_Codes>T116 T123</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Glycosylated hemoglobin A</FPU_Name><FPU_DefMSH>Minor hemoglobin components of human erythrocytes designated A1a, A1b, and A1c. Hemoglobin A1c is most important since its sugar moiety is glucose covalently bound to the terminal amino acid of the beta chain. Since normal glycohemoglobin concentrations exclude marked blood glucose fluctuations over the preceding three to four weeks, the concentration of glycosylated hemoglobin A is a more reliable index of the blood sugar average over a long period of time.</FPU_DefMSH><FPU_Code>C0019018</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/HmglbnAc.htm</FPU_URL></item><item><FPU_Page>Hemoglobin A1C</FPU_Page><FPU_LG_English>Glycated Hemoglobins, Glycosylated Hemoglobin, Hemoglobin, Glycosylated, Hemoglobins, Glycated, Hemoglobin.glycated, glycosylated hemoglobin, glycosylate hemoglobin, glycosylate haemoglobin, glycosylated hemoglobins, glycated haemoglobin, glycosylated hb, glycated hemoglobin, glycosylated haemoglobin, hemoglobin glycated, Glycated haemoglobin, Glycated hemoglobin, Glycosylated Hb, Glycosylated haemoglobin, Glycosylated hemoglobin, Glycosylated hemoglobin (substance)</FPU_LG_English><FPU_LG_French>Hémoglobine glyquée, Hémoglobine glycosylée, Glycohémoglobine</FPU_LG_French><FPU_SnomedCT>259689004, 143080000, 165678002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Biologically Active Substance (T123)
</FPU_Concepts><FPU_Concepts_Codes>T116 T123</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hemoglobin, Glycosylated</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0017853</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/HmglbnAc.htm</FPU_URL></item><item><FPU_Page>Parathyroid Hormone</FPU_Page><FPU_LG_English>Hormone, Parathyroid, Parathormone, Parathyrin, Parathyroid Hormone (1-84), PTH (1-84), PARATHYROID HORMONE PREPARATIONS, PARATHYROID HORMONES, Parathormone preparation, NOS, Parathormone, NOS, Parathyroid extract, NOS, Parathyroid hormone preparation, NOS, Parathyroid hormone, NOS, PTH, parathyroid hormone, parathormone, parathyrin, PARATHYROID, parathyroid (medication), parathyroid, A1A PARATHYROID HORMONE PREPARATIONS, B34 PARATHYROID HORMONES, Parathormone (substance), Parathyroid Hormone, Parathyroid Hormone [Chemical/Ingredient], Parathyroid-class Hormone, [HS600] PARATHYROID, Parathyroid Hormone [EPC], Parathyroid hormones, parathyroid hormones, Parathyroid Hormones, Parathyroid hormone, PTH - Parathyroid hormone, Parathyroid hormone preparation, Parathormone preparation, Parathyroid extract, Parathyroid hormone agent (substance), Parathyroid hormone agent, Parathyroid hormone preparation (product), Parathyroid hormone preparation (substance), Parathyroid, Parathyroid hormone (substance), Intact parathyroid hormone (substance)</FPU_LG_English><FPU_LG_French>Parathyrine, PTH (Parathyroid hormone), PTH (1-84), Hormone parathyroïdienne, Parathormone</FPU_LG_French><FPU_SnomedCT>27518004, 68136009, 4076007, 373752003</FPU_SnomedCT><FPU_DefCSP>polypeptide hormone secreted by the parathyroid glands which maintains intracellular calcium levels in the body; parathyroid hormone increases intracellular calcium by promoting the release of calcium from bone, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.</FPU_DefCSP><FPU_Concepts>Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
</FPU_Concepts><FPU_Concepts_Codes>T116 T121 T125</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Parathyroid Hormone</FPU_Name><FPU_DefMSH>A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.</FPU_DefMSH><FPU_Code>C0030520</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/PrthyrdHrmn.htm</FPU_URL></item><item><FPU_Page>Glucose Tolerance Test 2 hour</FPU_Page><FPU_LG_English>Glucose tolerance test, 2 hours, Measurement of glucose 2 hours after glucose challenge for glucose tolerance test (procedure), Glucose tolerance test, 2 hours (procedure), Measurement of glucose 2 hours after glucose challenge for glucose tolerance test, Glucose tolerance 2-hour test each test, GTT 2-h tst ea.tst</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>49167009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Laboratory Procedure (T059)
</FPU_Concepts><FPU_Concepts_Codes>T059</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Measurement of glucose 2 hours after glucose challenge for glucose tolerance test</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0202049</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/GlcsTlrncTstHr.htm</FPU_URL></item><item><FPU_Page>Glucose Tolerance Test 3 hour</FPU_Page><FPU_LG_English>Glucose tolerance test, 3 hours, Measurement of glucose 3 hours after glucose challenge for glucose tolerance test (procedure), Measurement of glucose 3 hours after glucose challenge for glucose tolerance test, Glucose tolerance test, 3 hours (procedure), 3 hour glucose tolerance test, 3 hours glucose tolerance test, 3 glucose hour testing tolerance, Glucose tolerance 3-hour test each test, GTT 3-hour tst ea.tst</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>13165004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Laboratory Procedure (T059)
</FPU_Concepts><FPU_Concepts_Codes>T059</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Measurement of glucose 3 hours after glucose challenge for glucose tolerance test</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0202050</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/GlcsTlrncTst3Hr.htm</FPU_URL></item><item><FPU_Page>Dexamethasone Suppression Test</FPU_Page><FPU_LG_English>dexamethasone suppression test, Dexamethasone suppression test, DST, dexamethasone suppression tests, dst, Dexamethasone suppression test (procedure), Dexamethasone Suppression Test</FPU_LG_English><FPU_LG_French>Épreuve de freinage à la dexaméthasone</FPU_LG_French><FPU_SnomedCT>392884002, 393839005, 252190006</FPU_SnomedCT><FPU_DefCSP>injection of dexamethasone causes serum cortisol to fall; this can be correlated with behavioral measures of depression, but the test is not reliable enough for diagnostic use.</FPU_DefCSP><FPU_Concepts>Laboratory Procedure (T059)
</FPU_Concepts><FPU_Concepts_Codes>T059</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Dexamethasone suppression test</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0430115</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/DxmthsnSprsnTst.htm</FPU_URL></item><item><FPU_Page>Serum Glucose</FPU_Page><FPU_LG_English>serum glucose, Serum Glucose, Glucose, serum, measurement, Serum Glucose Measurement, Serum glucose, glucose serum tests, glucose serum test, serum glucose test, glucose serum, Serum Glucose Test, Glucose measurement, serum, Glucose measurement, serum (procedure)</FPU_LG_English><FPU_LG_French>Glucose sérique</FPU_LG_French><FPU_SnomedCT>22569008</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Laboratory Procedure (T059)
</FPU_Concepts><FPU_Concepts_Codes>T059</FPU_Concepts_Codes><FPU_DefNCI>A quantitative measurement of the amount of glucose present in a sample of serum.</FPU_DefNCI><FPU_Name>Glucose measurement, serum</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0202041</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/SrmGlcs.htm</FPU_URL></item><item><FPU_Page>Serum Glucose</FPU_Page><FPU_LG_English>Hyperglycemias, HYPERGLYCAEMIA, HYPERGLYCEMIA, Hyperglycemia, NOS, [D]Hyperglycaemia, [D]Hyperglycemia, Hyperglycaemia, NOS, Hyperglycaemia, unspecified, Hyperglycemia, unspecified, [D]Hyperglycemia (context-dependent category), Hyperglycemia NOS, [X]Hyperglycaemia, unspecified, [X]Hyperglycemia, unspecified, hyperglycemia, hyperglycemia (diagnosis), elevated blood sugar, elevated glucose, [D]Hyperglycaemia (situation), Hyperglycaemia (disorder), Hyperglycaemia NOS, [X]Hyperglycemia, unspecified (finding), [D]Hyperglycemia (situation), Hyperglycemia, BLOOD GLUCOSE, HIGH, GLUCOSE, HIGH BLOOD, HIGH BLOOD GLUCOSE, Hyperglycemia [Disease/Finding], hyperglycaemia, high blood sugar level, high blood sugar, Hyperglycaemia, Hyperglycemia (disorder), blood sugar; high, blood; sugar, high, high; blood sugar, sugar; blood, high, [X]Hyperglycemia, unspecified (context-dependent category)</FPU_LG_English><FPU_LG_French>HYPERGLYCEMIE, Hyperglycémie SAI, Hyperglycémie</FPU_LG_French><FPU_SnomedCT>315299009, 390730002, 154719004, 207643008, 80394007, 144187006, 270004003, 207289007</FPU_SnomedCT><FPU_DefCSP>abnormally high blood glucose level.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A high level of blood sugar. It is usually an indication of diabetes mellitus. A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance. Higher than normal amount of glucose (a type of sugar) in the blood. Hyperglycemia can be a sign of diabetes or other conditions.</FPU_DefNCI><FPU_Name>Hyperglycemia</FPU_Name><FPU_DefMSH>Abnormally high BLOOD GLUCOSE level.</FPU_DefMSH><FPU_Code>C0020456</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/SrmGlcs.htm</FPU_URL></item><item><FPU_Page>Serum Glucose</FPU_Page><FPU_LG_English>D Glucose, D-Glucose, Dextrose, Glucose, glucose, D-glucopyranose monohydrate preparation, D-glucose preparation, Glucose [endocrine], Glucose, NOS, d-Glucose preparation, Dextrose (substance), D-glucose, Glucose [endocrine] (product), foods dextrose, glucose (dextrose), glucose (dextrose) (medication), foods glucose (dextrose), dextrose (medication), Dextrose preparation, Dextrose preparation (product), 6-(hydroxymethyl)oxane-2,3,4,5-tetrol, DEXTROSE, Glucose [Chemical/Ingredient], endocrine glucose, glucose preparations, d-glucose, glucoses, dextrose, Dextrose product, Glucose preparation, Glucose product, Glucose (substance), Glucose preparation (product), Dextrose preparation (substance), Glucose [endocrine] (substance), Glucose preparation (substance), GLUCOSE</FPU_LG_English><FPU_LG_French>Dextrose, Glucose</FPU_LG_French><FPU_SnomedCT>387370006, 67079006, 325307004, 111138002, 66611007, 386987008</FPU_SnomedCT><FPU_DefCSP>aldohexose occurring as the D form and found as a free monosaccharide in fruits and other parts of plants and in the normal blood of all animals; the end product of carbohydrate metabolism and the chief source of energy for most living organisms.</FPU_DefCSP><FPU_Concepts>Carbohydrate (T118)
, Pharmacologic Substance (T121)
, Biologically Active Substance (T123)
</FPU_Concepts><FPU_Concepts_Codes>T118 T121 T123</FPU_Concepts_Codes><FPU_DefNCI>A hexose with an aldehyde group; in which each of the 5 remaining carbons other than the aldehyde group has one hydroxyl group in the R,S,R, and R configuration counting from the first hydroxyl containing carbon next to the aldehyde in the straight chain (Fisher) projection; otherwise all carbons have exclusively hydrogens. Occurs mostly as pyran (6-membered oxygen containing ring or oxane) and rarely as furan (5-membered oxygen containing ring) or straight chain. When glucose forms a ring an additional ""anomeric"" asymmetric carbon is created which is denoted as ""alpha"" or ""beta"". For isomers see http://en.wikipedia.org/wiki/Glucose. A type of sugar; the chief source of energy for living organisms. A simple sugar monosaccharide having two isoforms, alpha and beta, with a chemical structure of C6H12O6 that acts as an energy source for both plants and animals by reacting with oxygen, generating carbon dioxide and water, and releasing energy.</FPU_DefNCI><FPU_Name>Glucose</FPU_Name><FPU_DefMSH>A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.</FPU_DefMSH><FPU_Code>C0017725</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/SrmGlcs.htm</FPU_URL></item><item><FPU_Page>Serum Glucose</FPU_Page><FPU_LG_English>Blood Glucose, Blood Sugar, Glucose, Blood, Sugar, Blood, Blood sugar, blood glucose, Blood Glucose [Chemical/Ingredient], bloods sugar, glucose blood, sugar blood, blood sugars, blood sugar, glycemia</FPU_LG_English><FPU_LG_French>Glycémie</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP>levels of glucose found in the blood.</FPU_DefCSP><FPU_Concepts>Carbohydrate (T118)
</FPU_Concepts><FPU_Concepts_Codes>T118</FPU_Concepts_Codes><FPU_DefNCI>Glucose (a type of sugar) found in the blood.</FPU_DefNCI><FPU_Name>Blood Glucose</FPU_Name><FPU_DefMSH>Glucose in blood.</FPU_DefMSH><FPU_Code>C0005802</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/SrmGlcs.htm</FPU_URL></item><item><FPU_Page>Free Thyroxine Index</FPU_Page><FPU_LG_English>free thyroxine index (lab test), free thyroxine index, Free thyroxine index (&amp;amp; level) (procedure), Free thyroxine index test, FTI (free T4 index), FTI (free thyroxine index), free T4 index, free thyroxine index test, Free thyroxine index, FT4 index, FTI, FT4I, FTI - Free thyroxine index, Free thyroxine index level, Free thyroxine index (procedure), Free thyroxine index (&amp;amp; level)</FPU_LG_English><FPU_LG_French>Index de thyroxine libre</FPU_LG_French><FPU_SnomedCT>143690007, 166333003, 39700003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Laboratory Procedure (T059)
</FPU_Concepts><FPU_Concepts_Codes>T059</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Free thyroxine index test</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0202024</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/FrThyrxnIndx.htm</FPU_URL></item><item><FPU_Page>Buccal Smear</FPU_Page><FPU_LG_English>Buccal smear for Barr bodies (procedure), Smear buccal, buccal smears, buccal smear, Buccal smear, Buccal smear procedure, Buccal smear procedure (procedure), Buccal smear for Barr bodies, Buccal smear for Barr bodies (procedure) [Ambiguous], buccal smear biopsy procedure</FPU_LG_English><FPU_LG_French>Frottis buccal</FPU_LG_French><FPU_SnomedCT>31402005, 303995001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Diagnostic Procedure (T060)
</FPU_Concepts><FPU_Concepts_Codes>T060</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>buccal smear biopsy procedure</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0581714</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/BclSmr.htm</FPU_URL></item><item><FPU_Page>Buccal Smear</FPU_Page><FPU_LG_English>Barr Bodies, Bodies, Barr, Chromatin, Sex, Chromatins, Sex, Sex Chromatin, Sex Chromatins, sex chromatin, Barr chromatin body, Barr bodies, barr bodies, chromatin sex, barr body, Barr body, Sex chromatin, Sex chromatin (substance), Barr Body</FPU_LG_English><FPU_LG_French>Corpuscules de Barr, Chromatine sexuelle</FPU_LG_French><FPU_SnomedCT>58348001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Cell Component (T026)
</FPU_Concepts><FPU_Concepts_Codes>T026</FPU_Concepts_Codes><FPU_DefNCI>The inactive, condensed X chromosome in a female somatic cell.</FPU_DefNCI><FPU_Name>Sex Chromatin</FPU_Name><FPU_DefMSH>In the interphase nucleus, a condensed mass of chromatin representing an inactivated X chromosome. Each X CHROMOSOME, in excess of one, forms sex chromatin (Barr body) in the mammalian nucleus. (from King &amp;amp; Stansfield, A Dictionary of Genetics, 4th ed)</FPU_DefMSH><FPU_Code>C0036867</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Lab/BclSmr.htm</FPU_URL></item><item><FPU_Page>Suppurative Thyroiditis</FPU_Page><FPU_LG_English>Infectious Thyroiditides, Infectious Thyroiditis, Suppurative Thyroiditides, Suppurative Thyroiditis, Thyroiditides, Infectious, Thyroiditides, Suppurative, Thyroiditis, Infectious, THYROIDITIS, ACUTE SUPPURATIVE, Infectious thyroiditis, NOS, THYROIDITIS ACUTE PYOGENIC, INFECT THYROIDITIS, THYROIDITIS INFECT, Suppurative thyroiditis, Thyroiditis, Suppurative [Disease/Finding], acute suppurative thyroiditis, Thyroiditis, Suppurative, Acute suppurative thyroiditis, Acute suppurative thyroiditis (disorder), Infectious thyroiditis (disorder), Infectious thyroiditis, suppurative; thyroiditis, thyroiditis; suppurative, Infectious Thyroiditides, Acute, Infectious Thyroiditis, Acute, Suppurative Thyroiditides, Acute, Suppurative Thyroiditis, Acute, Thyroiditides, Acute Infectious, Thyroiditides, Acute Suppurative, Thyroiditis, Acute Infectious, Thyroiditis, Acute Suppurative, Acute Infectious Thyroiditides, Acute Infectious Thyroiditis, Acute Suppurative Thyroiditides, Acute Suppurative Thyroiditis</FPU_LG_English><FPU_LG_French>Thyroïdite aigüe infectieuse, Thyroïdite aiguë infectieuse, Thyroïdite aigüe d'origine infectieuse, Thyroïdite suppurée, Thyroïdite infectieuse, Thyroïdite aiguë d'origine infectieuse</FPU_LG_French><FPU_SnomedCT>25476006, 3511005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Thyroiditis, Suppurative</FPU_Name><FPU_DefMSH>Acute inflammatory disease of the THYROID GLAND due to infections by BACTERIA; FUNGI; or other microorganisms. Symptoms include tender swelling, FEVER, and often with LEUKOCYTOSIS.</FPU_DefMSH><FPU_Code>C0040150</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/ID/SprtvThyrdts.htm</FPU_URL></item><item><FPU_Page>Subacute Granulomatous Thyroiditis</FPU_Page><FPU_LG_English>Subacute Thyroiditides, Thyroiditis, Subacute, SUBACUTE THYROIDITIS, THYROIDITIS, DE QUERVAIN, THYROIDITIS, GIANT CELL, THYROIDITIS, PSEUDOTUBERCULOUS, THYROIDITIS, SUBACUTE, de Quervain's thyroiditis, Giant-cell thyroiditis, Non-supp subacute thyroiditis, THYROIDITIS SUBACUTE, Non-suppurative subacute thyroiditis (disorder), Granulomatous thyroiditis, De Quervain's thyroiditis, Non-suppurative subacute thyroiditis, Subacute granulomatous thyroiditis (disorder), Subacute granulomatous thyroiditis, Giant cell thyroiditis, subacute thyroiditis, subacute thyroiditis (diagnosis), De Quervain's thyroiditis (disorder), Giant-cell thyroiditis (disorder), Granulomatous thyroiditis (disorder), deQuervain's thyroiditis, Thyroiditis subacute, de Quervain thyroiditis, Thyroiditis, Subacute [Disease/Finding], subacute thyroidities, de quervains thyroiditis, de quervain thyroiditis, granulomatous thyroiditis, thyroiditis de quervain, thyroiditis subacute, dequervain's thyroiditis, de quervain's thyroiditis, Pseudogranulomatous thyroiditis, Subacute thyroiditis (disorder), Subacute thyroiditis, de Quervain; thyroiditis, giant cell; thyroiditis, granulomatous; thyroiditis, pseudotuberculous; thyroiditis, subacute; thyroiditis, thyroiditis; de Quervain, thyroiditis; giant cell, thyroiditis; granulomatous, thyroiditis; pseudotuberculous, thyroiditis; subacute, Subacute Thyroiditis, De Quervain's Thyroiditis, Subacute Granulomatous Thyroiditis, Giant cell thyroiditis,, De Quervain Thyroiditis, Thyroiditis, De Quervain, Cell Thyroiditides, Giant, Cell Thyroiditis, Giant, Giant Cell Thyroiditides, Giant Cell Thyroiditis, Granulomatous Thyroiditides, Granulomatous Thyroiditis, Nonsuppurative Thyroiditides, Subacute, Nonsuppurative Thyroiditis, Subacute, Painful Thyroiditides, Subacute, Painful Thyroiditis, Subacute, Subacute Nonsuppurative Thyroiditides, Subacute Nonsuppurative Thyroiditis, Subacute Painful Thyroiditides, Subacute Painful Thyroiditis, Thyroiditides, Giant Cell, Thyroiditides, Subacute Nonsuppurative, Thyroiditides, Subacute Painful, Thyroiditides, Subacute, Thyroiditis, Giant Cell, Thyroiditis, Granulomatous, Thyroiditis, Subacute Nonsuppurative, Thyroiditis, Subacute Painful, Thyroiditides, Granulomatous</FPU_LG_English><FPU_LG_French>Thyroïdite de Quervain, Thyroïdite sous-aiguë, Thyroïdite granulomateuse à cellules géantes, Thyroïdite subaigüe de De Quervain, Thyroïdite subaiguë granulomateuse, Thyroïdite subaigüe granulomateuse, Thyroïdite subaigüe, Thyroïdite de De Quervain, Thyroïdite granulomateuse, Thyroïdite subaiguë</FPU_LG_French><FPU_SnomedCT>38727009, 237533003, 428041004, 237530000, 237531001, 237532008, 154666006, 190296009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Subacute thyroiditis</FPU_Name><FPU_DefMSH>Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.</FPU_DefMSH><FPU_Code>C0040149</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/ID/SbctGrnlmtsThyrdts.htm</FPU_URL></item><item><FPU_Page>Hypoglycemia Management</FPU_Page><FPU_LG_English>Hypoglycemia Management, hypoglycaemia management, hypoglycemia management, Hypoglycaemia management, Hypoglycemia management (procedure), Hypoglycemia management</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>386328006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Therapeutic or Preventive Procedure (T061)
</FPU_Concepts><FPU_Concepts_Codes>T061</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hypoglycemia management</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0150254</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Hypoglycemia/HypglycmMngmnt.htm</FPU_URL></item><item><FPU_Page>Marfan's Syndrome</FPU_Page><FPU_LG_English>ARACHNODACTYLY, DOLICHOSTENOMELIA, HAND SPIDERLIKE, Arachnodactylies, Arachnodactyly, Arachnodactyly (&amp;amp; [congenital]) (disorder), Congenital arachnodactyly (disorder), Arachnodactyly [Disease/Finding], fingers spider, Dolichostenomelia, Spider finger, Congenital arachnodactyly, Arachnodactyly (disorder), arachnodactyly, dolichostenomelia, fingers; spider, spider; fingers, Arachnodactyly (&amp;amp; [congenital])</FPU_LG_English><FPU_LG_French>Arachnodactylie</FPU_LG_French><FPU_SnomedCT>205816001, 271434006, 62250003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Arachnodactyly</FPU_Name><FPU_DefMSH>An abnormal bone development that is characterized by extra long and slender hands and fingers, such that the clenched thumb extends beyond the ulnar side of the hand. Arachnodactyly can include feet and toes. Arachnodactyly has been associated with several gene mutations and syndromes.</FPU_DefMSH><FPU_Code>C0003706</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Growth/MrfnsSyndrm.htm</FPU_URL></item><item><FPU_Page>Marfan's Syndrome</FPU_Page><FPU_LG_English>Marfan's Syndrome, Marfans Syndrome, Syndrome, Marfan, Syndrome, Marfan's, MARFAN'S SYNDROME, MARFAN SYNDROME, MFS, MFS1, MARFAN SYNDROME, TYPE I, Marfan's syndrome (diagnosis), Marfan Syndrome, Marfan syndrome, Marfan's syndrome, unspecified, Marfan Syndrome [Disease/Finding], marfan syndrome, marfan's syndrome, marfan's disease, Marfans syndrome, Marfan's syndrome, Marfan's disease, Marfan's syndrome (disorder), Marfan, marfans syndrome</FPU_LG_English><FPU_LG_French>Syndrome de Marfan, Maladie de Marfan</FPU_LG_French><FPU_SnomedCT>157024004, 19346006, 157033002, 268359006</FPU_SnomedCT><FPU_DefCSP>disorder of connective tissue characterized by tall stature, elongated extremities, subluxation of the lens, dilatation of the ascending aorta, and "pigeon breast"; inherited as an autosomal dominant trait.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A genetic syndrome inherited as an autosomal dominant trait. It is caused by mutations in the FBN1 gene. It is characterized by tall stature, elongated extremities, mitral valve prolapse, aortic dilatation, aortic dissection, and sublaxation of the lens.</FPU_DefNCI><FPU_Name>Marfan Syndrome</FPU_Name><FPU_DefMSH>An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome is associated with mutations in the gene encoding fibrillin, a major element of extracellular microfibrils of connective tissue.</FPU_DefMSH><FPU_Code>C0024796</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Growth/MrfnsSyndrm.htm</FPU_URL></item><item><FPU_Page>Insulinoma</FPU_Page><FPU_LG_English>Island Cell Tumor, Island Cell Tumors, Islet Cell Tumors, Nesidioblastoma, Tumor, Island Cell, Tumor, Islet Cell, Tumors, Island Cell, Tumors, Islet Cell, NESIDIOBLASTOMA, Pancreatic Endocrine Neoplasm, Pancreatic neuroendocrine tumour, Pancreatic neuroendocrine tumor, neoplasm of islets of Langerhans (diagnosis), neoplasm of islets of Langerhans, islet cell tumors, islet cell tumour, endocrine pancreas tumors, islet cell tumor, endocrine pancreas tumor, endocrine pancreatic tumors, islet cell adenoma, pancreatic endocrine tumor, nesidioblastoma, Pancreatic Neuroendocrine Neoplasm, Islet Cell Tumor, Islet cell tumor, Islet cell tumour, Pancreatic endocrine tumor, Pancreatic endocrine tumour, Tumor of endocrine pancreas, Tumour of endocrine pancreas, Islet cell neoplasm (morphologic abnormality), Islet cell neoplasm, Islet cell tumor (morphologic abnormality), Neoplasm of islets of Langerhans (disorder), Neoplasm of islets of Langerhans, Tumor of endocrine pancreas (disorder), islet cell tumor; pancreas, islet cell; tumor, pancreas, nesidioblastoma; pancreas, nesidioblastoma; unspecified site, pancreas; islet cell tumor, pancreas; nesidioblastoma, pancreas; tumor, islet cell, tumor; islet cell, pancreas, Endocrine tumor of pancreas, Endocrine tumour of pancreas</FPU_LG_English><FPU_LG_French>Tumeur neuroendocrinienne pancréatique, Nésidioblastome</FPU_LG_French><FPU_SnomedCT>261713004, 76345009, 128878003, 237596009, 399528006, 126864006, 154609001, 269636003, 188855000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Neoplastic Process (T191)
</FPU_Concepts><FPU_Concepts_Codes>T191</FPU_Concepts_Codes><FPU_DefNCI>A neoplasm with neuroendocrine differentiation that arises from the pancreas. It includes neuroendocrine tumors (low and intermediate grade) and neuroendocrine carcinomas (high grade).</FPU_DefNCI><FPU_Name>Islet Cell Tumor</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0242363</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/HemeOnc/Inslnm.htm</FPU_URL></item><item><FPU_Page>Insulinoma</FPU_Page><FPU_LG_English>Beta-cell adenoma, beta Cell Tumor, beta-Cell Tumor, beta-Cell Tumors, Insulinoma, Insulinomas, Insuloma, Insulomas, Tumor, beta-Cell, Tumors, beta-Cell, Adenoma, beta-Cell, Adenoma, beta Cell, Adenomas, beta-Cell, beta-Cell Adenomas, INSULINOMA, INSULOMA, PANCREAS, ISLET-CELL TUMOR, INSULIN-PRODUCING, beta-Cell Adenoma, Insulinoma, NOS, Pancreatic Insulin Producing Neoplasm, Insulinoma syndrome, Insulinoma NOS, [M]Insulinoma NOS, [M]Insulinoma NOS (morphologic abnormality), Insulinoma [Disease/Finding], insuloma, insulinomas, Pancreatic Insulinoma, beta cell tumor of the pancreas, pancreatic insulin-producing tumor, beta cell neoplasm, Pancreatic Insulin Producing Tumor, Pancreatic Insulin Producing Neuroendocrine Tumor, Pancreatic Insulin Producing NET, Beta cell adenoma, Insulinoma (disorder), Insulinoma (morphologic abnormality), islet cell insulinoma, pancreatic insulinoma, beta-cell; adenoma, pancreas, beta-cell; tumor, pancreas, beta-cell; tumor, unspecified site, insulinoma; pancreas, insulinoma; unspecified site, adenoma; beta-cell, pancreas, pancreas; adenoma, beta-cell, pancreas; beta-cell tumor, pancreas; insulinoma, pancreas; tumor, beta-cell, tumor; beta-cell, pancreas, tumor; beta-cell, unspecified site, Insulin-Producing Islet Cell Neoplasm, Insulin-Producing Islet Cell Tumor, Insulin-Producing Neoplasm of Islet Cells, Insulin-Producing Neoplasm of the Islet Cells, Insulin-Producing Tumor of Islet Cells, Insulin-Producing Tumor of the Islet Cells, Pancreatic Beta Cell Tumor, Beta Cell Neoplasm of Pancreas, Beta Cell Neoplasm of the Pancreas, Beta Cell Neoplasm, Beta Cell Tumor of Pancreas, Beta Cell Tumor of the Pancreas, Beta Cell Tumor, insulinoma</FPU_LG_English><FPU_LG_French>Insulinome, Tumeur bêta-langerhansienne insulino-sécrétante, Tumeur bêta-langerhansienne insulinosécrétante, Tumeur bêta-langerhansienne</FPU_LG_French><FPU_SnomedCT>134154009, 25324008, 302822000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Neoplastic Process (T191)
</FPU_Concepts><FPU_Concepts_Codes>T191</FPU_Concepts_Codes><FPU_DefNCI>An insulin-producing neuroendocrine neoplasm arising from the beta cells of the pancreas. Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin. An insulin-producing neuroendocrine neoplasm arising from the beta cells of the pancreas. It may or may not be associated with inappropriate secretion of insulin and an associated clinical syndrome. An abnormal mass that grows in the beta cells of the pancreas that make insulin. Beta cell neoplasms are usually benign (not cancer). They secrete insulin and are the most common cause of low blood sugar caused by having too much insulin in the body. An abnormal mass that grows in the beta cells of the pancreas that make insulin. Beta cell neoplasms are usually benign (not cancer). They secrete insulin and are the most common cause of low blood sugar caused by having too much insulin in the body.</FPU_DefNCI><FPU_Name>insulinoma</FPU_Name><FPU_DefMSH>A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.</FPU_DefMSH><FPU_Code>C0021670</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/HemeOnc/Inslnm.htm</FPU_URL></item><item><FPU_Page>Hypoglycemia</FPU_Page><FPU_LG_English>BLOOD SUGAR DECREASED, SUGAR BLOOD DECREASED, GLUCOSE BLOOD DECREASED, Glucose blood decreased, Blood sugar decreased, Decreased blood sugar, Sugar blood decreased, blood decreasing sugar, blood glucose decreased, Blood glucose decreased</FPU_LG_English><FPU_LG_French>Glucose sanguin diminué, DIMINUTION DE LA GLYCEMIE, Glycémie diminuée</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Blood glucose decreased</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0595883</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Hypoglycemia/Hypglycm.htm</FPU_URL></item><item><FPU_Page>Tall Stature</FPU_Page><FPU_LG_English>STATURE TALL, stature tall, Stature tall, Large stature, Tall stature, Tall stature (finding), stature; tall, tall; stature, tall stature</FPU_LG_English><FPU_LG_French>Grande taille</FPU_LG_French><FPU_SnomedCT>248328003</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Tall stature</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0241240</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Growth/TlStr.htm</FPU_URL></item><item><FPU_Page>Cerebral Gigantism</FPU_Page><FPU_LG_English>Giant, cerebral, CEREBRAL GIGANTISM, SOTOS SYNDROME, Soto syndrome, Sotos' syndrome (diagnosis), Sotos' syndrome, cerebral gigantism, macrosomia-mental retardation syndrome, mental retardation-overgrowth sequence, Nevo syndrome, Sotos sequence, Gigantisms, Cerebral, Cerebral Gigantisms, Gigantism, Cerebral, Syndrome, Sotos, Cerebral Gigantism, Sotos Syndrome, soto syndrome, sotos' syndrome, syndrome cerebral gigantism, sotos syndrome, Sotos Syndrome [Disease/Finding], Cerebral gigantism syndrome, Cerebral giant, Cerebral gigantism, Sotos syndrome, Sotos' syndrome (disorder), Sotos</FPU_LG_English><FPU_LG_French>Syndrome de Soto, Gigantisme cérébral, Syndrome de Sotos</FPU_LG_French><FPU_SnomedCT>75968004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI>A rare genetic syndrome caused by mutations in the NSD1 gene. It is characterized by excessive physical growth early in life, mild mental retardation, and delayed cognitive and social development. Children affected by this syndrome are tall with larger than normal heads.</FPU_DefNCI><FPU_Name>Sotos' syndrome</FPU_Name><FPU_DefMSH>Congenital or postnatal overgrowth syndrome most often in height and occipitofrontal circumference with variable delayed motor and cognitive development. Other associated features include advanced bone age, seizures, NEONATAL JAUNDICE; HYPOTONIA; and SCOLIOSIS. It is also associated with increased risk of developing neoplasms in adulthood. Mutations in the NSD1 protein and its HAPLOINSUFFICIENCY are associated with the syndrome.</FPU_DefMSH><FPU_Code>C0175695</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Growth/CrbrlGgntsm.htm</FPU_URL></item><item><FPU_Page>Constitutional Short Stature</FPU_Page><FPU_LG_English>Nanism, DWARF, DWARFISM, Dwarf, NANISM, Nanasoma, Physiologic dwarf, Dwarf, NOS, Dwarfism, NOS, RUNTING, Short stature, constitution, Short stature, constitutional, Short stature, hereditary, Constitutional dwarfism, Physiologic dwarfism, Constitutional short stature, Constitutional short stature (disorder), [D]Short stature, constitutional (context-dependent category), [D]Short stature, constitution, [D]Short stature, constitutional, [D]Short stature, hereditary, dwarfism (diagnosis), dwarfism, Normal dwarfism, True dwarf, Pure dwarfism, constitutional dwarfism, constitutional dwarfism (diagnosis), Little person, Dwarfism NOS, Runting, [D]Short stature, constitutional (situation), Short stature disorder, Dwarfism [Disease/Finding], dwarf, primordial dwarf, dwarfs, short stature, constitutional short stature, runts, runt, hereditary short stature, Normal dwarf, Primordial dwarf, Pure dwarf, Nanosoma, Nanosomia, True dwarfism, Primordial dwarfism, Dwarfism (disorder), Primordial dwarfism (disorder), Short stature disorder (disorder), Dwarfism, nanism, constitutional; dwarfism, dwarfism; constitutional, short; stature, constitutional, stature; short, constitutional, Dwarfism (disorder) [Ambiguous]</FPU_LG_English><FPU_LG_French>NANISME, Nanisme SAI, Maladie des rabougris, Nain, Nanisme</FPU_LG_French><FPU_SnomedCT>190584003, 422065006, 206931003, 237837007, 185797004, 90482002, 237836003, 205467007, 248299001, 190585002</FPU_SnomedCT><FPU_DefCSP>condition of being undersized as a result of premature arrest of skeletal growth.</FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Dwarfism</FPU_Name><FPU_DefMSH>A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.</FPU_DefMSH><FPU_Code>C0013336</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Growth/CnsttnlShrtStr.htm</FPU_URL></item><item><FPU_Page>Achondroplasia</FPU_Page><FPU_LG_English>Achondroplasias, CHONDRODYSTROPHIA FETALIS, DWARFISM, ACHONDROPLASTIC, Dwarf, achondroplastic, Achondroplastic physique, Chondrodystrophia foetalis, Physiologic dwarfism, Achondroplasia, Achondroplasia syndrome, Chondrodystrophy syndrome, ACHONDROPLASIA, ACH, achondroplasia, achondroplasia (diagnosis), DWARFISM ACHONDROPLASTIC, Achondroplasia [Disease/Finding], Achondroplastic Dwarf, chondrodystrophia, achondroplastic dwarfism, Chondrodystrophia fetalis, Congenital osteosclerosis, Achondroplastic dwarf, Achondroplastic dwarfism, Achondroplasia (disorder), Osteosclerosis congenita, chondrodysplasia; fetalis, dwarfism; achondroplastic, fetal; chondrodysplasia, achondroplastic; dwarfism, Achondroplastic physique (finding), osteosclerosis congenita, Chondrodystrophia, achondroplastic dwarf</FPU_LG_English><FPU_LG_French>Nain achondroplastique, Achondroplasie</FPU_LG_French><FPU_SnomedCT>190584003, 268273004, 86268005, 205467007, 268350005, 248299001</FPU_SnomedCT><FPU_DefCSP>autosomal dominant disorder that is the most frequent form of short-limb dwarfism; a disturbance of epiphyseal chondroblastic growth, causing inadequate enchondral bone formation.</FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI>An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, genu varum, and trident hand. (MeSH)</FPU_DefNCI><FPU_Name>Achondroplasia</FPU_Name><FPU_DefMSH>An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, GENU VARUM, and trident hand. (Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim, MIM#100800, April 20, 2001)</FPU_DefMSH><FPU_Code>C0001080</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Growth/Achndrpls.htm</FPU_URL></item><item><FPU_Page>Short Stature</FPU_Page><FPU_LG_English>STATURE SHORTNESS, SHORT STATURE, Short stature, [D]Short stature (context-dependent category), Stature Short, [D]Short stature, short stature, short stature (physical finding), [D]Short stature (situation), short stature was noted, Stature short, Short stature NOS, Short;stature, stature short, small stature, Small stature, SS - Short stature, short; stature, stature; short, Short stature (finding), Short;growth</FPU_LG_English><FPU_LG_French>Petite taille, Insuffisance staturale, Petite stature</FPU_LG_French><FPU_SnomedCT>206930002, 158283003, 237836003, 277266007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Short stature</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0349588</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Growth/ShrtStr.htm</FPU_URL></item><item><FPU_Page>Unintentional Weight Loss</FPU_Page><FPU_LG_English>CACHECTIC, CACHEXIA, Cachexia, NOS, Cachexia NOS, [D]Cachexia, [D]Cachexia NOS, Cachexia, [D]Cachexia (context-dependent category), [D]Cachexia NOS (context-dependent category), cachectic (physical finding), cachectic, cachexia, Cachexia (disorder), [D]Cachexia (situation), [D]Cachexia NOS (situation), Cachexia [Disease/Finding], General body deterioration, Cachectic, Cachexia (finding), Cachexia (disorder) [Ambiguous]</FPU_LG_English><FPU_LG_French>CACHEXIE, Cachexie</FPU_LG_French><FPU_SnomedCT>207558009, 207560006, 28928000, 158737005, 238108007, 285384003</FPU_SnomedCT><FPU_DefCSP>state of general ill health characterized by malnutrition, weakness, and emaciation; occurs during the course of a chronic disease.</FPU_DefCSP><FPU_Concepts>Sign or Symptom (T184)
</FPU_Concepts><FPU_Concepts_Codes>T184</FPU_Concepts_Codes><FPU_DefNCI>The loss of body weight and muscle mass frequently seen in patients with cancer, AIDS, or other diseases.</FPU_DefNCI><FPU_Name>Cachexia</FPU_Name><FPU_DefMSH>General ill health, malnutrition, and weight loss, usually associated with chronic disease.</FPU_DefMSH><FPU_Code>C0006625</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Geri/UntntnlWghtLs.htm</FPU_URL></item><item><FPU_Page>Unintentional Weight Loss</FPU_Page><FPU_LG_English>Wasting syndrome, Wasting disease, NOS, Wasting Disease, Wasting Diseases, Wasting Syndrome, Wasting Syndromes, [D]Wasting disease, [D]Wasting disease (context-dependent category), WASTING GENERALIZED, WASTING DIS, wasting syndrome, Wasting disease (finding), Wasting generalized, WASTING SYNDROME, [D]Wasting disease (situation), Wasting Syndrome [Disease/Finding], wasting diseases, wasting disease, Wasting disease, Wasting disease (disorder), disease (or disorder); wasting, disease; wasting, syndrome; wasting, wasting; disease, wasting; syndrome</FPU_LG_English><FPU_LG_French>Atrophie généralisée, Syndrome de dépérissement, Syndrome cachectique, Syndrome de cachexie progressive, Syndrome de cachexie</FPU_LG_French><FPU_SnomedCT>207559001, 271878009, 288517002, 28928000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Wasting Syndrome</FPU_Name><FPU_DefMSH>A condition of involuntary weight loss of greater then 10% of baseline body weight. It is characterized by atrophy of muscles and depletion of lean body mass. Wasting is a sign of MALNUTRITION as a result of inadequate dietary intake, malabsorption, or hypermetabolism.</FPU_DefMSH><FPU_Code>C0043046</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Geri/UntntnlWghtLs.htm</FPU_URL></item><item><FPU_Page>Diabetic Retinopathy</FPU_Page><FPU_LG_English>Retinopathy, diabetic, Diabetic Retinopathies, Retinopathies, Diabetic, DIABETIC RETINOPATHY, Retinopathy, Diabetic, Diabetic retinopathy, NOS, Diabetic retinopathy NOS, DR - Diabetic retinopathy, DR, diabetic retinopathy (diagnosis), diabetic retinopathy, Retina abnormal - diabet-relat, Retinopathy diabetic, Diabetic retinopathy NOS (disorder), Diabetic Retinopathy [Disease/Finding], Retinopathy;diabetic, Diabetic retinopathy, Retinal abnormality - diabetes-related, Diabetic retinopathy (disorder), Diabetic Retinopathy, Retinal abnormality - diabetes-related (disorder), Retinopathy - diabetic</FPU_LG_English><FPU_LG_French>Rétinopathie diabétique</FPU_LG_French><FPU_SnomedCT>4855003, 163997001, 141196007, 155107006, 193353002, 154678005, 267471001, 309595004</FPU_SnomedCT><FPU_DefCSP>retinal changes occurring in diabetes mellitus, marked by microaneurysms, exudates, and hemorrhages, and sometimes by neovascularization.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Diabetic Retinopathy</FPU_Name><FPU_DefMSH>Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.</FPU_DefMSH><FPU_Code>C0011884</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Eye/DbtcRtnpthy.htm</FPU_URL></item><item><FPU_Page>Waist-to-Hip Ratio</FPU_Page><FPU_LG_English>obesity android, android obesity, Android obesity, Android obesity (disorder)</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>238132000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Android obesity</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0342940</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/WstTHpRt.htm</FPU_URL></item><item><FPU_Page>Waist-to-Hip Ratio</FPU_Page><FPU_LG_English>Anthropometry, anthropometry</FPU_LG_English><FPU_LG_French>Anthropométrie</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP>measurement of the physical dimensions of the human or other primate body characteristics such as size, breadth, girth, weight, proportion and distance between anatomical points; also includes segment masses, the centers of gravity of body segments, and the ranges of joint motion, which are used in biomechanical analyses of work postures; in anthropology it is used to refer to different body sizes and proportions of individuals belonging to different populations.</FPU_DefCSP><FPU_Concepts>Research Activity (T062)
</FPU_Concepts><FPU_Concepts_Codes>T062</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Anthropometry</FPU_Name><FPU_DefMSH>The technique that deals with the measurement of the size, weight, and proportions of the human or other primate body.</FPU_DefMSH><FPU_Code>C0003188</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/WstTHpRt.htm</FPU_URL></item><item><FPU_Page>Male Tanner Stage</FPU_Page><FPU_LG_English>Tanner boy genital development, male genital development Tanner stage, Tanner boys genital development (physical finding), Boys genital development, Tanner boys genital development, G - Genitalia stage, Tanner boys genital development stage (observable entity), Tanner boys genital development stage</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>251805007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Tanner boys genital development stage</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0429596</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/MlTnrStg.htm</FPU_URL></item><item><FPU_Page>Glucose Metabolism</FPU_Page><FPU_LG_English>glucose metabolic process, glucose metabolism, cellular glucose metabolic process, Glucose Metabolism</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP>sum of chemical changes that occur within the tissues of an organism consisting of anabolism (biosynthesis) and catabolism of glucose; the buildup and breakdown of glucose for utilization by the organism.</FPU_DefCSP><FPU_Concepts>Molecular Function (T044)
</FPU_Concepts><FPU_Concepts_Codes>T044</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>glucose metabolism</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0596620</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/GlcsMtblsm.htm</FPU_URL></item><item><FPU_Page>Sexual Development</FPU_Page><FPU_LG_English>adrenarche, Adrenarche (finding), Adrenarche</FPU_LG_English><FPU_LG_French>Adrénarche, Puberté surrénalienne</FPU_LG_French><FPU_SnomedCT>103020000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Biologically Active Substance (T123)
</FPU_Concepts><FPU_Concepts_Codes>T123</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Adrenarche</FPU_Name><FPU_DefMSH>A stage of development at which the ADRENAL GLANDS undergo maturation leading to the capability of producing increasing amounts of adrenal androgens, DEHYDROEPIANDROSTERONE and ANDROSTENEDIONE. Adrenarche usually begins at about 7 or 8 years of age before the signs of PUBERTY and continues throughout puberty.</FPU_DefMSH><FPU_Code>C0686792</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/SxlDvlpmnt.htm</FPU_URL></item><item><FPU_Page>Sexual Development</FPU_Page><FPU_LG_English>Tanner Scale, Tanner Stages</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Intellectual Product (T170)
</FPU_Concepts><FPU_Concepts_Codes>T170</FPU_Concepts_Codes><FPU_DefNCI>A scale of physical development in children, adolescents and adults based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. (Tanner JM. Growth at adolescence. 2d ed. Oxford: Blackwell, 1962)</FPU_DefNCI><FPU_Name>Tanner Scale</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C2826146</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/SxlDvlpmnt.htm</FPU_URL></item><item><FPU_Page>Sexual Development</FPU_Page><FPU_LG_English>Endocrine disorder related to puberty, NOS, Endocrine disorder related to puberty (disorder), Endocrine disorder related to puberty</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>4900002</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Endocrine disorder related to puberty</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0271522</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/SxlDvlpmnt.htm</FPU_URL></item><item><FPU_Page>Female Tanner Stage</FPU_Page><FPU_LG_English>female pubic hair Tanner stage, Tanner girls pubic hair (physical finding), Tanner girls pubic hair</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Tanner girls pubic hair</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C2197575</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/FmlTnrStg.htm</FPU_URL></item><item><FPU_Page>Female Tanner Stage</FPU_Page><FPU_LG_English>Tanner girl breast development, breast development Tanner stage, Tanner girls breast development (physical finding), girls development breast, breast development girls, girl breast development, tanner girls breast development stage, B - Breast stage, Girls breast development, Tanner girls breast development, Tanner girls breast development stage (observable entity), Tanner girls breast development stage</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>251811005</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Tanner girls breast development stage</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0429602</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/FmlTnrStg.htm</FPU_URL></item><item><FPU_Page>Body Mass Index</FPU_Page><FPU_LG_English>Body Mass Index, Index, Body Mass, Quetelets Index, Body mass index, BMI, body mass index (BMI), quetelet index, body mass index, Body mass index procedure, Quetelet Index, Quetelet's Index, Index, Quetelet</FPU_LG_English><FPU_LG_French>Index de Quetelet, IMC (Indice de Masse Corporelle), Indice de masse corporelle, Indice de Quetelet, Index de masse corporelle</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Diagnostic Procedure (T060)
</FPU_Concepts><FPU_Concepts_Codes>T060</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Body mass index procedure</FPU_Name><FPU_DefMSH>An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)</FPU_DefMSH><FPU_Code>C0005893</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/BdyMsIndx.htm</FPU_URL></item><item><FPU_Page>Body Mass Index</FPU_Page><FPU_LG_English>Body mass index, NOS, Quetelet index, Quetelet index (observable entity), BODY MASS INDEX, Quetelet Index, body mass index (physical finding), body mass index, BMI, quetelet index, body mass index (BMI), Body mass index (observable entity), BMI - Body mass index, Body mass index, Body mass index - observation, Body mass index [dup] (observable entity), Body Mass Index</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>248359001, 60621009, 162859006, 363807006, 140075008</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Clinical Attribute (T201)
</FPU_Concepts><FPU_Concepts_Codes>T201</FPU_Concepts_Codes><FPU_DefNCI>A general indicator of the body fat an individual is carrying based upon the ratio of weight to height. (NCI) A measure that relates body weight to height. BMI is sometimes used to measure total body fat and whether a person is a healthy weight. Excess body fat is linked to an increased risk of some diseases including heart disease and some cancers. A general indicator of the body fat an individual is carrying based upon the ratio of weight to height.</FPU_DefNCI><FPU_Name>Body mass index</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1305855</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Exam/BdyMsIndx.htm</FPU_URL></item><item><FPU_Page>Type 1 Diabetes Mellitus</FPU_Page><FPU_LG_English>Brittle Diabetes Mellitus, Diabetes Mellitus, Brittle, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Juvenile Onset, Diabetes Mellitus, Juvenile-Onset, Diabetes Mellitus, Ketosis Prone, Diabetes Mellitus, Ketosis-Prone, IDDM, Juvenile-Onset Diabetes Mellitus, Ketosis-Prone Diabetes Mellitus, DIABETES MELLITUS, INSULIN DEPENDENT, DIABETES MELLITUS, TYPE 1, Diabetes Mellitus, Insulin Dependent, Diabetes mellitus, type I, JUVENILE ONSET DIABETES MELLITUS, insulin dependent diabetes mellitus, DIABETES MELLITUS (JUVENILE ONSET), DIABETES MELLITUS INSULIN DEPENDENT, Insulin depend diabetes mellit, Juvenile onset diabet mellitis, Diabetes Mellitus, Sudden Onset, Diabetes Mellitus, Sudden-Onset, Mellitus, Sudden-Onset Diabetes, Sudden-Onset Diabetes Mellitus, Diabetes mellitus, growth onset type, Diabetes mellitus, juvenile onset type, DIABETES MELLITUS, INSULIN-DEPENDENT, DIABETES MELLITUS, TYPE I, JOD, IDDM1, INSULIN-DEPENDENT DIABETES MELLITUS 1, JUVENILE-ONSET DIABETES, Diabetes mellitus, insulin-dependent, DIABETES MELLITUS, INSULIN-DEPENDENT, 1, DIABETES MELLITUS TYPE 01, juvenile diabetes mellitus, ketosis prone diabetes, IDD, Juvenile diabetes, Diabetes mellitus juvenile onset, Diabetes mellitus insulin-dependent, Ketosis-prone diabetes mellitus, Insulin dependent diabetic, type I diabetes, insulin-dependent diabetes mellitus, juvenile-onset diabetes mellitus, type I diabetes mellitus (diagnosis), type I diabetes mellitus, iddm, juvenile onset diabetes mellitus, diabetes, type i, jodm, diabetes type i, Diabetes mellitus: [juvenile] or [insulin dependent] (disorder), Type I diabetes mellitus (disorder), Type 1 Diabetes, Insulin Dependent Diabetes Mellitus, Type I Diabetes, Insulin Dependent Diabetes, Type I Diabetes Mellitus, Juvenile Diabetes, IDDM-Insulin-depend diab mell, Insulin-depend diabet mellitus, Insulin-dependent diabetes, Diabetes Type 1, Insulin-Dependent Diabetes Mellitus, DIABETES MELLITUS, KETOSIS-PRONE, Type 1 diabetes, Diabetes mellitus, type 1, KPD, brittle diabetes (mellitus), juvenile onset diabetes (mellitus), ketosis-prone diabetes (mellitus), Diabetes Mellitus, Type 1 [Disease/Finding], Diabetes;Type 1, diabetes type 1, Diabetes;insulin dependent, Diabetes;juvenile onset, type i diabetes, type 1 diabetes mellitus, diabetes mellitus type i, diabetes mellitus type 1, type i diabetes mellitus, Insulin dependent diabetes mellitus, Diabetes mellitus type I, Juvenile onset diabetes mellitus, Type 1 diabetes mellitus, Insulin-dependent diabetes mellitus, IDDM - Insulin-dependent diabetes mellitus, Type I diabetes mellitus, Diabetes mellitus type 1 (disorder), Diabetes mellitus type 1, Diabetes insulin dependent, diabetes; insulin-dependent, diabetes; juvenile-onset, diabetes; ketosis-prone, diabetes; type I, insulin-dependent; diabetes, juvenile-onset; diabetes, ketosis, prone; diabetes, type I; diabetes, Diabetes mellitus - juvenile, Diabetes mellitus: [juvenile] or [insulin dependent], Insulin dependent diabetes mel, Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus, insulin dependent diabetes, type 1 diabetes, juvenile onset of diabetes</FPU_LG_English><FPU_LG_French>Diabète insulino-dépendant, Diabétique insulino-dépendant, Apparition juvénile de diabète sucré, Diabète sucré de type I, DID, DID1, Diabète de type I, Diabète insulinodépendant, Diabète juvénile, Diabète de type 1, DSID (Diabète Sucré InsulinoDépendant), DSID, Diabète instable, Diabète sucré de type 1, Diabète sucré insulino-dépendant, Diabète sucré insulinodépendant</FPU_LG_French><FPU_SnomedCT>154673001, 190362004, 267469001, 46635009, 190322003</FPU_SnomedCT><FPU_DefCSP>subtype of diabetes mellitus that is characterized by insulin deficiency; it is manifested by the sudden onset of severe hyperglycemia, rapid progression to diabetic ketoacidosis, and death unless treated with insulin; the disease may occur at any age, but is most common in childhood or adolescence.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>Diabetes mellitus characterized by insulin deficiency, sudden onset, severe hyperglycemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.</FPU_DefNCI><FPU_Name>Diabetes Mellitus, Insulin-Dependent</FPU_Name><FPU_DefMSH>A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.</FPU_DefMSH><FPU_Code>C0011854</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/TypDbtsMlts.htm</FPU_URL></item><item><FPU_Page>Type 2 Diabetes Mellitus</FPU_Page><FPU_LG_English>Noninsulin dependent diabetes mellitus, Adult-Onset Diabetes Mellitus, Diabetes Mellitus, Adult Onset, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Ketosis Resistant, Diabetes Mellitus, Ketosis-Resistant, Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Stable, Ketosis-Resistant Diabetes Mellitus, NIDDM, Non-Insulin-Dependent Diabetes Mellitus, Stable Diabetes Mellitus, DIABETES MELLITUS, NON-INSULIN DEPENDENT, ADULT ONSET DIABETES MELLITUS, DIABETES MELLITUS, TYPE 2, DIABETES, ADULT ONSET, DIABETES, KETOSIS RESISTANT, DIABETES, MATURITY ONSET, Diabetes Mellitus, Maturity Onset, Diabetes Mellitus, Maturity-Onset, Diabetes mellitus, type II, MOD, MODY, Maturity Onset Diabetes Mellitus, Maturity-Onset Diabetes Mellitus, noninsulin dependent diabetes mellitus, DIABETES MELLITUS (ADULT ONSET), NCDMM, Maturity onset diabetes mellit, NIDDM-Non-ins dep diabetes mel, Diabetes Mellitus, Slow Onset, Diabetes Mellitus, Slow-Onset, Slow-Onset Diabetes Mellitus, Diabetes mellitus, adult onset type, Noninsulin-dependent diabetes mellitus, NONINSULIN-DEPENDENT DIABETES MELLITUS, Diabetes mellitus, noninsulin-dependent, DIABETES MELLITUS, NONINSULIN-DEPENDENT, MATURITY-ONSET DIABETES, DIABETES MELLITUS, TYPE II, DIABETES MELLITUS NON INSULIN-DEP, DIABETES MELLITUS TYPE 02, adult onset diabetes mellitus, ketosis resistant diabetes, Diabetes mellitus non insulin-dep, Diabetes mellitus maturity onset, Diabetes mellitus non-insulin-dependent, Maturity onset diabetes, type II diabetes mellitus, AODM, type II diabetes mellitus (diagnosis), type 2 diabetes, non-insulin dependent diabetes mellitus, aodm, niddm, diabetes type ii, diabetes, type ii, Type II diabetes mellitus (disorder), Diabetes mellitus: [adult onset] or [noninsulin dependent] (disorder), Diabetes mellitus - adult ons, Type 2 Diabetes, Type II Diabetes Mellitus, Non-Insulin Dependent Diabetes Mellitus, Adult-Onset Diabetes, Type 2 Diabetes Mellitus Non-Insulin Dependent, Type II Diabetes, Non-ins-dep diabetes mellitus, DIABETES MELLITUS NON INSULIN DEPENDENT, DIABETES MELLITUS NOS LATE ONSET, Type II diabetes, T2D, T2DM - Type 2 Diabetes mellitus, Diabetes, Type 2, Diabetes Mellitus, Type 2 [Disease/Finding], diabetes mellitus type ii, Diabetes;Type 2, Diabetes;adult onset, Diabetes;non insulin depend, type II diabetes, type ii diabetes mellitus, diabetes type 2, diabete type 2, late onset diabetes, maturity onset diabetes, diabetes mellitus type 2, non-insulin dependent diabetes, type 2 diabetes mellitus, Diabetes mellitus type II, Non-insulin dependent diabetes mellitus, Maturity onset diabetes mellitus, NIDDM - Non-insulin dependent diabetes mellitus, Type 2 diabetes mellitus, Non-insulin-dependent diabetes mellitus, Diabetes mellitus - adult onset, Type II diabetes mellitus, Diabetes mellitus type 2 (disorder), Diabetes mellitus type 2, Diabetes non-insulin dependent, diabetes, NIDDM; diabetes, diabetes; NIDDM, diabetes; adult-onset, diabetes; maturity-onset, diabetes; non-insulin-dependent, diabetes; nonketotic, diabetes; type II, maturity-onset; diabetes, non-insulin-dependent; diabetes, nonketotic; diabetes, adult-onset; diabetes, type II; diabetes, Diabetes mellitus -adult onset, Diabetes mellitus: [adult onset] or [noninsulin dependent], Noninsulin dependent diab.mell, Diabetes Mellitus, Type II, Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus, Non-Insulin Dependent Diabetes, non insulin dependent diabetes, adult onset diabetes</FPU_LG_English><FPU_LG_French>Diabète sucré non dépendant d'insuline, Diabète sucré de la maturité, Diabète sucré non insulino-dépendant, Diabète sucré non insulino dép, Diabète sucré de type II, DIABETE NON INSULINO-DEPENDANT, DID2, Diabète avec insulinorésistance, Diabète avec intolérance au glucose, Diabète de la maturité, Diabète de type II, Diabète gras, Diabète non insulinodépendant, DNID, Diabète de type 2, DSNID, Diabète sucré de type 2</FPU_LG_French><FPU_SnomedCT>190384004, 154672006, 267468009, 44054006, 190323008</FPU_SnomedCT><FPU_DefCSP>subclass of diabetes mellitus that is not insulin responsive or dependent; characterized initially by insulin resistance and hyperinsulinemia and eventually by glucose intolerance, hyperglycemia, and overt diabetes; type II diabetes mellitus is no longer considered a disease exclusively found in adults; patients seldom develop ketosis but often exhibit obesity.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.</FPU_DefNCI><FPU_Name>Diabetes Mellitus, Non-Insulin-Dependent</FPU_Name><FPU_DefMSH>A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.</FPU_DefMSH><FPU_Code>C0011860</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/TypDbtsMlts1.htm</FPU_URL></item><item><FPU_Page>Diabetes Mellitus</FPU_Page><FPU_LG_English>Diabetes, Diabetes Mellitus, DIABETES MELLITUS, Diabetes mellitus, NOS, diabetes, Unspecified diabetes mellitus, dm, diabetes mellitus, diabetes mellitus (diagnosis), DM, Diabetes mellitus NOS, DIABETES MELLITUS NOS DIAGNOSED, DIABETES MELLITUS NOS, diabetes NOS, Diabetes Mellitus [Disease/Finding], diabete mellitus, disorder diabetes mellitus, diabetes (DM), diabetes mellitus (DM), Diabetes mellitus (E08-E13), Diabetes mellitus, DM - Diabetes mellitus, Diabetes mellitus (disorder), Diabetes NOS</FPU_LG_English><FPU_LG_French>DIABETE SUCRE, Diabète sucré SAI, Diabete sucre, Diabète, Diabète sucré</FPU_LG_French><FPU_SnomedCT>191044006, 73211009, 154671004, 267467004</FPU_SnomedCT><FPU_DefCSP>heterogeneous group of disorders that share glucose intolerance in common.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization. A disease in which the body does not control the amount of glucose (a type of sugar) in the blood and the kidneys make a large amount of urine. This disease occurs when the body does not make enough insulin or does not use it the way it should.</FPU_DefNCI><FPU_Name>Diabetes Mellitus</FPU_Name><FPU_DefMSH>A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.</FPU_DefMSH><FPU_Code>C0011849</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/DbtsMlts.htm</FPU_URL></item><item><FPU_Page>Insulin Resistance Syndrome</FPU_Page><FPU_LG_English>Metabolic Syndrome, metabolic syndromes, syndrome metabolic, Metabolic syndrome, metabolic syndrome</FPU_LG_English><FPU_LG_French>Syndrome métabolique</FPU_LG_French><FPU_SnomedCT></FPU_SnomedCT><FPU_DefCSP>a multifaceted syndrome characterized by clustering of insulin resistance and hyperinsulinemia, associated with dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin dependent diabetes mellitus, and an increased risk of cardiovascular events.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Metabolic syndrome</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0948265</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/InslnRstncSyndrm.htm</FPU_URL></item><item><FPU_Page>Insulin Resistance Syndrome</FPU_Page><FPU_LG_English>[D]Impaired fasting glycaemia (context-dependent category), impaired fasting glucose (diagnosis), impaired fasting glucose, [D]Impaired fasting glycaemia (situation), [D]Impaired fasting glucose, Impaired fasting glycaemia (disorder), Impaired fasting glycaemia, Impaired fasting glycaemia -RETIRED-, [D]Impaired fasting glycaemia, Impaired fasting glucose</FPU_LG_English><FPU_LG_French>Diminution du glucose à jeun</FPU_LG_French><FPU_SnomedCT>390937007, 389984002, 390731003, 390951007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Finding (T033)
</FPU_Concepts><FPU_Concepts_Codes>T033</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Impaired fasting glycaemia</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C1272092</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/InslnRstncSyndrm.htm</FPU_URL></item><item><FPU_Page>Insulin Resistance Syndrome</FPU_Page><FPU_LG_English>Angina Pectoris with Normal Coronary Arteriogram, Angina, Microvascular, Chest pain norm cor angio, Cardiac syndrome X (disorder), Syndrome X (Cardiac), Microvascular Angina [Disease/Finding], cardiac syndrome x, syndrome x, microvascular angina, Cardiac Syndrome X, Cardiac syndrome X, Chest pain with normal coronary angiography, Cardiac syndrome X (finding), Microvascular Angina, Syndrome X, Cardiac, Angina Syndrome Xs, Angina Syndrome X, Angina X Syndromes, Angina X Syndrome, Syndrome X, Angina, Syndrome Xs, Angina, Syndrome, Angina X, X Syndrome, Angina, Syndrome X, syndrome X, Microvascular angina</FPU_LG_English><FPU_LG_French>Syndrome cardiaque X, Angor microvasculaire, Angine de poitrine à coronarographie normale, Angor à coronaires saines, Angine microvasculaire, Angor avec coronaires normales, Angine de poitrine à coronaires saines, Angor à coronarographie normale, Syndrome X cardiaque</FPU_LG_French><FPU_SnomedCT>194869009, 233845001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Microvascular Angina</FPU_Name><FPU_DefMSH>ANGINA PECTORIS or angina-like chest pain with a normal coronary arteriogram and positive EXERCISE TEST. The cause of the syndrome is unknown. While its recognition is of clinical importance, its prognosis is excellent. (Braunwald, Heart Disease, 4th ed, p1346; Jablonski Dictionary of Syndromes &amp;amp; Eponymic Diseases, 2d ed). It is different from METABOLIC SYNDROME X, a syndrome characterized by INSULIN RESISTANCE and HYPERINSULINEMIA, that has increased risk for cardiovascular disease.</FPU_DefMSH><FPU_Code>C0206064</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/InslnRstncSyndrm.htm</FPU_URL></item><item><FPU_Page>Insulin Resistance Syndrome</FPU_Page><FPU_LG_English>Glucose Intolerance, Glucose Intolerances, Intolerances, Glucose, GLUCOSE INTOLERANCE, Intolerance, Glucose, Impaired glucose tolerance, NOS, IGT - Impair glucose tolerance, glucose intolerance (diagnosis), glucose intolerance, Glucose: [intolerance] or [malabsorption] (disorder), impaired glucose tolerance, impaired glucose tolerance (diagnosis), prediabetes, Glucose tolerance impaired, Impaired glucose tolerance, Glucose Intolerance [Disease/Finding], chemicals diabetes, chemical diabetes, glucose impaired tolerance, Intolerance;glucose, malabsorption of glucose, diabetes chemical, latent diabetes, glucose malabsorption, Chemical diabetes, Latent diabetes, Prediabetic nonclinical diabetes, Glucose intolerance, IGT - Impaired glucose tolerance, Malabsorption of glucose, Impaired glucose tolerance (disorder), Malabsorption of glucose (disorder), chemicals; diabetes, diabetes; chemical, diabetes; latent, glucose; intolerance, glucose; malabsorption, intolerance; glucose, latent; diabetes, malabsorption; glucose, Glucose: [intolerance] or [malabsorption], Impaired;glucose tolerance</FPU_LG_English><FPU_LG_French>Diabète latent, Diabète chimique, Intolérance au glucose</FPU_LG_French><FPU_SnomedCT>154720005, 190752008, 9414007, 267426009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A condition referring to fasting plasma glucose levels being less than 140 mg per deciliter while the plasma glucose levels after a glucose tolerance test being more than 200 mg per deciliter at 30, 60, or 90 minutes. It is observed in patients with diabetes mellitus. Other causes include immune disorders, genetic syndromes, and cirrhosis. A disorder characterized by an inability to properly metabolize glucose.</FPU_DefNCI><FPU_Name>Impaired glucose tolerance</FPU_Name><FPU_DefMSH>A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.</FPU_DefMSH><FPU_Code>C0271650</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/InslnRstncSyndrm.htm</FPU_URL></item><item><FPU_Page>Insulin Resistance Syndrome</FPU_Page><FPU_LG_English>Resistance, Insulin, Insulin resistance syndrome, Insulin Resistance [Disease/Finding], insulin resistance syndrome, Drug resistance to insulin, Insulin resistance, Drug resistance to insulin (disorder), Insulin Resistance, insulin resistance</FPU_LG_English><FPU_LG_French>Syndrome d'insulino-résistance, Insulinorésistance, Insulino-résistance, Résistance à l'insuline</FPU_LG_French><FPU_SnomedCT>48606007</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Pathologic Function (T046)
</FPU_Concepts><FPU_Concepts_Codes>T046</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Insulin Resistance</FPU_Name><FPU_DefMSH>Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.</FPU_DefMSH><FPU_Code>C0021655</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/InslnRstncSyndrm.htm</FPU_URL></item><item><FPU_Page>Diabetic Ketoacidosis</FPU_Page><FPU_LG_English>Diabetic keto-acidosis, Acidoses, Diabetic, Acidosis, Diabetic, Diabetic Acidoses, Diabetic Acidosis, Diabetic Ketoacidoses, Ketoacidoses, Diabetic, Ketoacidosis, Diabetic, Diabetes with ketoacidosis, ACIDOSIS DIABETIC, ACIDOSIS, DIABETIC, DIABETIC ACIDOSIS, DIABETIC KETOACIDOSIS, DKA, diabetic acidosis, Diabetes Mellitus with Ketoacidosis, Diabetic acidosis without coma, Diabetic ketosis without coma, DKA - Diabetic ketoacidosis, Diab.mell.+ketoacid -onset NOS, Diabetes mellitus NOS with ketoacidosis, Diabetic acidosis, NOS, Diabetic ketoacidosis, Diabetes mellitus with ketoacidosis, Diabetic acidosis, Diabetes with ketoacidosis (disorder), Ketoacidosis in diabetes mellitus (disorder), Ketoacidosis in diabetes mellitus, Diab.mell.with ketoacidosis, diabetes with ketoacidosis, diabetes mellitus with ketoacidosis, diabetes mellitus with ketoacidosis (diagnosis), Diabetes mellitus (&amp;amp; [ketoacidosis]) (disorder), Acidosis diabetic, Ketoacidosis (diabetic), Diabetic ketosis, KETOACIDOSIS DIABETIC, Diabetes mellitus NOS with ketoacidosis (disorder), KETOACIDOSIS, DIABETIC, Diabetic Ketoacidosis [Disease/Finding], diabetic ketoacidosis, diabetic ketoacidoses, diabetic ketosis, diabetic ketoses, Diabetes mellitus (&amp;amp; [ketoacidosis]), Ketoacidosis - diabetic, Diabetic Ketoses, Diabetic Ketosis, Ketoses, Diabetic, Ketosis, Diabetic, Diabetic Ketoacidosis</FPU_LG_English><FPU_LG_French>ACIDOCETOSE DIABETIQUE, Diabète sucré avec kétoacidose, Kétoacidose (diabétique), Diabète avec kétoacidose, Acidocétose diabétique, Acidose diabétique, Cétose diabétique, Acido-cétose diabétique</FPU_LG_French><FPU_SnomedCT>24927004, 420422005, 154671004, 267467004, 190328004</FPU_SnomedCT><FPU_DefCSP>complication of diabetes resulting from severe insulin deficiency coupled with an absolute or relative increase in glucagon concentration; metabolic acidosis is caused by the breakdown of adipose stores and resulting increased levels of free fatty acids; glucagon accelerates the oxidation of the free fatty acids producing excess ketone bodies (ketosis).</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A type of metabolic acidosis produced by accumulation of ketone bodies resulting from uncontrolled diabetes mellitus. The metabolic condition resulted from uncontrolled diabetes mellitus, in which the shift of acid-base status of the body toward the acid side because of loss of base or retention of acids other than carbonic acid is accompanied by the accumulation of ketone bodies in body tissues and fluids.</FPU_DefNCI><FPU_Name>Diabetic Ketoacidosis</FPU_Name><FPU_DefMSH>A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA.</FPU_DefMSH><FPU_Code>C0011880</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/DbtcKtcds.htm</FPU_URL></item><item><FPU_Page>Diabetic Education</FPU_Page><FPU_LG_English>Diabetic patient education, diabetic patient education, Diabetic patient education (procedure), Diabetic patient education (regime/therapy), Diabetic education (procedure), Diabetic education</FPU_LG_English><FPU_LG_French></FPU_LG_French><FPU_SnomedCT>6143009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Health Care Activity (T058)
</FPU_Concepts><FPU_Concepts_Codes>T058</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Diabetic education</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0204935</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/DM/DbtcEdctn.htm</FPU_URL></item><item><FPU_Page>Granuloma Annulare</FPU_Page><FPU_LG_English>GRANULOMA ANNULARE, granuloma annulare (diagnosis), granuloma annulare, Granuloma Annulare [Disease/Finding], annulares granuloma, annulare granuloma, Granuloma annulare, GA - Granuloma annulare, Granuloma annulare (disorder), granuloma; annulare, annulare; granuloma, Granulome annulare, Granuloma Annulare</FPU_LG_English><FPU_LG_French>GRANULOME ANNULAIRE, Granulome annulaire</FPU_LG_French><FPU_SnomedCT>65508009, 156368000, 200953005, 267850001</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A localized or generalized inflammatory skin disorder characterized by the formation of papules and ring-shaped plaques in the skin. Morphologically these lesions are granulomatous inflammatory processes with central necrosis surrounded by palisading histiocytes.</FPU_DefNCI><FPU_Name>Granuloma Annulare</FPU_Name><FPU_DefMSH>Benign granulomatous disease of unknown etiology characterized by a ring of localized or disseminated papules or nodules on the skin and palisading histiocytes surrounding necrobiotic tissue resulting from altered collagen structures.</FPU_DefMSH><FPU_Code>C0085074</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Derm/GrnlmAnlr.htm</FPU_URL></item><item><FPU_Page>Parathyroid Anatomy</FPU_Page><FPU_LG_English>Parathyroid gland, Gland, Parathyroid, Glands, Parathyroid, Parathyroid Glands, PARATHYROID GLANDS, Parathyroid gland, NOS, Parathyroid glands, parathyroid, Parathyroid, NOS, B7 PARATHYROID GLANDS, Glandula parathyroidea, parathyroid glands, parathyroids, parathyroid gland, Parathyroid, Parathyroid structure, Parathyroid structure (body structure), Parathyroid Gland, Head and Neck, Parathyroid</FPU_LG_English><FPU_LG_French>Glande parathyroïde, Parathyroïde, Glandes parathyroïdes, Parathyroïdes</FPU_LG_French><FPU_SnomedCT>111002, 181121007</FPU_SnomedCT><FPU_DefCSP>small paired endocrine glands in the region of the thyroid gland which secrete parathyroid hormone and are concerned with the metabolism of calcium and phosphorus.</FPU_DefCSP><FPU_Concepts>Body Part, Organ, or Organ Component (T023)
</FPU_Concepts><FPU_Concepts_Codes>T023</FPU_Concepts_Codes><FPU_DefNCI>One of two small paired endocrine glands, superior and inferior, usually found embedded in the connective tissue capsule on the posterior surface of the thyroid gland; these glands secrete parathyroid hormone that regulates the metabolism of calcium and phosphorus. The parenchyma is composed of chief and oxyphilic cells arranged in anastomosing cords.</FPU_DefNCI><FPU_Name>Parathyroid gland</FPU_Name><FPU_DefMSH>Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.</FPU_DefMSH><FPU_Code>C0030518</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Anatomy/PrthyrdAntmy.htm</FPU_URL></item><item><FPU_Page>Parathyroid Anatomy</FPU_Page><FPU_LG_English>Other specified disorders of parathyroid gland, Oth spc diso/parathyrd glnd, [X]Oth spc diso/parathyrd glnd, [X]Other specified disorders of parathyroid gland, [X]Other specified disorders of parathyroid gland (disorder), Parathyroid disorder NEC</FPU_LG_English><FPU_LG_French>Autres troubles précisés de la parathyroïde</FPU_LG_French><FPU_SnomedCT>191055006</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Other specified disorders of parathyroid gland</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0154195</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Anatomy/PrthyrdAntmy.htm</FPU_URL></item><item><FPU_Page>Thyroid Anatomy</FPU_Page><FPU_LG_English>Disease, Thyroid, Diseases, Thyroid, Thyroid Diseases, Unspecified disorder of thyroid, THYROID DISEASE, THYROID DISORDER, Disorders of thyroid gland, THYROID DISEASE, NOS, DISORDER THYROID, Thyroid, Thyroid Disease, DISEASES OF THE THYROID GLAND, Disease of thyroid gland, Disease of thyroid gland, NOS, Diseases of Thyroid Gland, Disorder of thyroid gland, NOS, HYPOTHYROIDISM, HYPERTHYROIDISM AND OTHER DISORDERS, Thyroid disorder NOS, Disorder of thyroid, unspecified, Thyroid disorder, NOS, THYROID DIS, SECTION B-8 DISEASES OF THE THYROID GLAND, B-80 HYPOTHYROIDISM, HYPERTHYROIDISM AND OTHER DISORDERS, thyroid disorder, thyroid disorder (diagnosis), Thyroid gland disorders, Disorder thyroid, THYROID ABNORMAL, Disorder of thyroid NOS, Thyroid disorder NOS (disorder), Thyroid disorders, Thyroid Diseases [Disease/Finding], thyroid gland disease, thyroid gland diseases, abnormal thyroid, diseases of the thyroid gland, thyroid disease, thyroid diseases, thyroid gland disorder, thyroid disorders, thyroid abnormal, thyroid gland disorders, Disorders of thyroid gland (E00-E07), Thyroid disease, Thyroid disorder, disease (or disorder); thyroid, thyroid; disorder, Disorder of thyroid gland, Disease of thyroid gland (disorder), Disorder of thyroid gland (disorder), Thyroid Disorders, Thyroid Gland Diseases, Thyroid Gland Disease, Thyroid Gland Disorders, Thyroid Gland Disorder, DISORDERS OF THYROID GLAND</FPU_LG_English><FPU_LG_French>Trouble de la thyroïde non précisé, Trouble thyroïdien SAI, TROUBLE THYROIDIEN, Trouble thyroïdien, Troubles de la glande thyroïde, Maladies thyroidiennes, Maladies de la thyroïde</FPU_LG_French><FPU_SnomedCT>14304000, 191036006, 154649009, 190311002, 190232008</FPU_SnomedCT><FPU_DefCSP>condition in which there is a deviation from or interruption of the normal structure or function of the thyroid gland, which is a highly vascular endocrine gland that produces the thyroid hormones which are concerned in regulating the metabolic rate of the body.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Thyroid Diseases</FPU_Name><FPU_DefMSH>Pathological processes involving the THYROID GLAND.</FPU_DefMSH><FPU_Code>C0040128</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Anatomy/ThyrdAntmy.htm</FPU_URL></item><item><FPU_Page>Thyroid Anatomy</FPU_Page><FPU_LG_English>Gland, Thyroid, Glands, Thyroid, Thyroid Gland, Thyroid Glands, Thyroid gland, NOS, THYROID GLAND, Thyroid, Thyroids, thyroid gland, thyroid, Thyroid, NOS, B6 THYROID GLAND, Glandula thyroidea, THYROID, thyroid glands, thyroids, Thyroid gland, Thyroid structure, Thyroid structure (body structure), Head and Neck, Thyroid</FPU_LG_English><FPU_LG_French>Corps thyroïde, Glande thyroide, Thyroïde</FPU_LG_French><FPU_SnomedCT>69748006</FPU_SnomedCT><FPU_DefCSP>endocrine gland normally situated in the lower part of the front of the neck; secretes, stores and releases the iodine dependent thyroid hormones thyroxine and triiodothyroine which play major endocrine roles in regulating metabolic rate; also secretes thyrocalcitonin.</FPU_DefCSP><FPU_Concepts>Body Part, Organ, or Organ Component (T023)
</FPU_Concepts><FPU_Concepts_Codes>T023</FPU_Concepts_Codes><FPU_DefNCI>An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control. An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control. (NCI) A gland located beneath the larynx (voice box) that makes thyroid hormone and calcitonin. The thyroid gland helps regulate growth and metabolism.</FPU_DefNCI><FPU_Name>Thyroid Gland</FPU_Name><FPU_DefMSH>A highly vascularized endocrine gland consisting of two lobes joined by a thin band of tissue with one lobe on each side of the TRACHEA. It secretes THYROID HORMONES from the follicular cells and CALCITONIN from the parafollicular cells thereby regulating METABOLISM and CALCIUM level in blood, respectively.</FPU_DefMSH><FPU_Code>C0040132</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Anatomy/ThyrdAntmy.htm</FPU_URL></item><item><FPU_Page>Acanthosis Nigricans</FPU_Page><FPU_LG_English>KERATOSIS NIGRICANS, ACANTHOSIS NIGRICANS, keratosis nigricans, acanthosis nigricans (diagnosis), acanthosis nigricans, Acanthosis Nigricans [Disease/Finding], acanthosis nigrican, Acanthosis nigricans, Keratosis nigricans, AN - Acanthosis nigricans, Acanthosis nigricans (disorder), keratosis; nigricans, nigricans; keratosis, Acanthosis Nigricans</FPU_LG_English><FPU_LG_French>Acanthosis nigricans</FPU_LG_French><FPU_SnomedCT>402599005, 72129000</FPU_SnomedCT><FPU_DefCSP>circumscribed melanosis consisting of a brown pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds; occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as in inherited disorder.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A melanotic cutaneous lesion that develops in the axilla and other body folds. It may be idiopathic, drug-induced, or it may be associated with the presence of an endocrine disorder or malignancy.</FPU_DefNCI><FPU_Name>Acanthosis Nigricans</FPU_Name><FPU_DefMSH>A circumscribed melanosis consisting of a brown-pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds. It occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as in inherited disorder.</FPU_DefMSH><FPU_Code>C0000889</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Derm/AcnthsNgrcns.htm</FPU_URL></item><item><FPU_Page>Adrenal Anatomy</FPU_Page><FPU_LG_English>Adrenal Glands, Gland, Adrenal, Glands, Adrenal, ADRENAL GLANDS, Adrenal gland, NOS, Adrenal glands, Suprarenal gland, B3 ADRENAL GLANDS, Glandula suprarenalis, Set of adrenal glands, ADRENAL GLAND, adrenals glands, adrenal glands, both adrenal glands, bilateral adrenal gland, suprarenal gland, adrenal gland, Adrenal gland, Adrenal structure, Adrenal structure (body structure), Adrenal Gland, Adrenals, Adrenal</FPU_LG_English><FPU_LG_French>Glandes surrénales, Surrénales, Surrénale, Glande surrénale</FPU_LG_French><FPU_SnomedCT>23451007</FPU_SnomedCT><FPU_DefCSP>paired glands situated in the retroperitoneal tissues at the superior pole of each kidney.</FPU_DefCSP><FPU_Concepts>Body Part, Organ, or Organ Component (T023)
</FPU_Concepts><FPU_Concepts_Codes>T023</FPU_Concepts_Codes><FPU_DefNCI>A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex). Suprarenal gland. A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex). (NCI) A small gland that makes steroid hormones, adrenaline, and noradrenaline. These hormones help control heart rate, blood pressure, and other important body functions. There are two adrenal glands, one on top of each kidney.</FPU_DefNCI><FPU_Name>Adrenal Glands</FPU_Name><FPU_DefMSH>A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.</FPU_DefMSH><FPU_Code>C0001625</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Anatomy/AdrnlAntmy.htm</FPU_URL></item><item><FPU_Page>Autoimmune Polyglandular Syndrome, Type II</FPU_Page><FPU_LG_English>Autoimmune Polyendocrinopathies, Polyendocrinopathy, Autoimmune, Autoimmune polyendocrinopathy, NOS, Autoimmune polyglandular syndrome, NOS, Polyglandular autoimmune syndrome, NOS, Autoimm polyglandular failure, Polyendocrine autoimmunity syn, Lloyd's syndrome (diagnosis), polyendocrine failure syndrome (diagnosis), endocrine Lloyd's syndrome, polyendocrine failure syndrome, Lloyd's syndrome (disorder), Autoimmune polyglandular failure (disorder), Autoimmune Polyendocrinopathy, Autoimmune Polyendocrinopathy Syndrome, Polyendocrinopathies, Autoimmune [Disease/Finding], lloyd's syndrome, autoimmune polyendocrinopathy, pga, aps, PGA, APS, Lloyd's syndrome, Autoimmune polyglandular failure, Polyendocrine autoimmunity syndrome, Polyglandular autoimmune syndrome, Autoimmune polyendocrinopathy (disorder), Autoimmune polyendocrinopathy, Autoimmune polyglandular syndrome, autoimmune; polyglandular syndrome, deficiency; polyglandular, autoimmune, polyglandular; deficiency, autoimmune, polyglandular; syndrome, autoimmune, syndrome; autoimmune polyglandular, syndrome; polyglandular, autoimmune, Polyendocrinopathies, Autoimmune</FPU_LG_English><FPU_LG_French>Polyendocrinopathies auto-immunes, Polyendocrinopathies autoimmunes</FPU_LG_French><FPU_SnomedCT>18947001, 190568004, 41864002, 190567009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A rare genetic syndrome characterized by autoantibodies production against more than one endocrine organ. The range of endocrinopathies includes hypoparathyroidism, adrenal insufficiency, hypogonadism, type 1 diabetes mellitus and hypothyroidism.</FPU_DefNCI><FPU_Name>Polyendocrinopathies, Autoimmune</FPU_Name><FPU_DefMSH>Autoimmune diseases affecting multiple endocrine organs. Type I is characterized by childhood onset and chronic mucocutaneous candidiasis (CANDIDIASIS, CHRONIC MUCOCUTANEOUS), while type II exhibits any combination of adrenal insufficiency (ADDISON'S DISEASE), lymphocytic thyroiditis (THYROIDITIS, AUTOIMMUNE;), HYPOPARATHYROIDISM; and gonadal failure. In both types organ-specific ANTIBODIES against a variety of ENDOCRINE GLANDS have been detected. The type II syndrome differs from type I in that it is associated with HLA-A1 and B8 haplotypes, onset is usually in adulthood, and candidiasis is not present.</FPU_DefMSH><FPU_Code>C0085409</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/AtmnPlyglndlrSyndrmTypI.htm</FPU_URL></item><item><FPU_Page>Autoimmune Polyglandular Syndrome, Type II</FPU_Page><FPU_LG_English>Autoimmune Syndrome Type II, Polyglandular, Schmidt Syndrome, Schmidt's Syndrome, Schmidts Syndrome, Syndrome, Schmidt's, Addison's disease, toxic diffuse goiter and insulin-dependent diabetes mellitus, Primary hypothyroidism and adrenocortical insufficiency, Diab mell,Add dis,myxoed, Polygland autoimm syn-typeII, Type 2 polyendoc autoimmun syn, Addison's disease, toxic diffuse goitre and insulin-dependent diabetes mellitus, POLYGLANDULAR AUTOIMMUNE SYNDROME, TYPE II, APS II, PGA II, DIABETES MELLITUS, ADDISON DISEASE, MYXEDEMA, POLYENDOCRINE AUTOIMMUNE SYNDROME, TYPE II, APS2, SCHMIDT SYNDROME, AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II, Schmidt's syndrome (disorder), Schmidt's syndrome (diagnosis), Carpenter syndrome, schmidt syndrome, schmidt's syndrome, schmidts syndrome, syndrome schmidt, Diabetes Mellitus, Addison's Disease, Myxedema, Polyglandular Deficiency Syndrome, Type 2, Autoimmune Polyendocrine Syndrome, Type 2, Multiple Endocrine Deficiency Syndrome, Type 2, Polyglandular Autoimmune Syndrome, Type 2, Schmidt's syndrome, APS type 2, Addison's disease with struma lymphomatosa, Polyglandular autoimmune syndrome, type 2, Diabetes mellitus, Addison's disease and myxedema, Diabetes mellitus, Addison's disease and myxoedema, PGA - Polyglandular autoimmune syndrome - type II, Polyglandular autoimmune syndrome - type II, Schmidt syndrome, Type 2 polyendocrine autoimmunity syndrome, Addison's disease, toxic diffuse goiter AND insulin-dependent diabetes mellitus, Addison's disease, toxic diffuse goitre AND insulin-dependent diabetes mellitus, Polyglandular autoimmune syndrome, type 2 (disorder), Primary hypothyroidism AND adrenocortical insufficiency, Schmidt, Polyglandular Type II Autoimmune Syndrome, Polyglandular autoimmune syndrome type II, Autoimmune Polyglandular Syndrome Type II</FPU_LG_English><FPU_LG_French>Polyendocrinopathie auto-immune de type 2, Polyendocrinopathie auto-immune de type II, Polyendocrinopathie autoimmune de type 2, Polyendocrinopathie autoimmune de type II, Syndrome de Schmidt</FPU_LG_French><FPU_SnomedCT>63805001, 83728000, 190567009</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Autoimmune Syndrome Type II, Polyglandular</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0085860</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/AtmnPlyglndlrSyndrmTypI.htm</FPU_URL></item><item><FPU_Page>Pheochromocytoma</FPU_Page><FPU_LG_English>HYPERTENSION, PAROXYSMAL, Hypertension, paroxysmal, paroxysmal hypertension (physical finding), paroxysmal hypertension, paroxysmal hypertension was observed, Hypertension paroxysmal, Paroxysmal hypertension, Paroxysmal hypertension (disorder), Paroxysmal Hypertension</FPU_LG_English><FPU_LG_French>Hypertension paroxystique</FPU_LG_French><FPU_SnomedCT>23130000</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Sign or Symptom (T184)
</FPU_Concepts><FPU_Concepts_Codes>T184</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Paroxysmal hypertension</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0221154</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/Phchrmcytm.htm</FPU_URL></item><item><FPU_Page>Pheochromocytoma</FPU_Page><FPU_LG_English>Pheochromocytomas, CHROMAFFINOMA, MEDULLARY, PARAGANGLIOMA, MEDULLARY, PHAEOCHROMOCYTOMA, Pheochromocytoma, NOS, Phaeochromocytoma, NOS, Adrenal Medullary Paraganglioma, Adrenal Medullary Pheochromocytoma, Adrenal Pheochromocytoma, Intraadrenal Paraganglioma, Chromaffin Paraganglioma of the Adrenal Gland, Adrenal Gland Chromaffin Paraganglioma, Adrenal Gland Chromaffinoma, Adrenal Gland Paraganglioma, Adrenal Gland Pheochromocytoma, PHEOCHROMOCYTOMA, Pheochromocytoma, adrenal, Pheochromocytoma syndrome, [M]Pheochromocytoma NOS, Phaeochromocytoma NOS, Pheochromocytoma NOS, chromaffinoma, Pheochromocytoma [Disease/Finding], chromaffin tumor, pheochromocytoma syndrome, pheochromocytomas, phaeochromocytoma, Chromaffin paraganglioma, Chromaffin tumor, Chromaffinoma, Chromaffin tumour, Phaeochromocytoma, [M]Phaeochromocytoma NOS, Chromaffinoma (disorder), Adrenal medullary paraganglioma, Pheochromocytoma (disorder), Pheochromocytoma (morphologic abnormality), pheochromocytoma, Chromaffin paraganglioma (disorder), Phaeochromocytoma (disorder), Phaeochromocytoma [Ambiguous], Pheochromocytoma, PCC</FPU_LG_English><FPU_LG_French>PHEOCHROMOCYTOME, Chromaffinome, Phéochromocytome</FPU_LG_French><FPU_SnomedCT>302835009, 85583005, 399343007, 360335004, 360332001, 154555009, 188337000, 269615000</FPU_SnomedCT><FPU_DefCSP>usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia; the cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.</FPU_DefCSP><FPU_Concepts>Neoplastic Process (T191)
</FPU_Concepts><FPU_Concepts_Codes>T191</FPU_Concepts_Codes><FPU_DefNCI>Tumor that forms in the center of the adrenal gland (gland located above the kidney) that causes it to make too much adrenaline. Pheochromocytomas are usually benign (not cancer) but can cause high blood pressure, pounding headaches, heart palpitations, flushing of the face, nausea, and vomiting. A benign or malignant neuroendocrine neoplasm of the sympathetic nervous system that secretes catecholamines. It arises from the chromaffin cells of the adrenal medulla. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor. Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen. Other growth patterns including trabecular pattern may also be present.</FPU_DefNCI><FPU_Name>Pheochromocytoma</FPU_Name><FPU_DefMSH>A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles &amp;amp; Practice of Oncology, 3d ed, p1298)</FPU_DefMSH><FPU_Code>C0031511</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/Phchrmcytm.htm</FPU_URL></item><item><FPU_Page>Endocrine Anatomy</FPU_Page><FPU_LG_English>Endocrine System, ENDOCRINE SYSTEM, ENDOCRINE SYSTEM: GENERAL TERMS, Endocrine Systems, System, Endocrine, Systems, Endocrine, Endocrine structure (body structure), Endocrine structure, Structure of endocrine system, Structure of endocrine system (body structure), Endocrine System in General, SECTION B ENDOCRINE SYSTEM, B0 ENDOCRINE SYSTEM: GENERAL TERMS, Systema endocrinum, Endocrine, endocrine systems, endocrine glands system, endocrine gland/system, endocrine system, Endocrine system structure, Endocrine system, Body System, Endocrine/Metabolic, Endocrine/Metabolic Body System, Hormonal System, Organ System, Endocrine/Metabolic, Endocrine/Metabolic Organ System, Metabolic/Endocrine Body System</FPU_LG_English><FPU_LG_French>Système endocrine, Système endocrinien</FPU_LG_French><FPU_SnomedCT>113331007</FPU_SnomedCT><FPU_DefCSP>ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions.</FPU_DefCSP><FPU_Concepts>Body System (T022)
</FPU_Concepts><FPU_Concepts_Codes>T022</FPU_Concepts_Codes><FPU_DefNCI>A system of glands and cells that make hormones that are released directly into the blood and travel to tissues and organs all over the body. The endocrine system controls growth, sexual development, sleep, hunger, and the way the body uses food. Collective designation for those tissues capable of secreting hormones.</FPU_DefNCI><FPU_Name>Endocrine system</FPU_Name><FPU_DefMSH>The system of glands that release their secretions (hormones) directly into the circulatory system. In addition to the ENDOCRINE GLANDS, included are the CHROMAFFIN SYSTEM and the NEUROSECRETORY SYSTEMS.</FPU_DefMSH><FPU_Code>C0014136</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Anatomy/EndcrnAntmy.htm</FPU_URL></item><item><FPU_Page>Cushing's Disease</FPU_Page><FPU_LG_English>Cushing Syndrome, Cushing's Syndrome, Syndrome, Cushing's, CUSHINGS SYNDROME, CUSHING SYNDROME, CUSHING'S SYNDROME, SYNDROME CUSHING'S, Cushing's syndrome NOS, Cushing's syndrome, unspecified, Cushing syndrome, Cushing's basophilism, pituitary basophilism, Syndrome, Cushing, Cushing's syndrome (diagnosis), Cushing's syndrome (disorder), Cushings syndrome, Syndrome Cushing's, CUSHING, Cushing's syndrome NOS (disorder), Cushing Syndrome [Disease/Finding], cushing's syndrome, cushing syndrome, Cushing disease, Cushing's syndrome, Cushing's syndrome III, Itsenko disease, Itsenko-Cushing syndrome, Suprarenogenic syndrome, Hypercortisolism, Cushings Syndrome, cushings syndrome</FPU_LG_English><FPU_LG_French>SYNDROME DE CUSHING, Syndrome de Cushing, Hypercortisolisme</FPU_LG_French><FPU_SnomedCT>154705004, 190505004, 47270006</FPU_SnomedCT><FPU_DefCSP>condition, more commonly seen in females, due to hyperadrenocorticism resulting from neoplasms of the adrenal cortex or the anterior lobe of the pituitary, or to prolonged excessive intake of glucocorticoids for therapeutic purposes; symptoms and signs may include rapidly developing adiposity of the face, neck, and trunk, kyphosis caused by osteoporosis of the spine, hypertension, diabetes mellitus, amenorrhea, hypertrichosis in females, impotence in males, dusky complexion with purple markings, polycythemia, pain in the abdomen and back, and muscular wasting and weakness.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A syndrome caused by high levels of cortisol in the blood either due to excessive production and secretion of corticosteroids secondary to pituitary or adrenocortical neoplasms, or intake of glucocorticoid drugs. Signs and symptoms include a round face, upper body obesity, fragile and thin skin, purple stretch marks in the skin, fatigue, muscle weakness, hypertension, diabetes mellitus, hypertrichosis and amenorrhea in women, impotence in men, and osteoporosis. A condition in which there is too much cortisol (a hormone made by the outer layer of the adrenal gland) in the body. Cushing syndrome may be caused by taking too many steroid drugs or by certain types of tumors. Tumors that make adrenocorticotropic hormone (ACTH) cause the adrenal gland to make too much cortisol. Symptoms of Cushing syndrome include a round face, thin arms and legs, severe fatigue and muscle weakness, high blood pressure, high blood sugar, purple or pink stretch marks on the skin, and weight gain, especially in the abdomen. A condition in which there is too much cortisol (a hormone made by the outer layer of the adrenal gland) in the body. In Cushing disease, this happens when an adenoma (benign tumor) in the pituitary gland makes too much adrenocorticotropic hormone (ACTH). This causes the adrenal gland to make too much cortisol. Symptoms include a round face, thin arms and legs, severe fatigue and muscle weakness, high blood pressure and high blood sugar, purple or pink stretch marks on the skin, and weight gain, especially in the abdomen.</FPU_DefNCI><FPU_Name>Cushing Syndrome</FPU_Name><FPU_DefMSH>A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.</FPU_DefMSH><FPU_Code>C0010481</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/CshngsDs.htm</FPU_URL></item><item><FPU_Page>Congenital Adrenal Hyperplasia</FPU_Page><FPU_LG_English>Adrenal Hyperplasia, Congenital, Adrenal Hyperplasias, Congenital, Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasias, Hyperplasia, Congenital Adrenal, Hyperplasias, Congenital Adrenal, ADRENAL HYPERPLASIA, CONGENITAL, Adrenal hyperplasia syndrome, congenital, CONGENITAL ADRENAL HYPERPLASIA, Congenital adrenal hyperplasia, NOS, CAH-Congenit adren hyperplasia, Congenital Adrenal Gland Hyperplasia, HYPERPLASIA CONGEN ADRENAL, ADRENAL HYPERPLASIA CONGEN, CONGEN ADRENAL HYPERPLASIA, congenital adrenal hyperplasia (diagnosis), congenital adrenal hyperplasia, ADRENAL HYPERPLASIA CONGENITAL, Adrenal Hyperplasia, Adrenal Hyperplasia, Congenital [Disease/Finding], hyperplasia congenital adrenal, adrenal congenital hyperplasia, hyperplasia adrenal congenital, CAH - Congenital adrenal hyperplasia, Congenital adrenal hyperplasia (disorder), Congenital adrenal hyperplasia, hyperplasia; adrenal, congenital, adrenal; hyperplasia, congenital</FPU_LG_English><FPU_LG_French>Hyperplasie surrénalienne congénitale, Hyperplasie surrénale congénitale, Hyperplasie congénitale des surrénales</FPU_LG_French><FPU_SnomedCT>237751000, 27037004</FPU_SnomedCT><FPU_DefCSP>group of syndromes caused by inherited defects in cortisol and/or aldosterone biosynthesis; ACTH elevation is caused by low levels of cortisol, whose production is impaired by absence or deficiency of one of the five enzymes necessary for its synthesis from cholesterol.</FPU_DefCSP><FPU_Concepts>Congenital Abnormality (T019)
, Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T019 T047</FPU_Concepts_Codes><FPU_DefNCI>A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.</FPU_DefNCI><FPU_Name>Congenital adrenal hyperplasia</FPU_Name><FPU_DefMSH>A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.</FPU_DefMSH><FPU_Code>C0001627</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/CngntlAdrnlHyprpls.htm</FPU_URL></item><item><FPU_Page>Hyperaldosteronism</FPU_Page><FPU_LG_English>ALDOSTERONISM, PRIMARY, CONN SYNDROME, HYPERALDOSTERONISM, PRIMARY, Hyperaldosteronism, primary, PRIMARY HYPERALDOSTERONISM, Aldosteronism Primary, Conn Syndrome, primary hyperaldosteronism, primary aldosteronism (diagnosis), primary aldosteronism, Primary aldosteronism (disorder), Conn's syndrome (diagnosis), Idiopathic aldosteronism, Idiopathic hyperaldosteronism, Conns Syndrome, Conn's Syndrome, Syndrome, Conn's, conn syndrome, conn's syndrome, conns syndrome, Conn's syndrome, Conn syndrome, Primary aldosteronism, Primary hyperaldosteronism, Idiopathic aldosteronism (disorder), Primary hyperaldosteronism (disorder), hyperaldosteronism; primary, primary; hyperaldosteronism, Conn, Primary aldosteronism (disorder) [Ambiguous], Syndrome, Conn, Primary Hyperaldosteronism, Hyperaldosteronism, Primary</FPU_LG_English><FPU_LG_French>Syndrome de conn, Syndrome de Conn, Hyperaldostéronisme primaire, Hyperaldostéronisme primaire à rénine basse</FPU_LG_French><FPU_SnomedCT>13536004, 258117004, 190507007, 154709005, 190506003, 267484005</FPU_SnomedCT><FPU_DefCSP>overproduction of aldosterone by an adrenal cortical adenoma, characterized typically by low potassium levels, underacidity of the body, muscular weakness, excess urination, excess thirst, and high blood pressure.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Conn Syndrome</FPU_Name><FPU_DefMSH>Primary hyperaldosteronism caused by the excess production of ALDOSTERONE by an ADENOMA of the ZONA GLOMERULOSA or CONN ADENOMA.</FPU_DefMSH><FPU_Code>C1384514</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/Hyprldstrnsm.htm</FPU_URL></item><item><FPU_Page>Hyperaldosteronism</FPU_Page><FPU_LG_English>Aldosteronism, Hyperaldosteronism, ALDOSTERONISM, HYPERALDOSTERONISM, Aldosteronism, NOS, Hyperaldosteronism, NOS, Hyperaldosteronism NOS, Hyperaldosteronism, unspecified, aldosteronism, aldosteronism (diagnosis), hyperaldosteronism, Aldosteronism NOS, Hyperaldosteronism NOS (disorder), Hyperaldosteronism [Disease/Finding], Aldosteronism (disorder)</FPU_LG_English><FPU_LG_French>Aldostéronisme SAI, Aldostéronisme, Hyperaldostéronisme, Hyperaldostéronisme primitif</FPU_LG_French><FPU_SnomedCT>190509005, 88213004, 190506003, 154709005, 267484005</FPU_SnomedCT><FPU_DefCSP>abnormality of electrolyte function caused by excessive secretion of aldosterone by the adrenal cortex.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Hyperaldosteronism</FPU_Name><FPU_DefMSH>A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.</FPU_DefMSH><FPU_Code>C0020428</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/Hyprldstrnsm.htm</FPU_URL></item><item><FPU_Page>Addison's Disease</FPU_Page><FPU_LG_English>ADRENAL CORTEX INSUFFIENCY, ADRENAL CORTEX HYPOFUNCTION, ADRENAL CORTICAL INSUFFICIENCY, INSUFFICIENCY ADRENAL CORTEX, Adrenal cortical hypofunction, NOS, Adrenocortical hypofunction, NOS, Corticoadrenal insufficiency, NOS, Hypoadrenocorticism, NOS, Corticoadrenal insuffic. NOS, Corticoadrenal insufficiency NOS, Adrenocortical insufficiency syndrome, Adrenal insufficiency NOS, Adrenal cortex hypofunction, Adrenal cortex insuffiency, Adrenal cortical insufficiency, Insufficiency adrenal cortex, Adrenal cortex insufficiency, corticoadrenal insufficiency (diagnosis), corticoadrenal insufficiency, adrenal cortical hypofunction, adrenal cortical insufficiency, Adrenal cortical hypofunction, Adrenal insufficiency, ADRENAL INSUFFICIENCY CORTICAL, Corticoadrenal insufficiency NOS (disorder), adrenal insufficiency, adrenal insufficiencies, adrenal cortex insufficiency, adrenocortical hypofunction, Adrenal Insufficiency, Adrenal cortical hypofunctions, Corticoadrenal insufficiency, Hypoadrenocorticism, Adrenal cortical hypofunction (disorder), Adrenocortical hypofunction, corticoadrenal; deficiency, corticoadrenal; hypofunction, deficiency; corticoadrenal, hypoadrenocorticism, hypofunction; adrenocortical, insufficiency; adrenal, adrenal cortex; deficiency, adrenal; insufficiency</FPU_LG_English><FPU_LG_French>Insuffisance corticosurrénale, Insuffisance cortico-surrénalienne, Hypofonction cortico-surrénale, Insuffisance corticale surrénalienne, Hypoadrénocorticisme, Insuffisance corticosurrénalienne, Hypofonction de la corticosurrénale, Insuffisance cortico-surrénale, HYPOFONCTIONN CORTICO-SURRENAL, INSUFFISANCE CORTICO-SURRENALE, Hypofonctions adréno-corticales</FPU_LG_French><FPU_SnomedCT>267398003, 386584007, 154707007, 267483004, 68588005, 190527008</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Adrenal cortical hypofunction</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0405580</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/AdsnsDs.htm</FPU_URL></item><item><FPU_Page>Addison's Disease</FPU_Page><FPU_LG_English>Disease, Addison, ADDISON DISEASE, ADDISON'S DISEASE, ADRENAL INSUFFICIENCY (ADDISON'S DISEASE), ADRENOCORTICAL INSUFFICIENCY, PRIMARY FAILURE, DISEASE ADDISON'S, Addison's disease, NOS, Primary adrenal deficiency, Primary adrenocortical insuff, Disease Addison's, Adrenal insufficiency (Addison disease), ADDISONS DIS, ADDISON DIS, Chronic Adrenal Insufficiency, Hypocortisolism, Addison's disease NOS, primary adrenal insufficiency, primary adrenal insufficiency (diagnosis), Addison's disease, NOS (disorder), Addison Disease, Addison disease, Addison Disease [Disease/Finding], Disease;Addisons, addison disease, addison's disease, Primary adrenal insufficiency, Addison's disease, Primary adrenocortical insufficiency, Primary hypoadrenalism, Addison's disease (disorder), Primary adrenocortical insufficiency (disorder), corticoadrenal; deficiency, primary, deficiency; adrenocortical, primary, deficiency; corticoadrenal, primary, disease (or disorder); bronzed skin (Addison) (bronze disease), hypoadrenocorticism; primary, insufficiency; adrenal, primary, insufficiency; suprarenal, primary, adrenal cortex; deficiency, primary, adrenal cortex; hypofunction, primary, adrenal; insufficiency, primary, primary; hypoadrenocorticism, Addison; disease or syndrome, suprarenal; insufficiency, primary, syndrome; Addison, Addison's disease [Ambiguous], Addison's Disease, Hypoadrenalism, Primary, Hypoadrenalisms, Primary, Insufficiencies, Primary Adrenocortical, Insufficiency, Primary Adrenocortical, Primary Adrenal Insufficiency, Primary Adrenocortical Insufficiencies, Primary Adrenocortical Insufficiency, Primary Hypoadrenalism, Adrenal Insufficiency, Primary, Adrenocortical Insufficiencies, Primary, Adrenocortical Insufficiency, Primary, Addisons Disease, Addisons disease</FPU_LG_English><FPU_LG_French>Hyposurrénalisme, MALADIE D'ADDISON, Insuffisance surrénalienne primaire, Insuffisance corticosurrénalienne primitive, Insuffisance surrénalienne primitive, Maladie d'Addison, Insuffisance surrénale lente, Insuffisance surrénale primitive</FPU_LG_French><FPU_SnomedCT>111562000, 367376006, 363732003, 373662000, 154707007, 267483004, 68588005</FPU_SnomedCT><FPU_DefCSP>disease characterized by hypotension, weight loss, anorexia, weakness, and sometimes a bronze-like melanotic hyperpigmentation of the skin; due to tuberculosis or autoimmune induced disease (hypofunction) of the adrenal glands that results in deficiency of aldosterone and cortisol.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>A hormonal disorder that occurs when the adrenal glands fail to release adequate amounts of glucocorticoids (cortisol), mineralocorticoids (aldosterone, 11-deoxycorticosterone), and androgens (dehydroepiandrosterone) to meet physiologic needs, despite release of ACTH from the pituitary.</FPU_DefNCI><FPU_Name>Addison Disease</FPU_Name><FPU_DefMSH>An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.</FPU_DefMSH><FPU_Code>C0001403</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/AdsnsDs.htm</FPU_URL></item><item><FPU_Page>Addison's Disease</FPU_Page><FPU_LG_English>ADDISONIAN CRISIS, ADRENAL APOPLEXY, ADRENAL CRISIS, ADRENAL STORM, ADRENOCORTICAL INSUFFICIENCY, ACUTE, CRISIS ADDISONIAN, CRISIS ADRENAL, Addisonian crisis, Adrenal Apoplexy, Adrenocortical insufficiency syndrome, acute, Adrenal crisis syndrome, adrenal crisis (diagnosis), adrenal crisis, Adrenal storm, Acute adrenal insufficiency (&amp;amp; [Addisonian crisis] or [adrenal crisis]) (disorder), Addisonian crisis (disorder), Addisonian crisis (diagnosis), Adrenocortical insufficiency acute, Crisis addisonian, Crisis adrenal, acute adrenal insufficiency, addisonian crisis, adrenal storm, severe adrenal insufficiency, Adrenal crisis, Severe adrenal insufficiency, Acute adrenal insufficiency, Adrenocortical crisis, Severe adrenal insufficiency (disorder), collapse; adrenal, crisis; Addison, crisis; adrenal, adrenal; collapse, adrenal; crisis, adrenal; shock, Addison; crisis, shock; adrenal, Acute adrenal insufficiency (&amp;amp; [Addisonian crisis] or [adrenal crisis])</FPU_LG_English><FPU_LG_French>Crise d'Addison, Crise surrénale, Crise d'insuffisance surrénale, Crise surrénalienne, CATACLYSME SURRENAL, CRISE SURRENALE, Insuffisance surrénalienne aiguë</FPU_LG_French><FPU_SnomedCT>190522002, 190526004, 237757001, 24867002, 154707007, 267483004</FPU_SnomedCT><FPU_DefCSP></FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI></FPU_DefNCI><FPU_Name>Addisonian crisis</FPU_Name><FPU_DefMSH></FPU_DefMSH><FPU_Code>C0151467</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/AdsnsDs.htm</FPU_URL></item><item><FPU_Page>Addison's Disease</FPU_Page><FPU_LG_English>ADRENAL INSUFFICIENCY, HYPOADRENALISM, ADRENAL HYPOFUNCTION, HYPOFUNCTION ADRENAL, Hypofunction, Adrenal Gland, hypoadrenalism, Adrenal insufficiency, NOS, INSUFFICIENCY ADRENAL, adrenal insufficiency, adrenal insufficiency (diagnosis), Adrenal gland hypofunction, Hypofunction adrenal, Adrenal insufficiency NOS, Insufficiency adrenal, Adrenal Cortical Insufficiency, Adrenal Insufficiency [Disease/Finding], Insufficiency;adrenal, adrenal failure, adrenal hypofunctions, adrenal insufficiencies, insufficiency adrenal, adrenal hypofunction, Adrenal failure, Adrenal hypofunction, Adrenal insufficiency, Adrenal hypofunction (disorder), Hypoadrenalism (disorder), Adrenal Gland Hypofunction, Hypoadrenalism, Adrenal Insufficiencies, Adrenal Insufficiency, Adrenal Gland Insufficiency</FPU_LG_English><FPU_LG_French>INSUFFISANCE SURRENALE, Hypofonction surrénalienne, Hypofonction surrénale, Insuffisance surrénalienne SAI, HYPOFONCTIONNEMENT SURRENAL, HYPOSURRENALISME, Insuffisance surrénale, Hypofonctionnement de la glande surrénale, Hypofonctionnement surrénalien, Insuffisance surrénalienne</FPU_LG_French><FPU_SnomedCT>237785004, 111563005, 386584007, 68588005, 190527008</FPU_SnomedCT><FPU_DefCSP>abnormally diminished activity of the adrenal gland.</FPU_DefCSP><FPU_Concepts>Disease or Syndrome (T047)
</FPU_Concepts><FPU_Concepts_Codes>T047</FPU_Concepts_Codes><FPU_DefNCI>An endocrine or hormonal disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex (Addison's disease or primary adrenal insufficiency) or to inadequate secretion of ACTH by the pituitary gland (secondary adrenal insufficiency). A disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.</FPU_DefNCI><FPU_Name>Adrenal gland hypofunction</FPU_Name><FPU_DefMSH>Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.</FPU_DefMSH><FPU_Code>C0001623</FPU_Code><FPU_URL>http://www.fpnotebook.com/Endo/Adrenal/AdsnsDs.htm</FPU_URL></item>
